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Abstract 
Exercise Induced Bronchoconstriction (EIB) is common amongst elite 
athletes. Short-acting β2-agonists represent the first-line treatment of EIB, 
however; limited data currently exists examining the ergogenic and 
pharmacokinetic impact of chronic short-acting β2-agonist administration. 
Furthermore, the ergogenic impact of acute and chronic administration of 
short-acting β2-agonists in asthmatic individuals is unknown. Whilst the 
short-acting β2-agonist salbutamol is permitted in and out of competition due 
to a known pharmacokinetic response, no urinary threshold has been 
established for the use of the alternative short-acting β2-agonist terbutaline.  
The purpose of study 1 was to investigate the ergogenic potential of 
the WADA upper daily limit of 1600 µg·day-1 salbutamol every day for 6 
weeks versus placebo, alongside combined resistance and endurance 
training. Findings  highlighted improvements in; 1 repetition maximum (1RM) 
bench press (Baseline: 65.6 ± 5.4 kg vs. 64.3 ± 4.9 kg – 6 weeks: 70.3 ± 4.9 
vs. 72.5 ± 5.4 kg) and leg press (Baseline: 250 ± 26.9 vs. 217.9 ± 19 kg – 6 
weeks: 282.5 ± 22.5 vs. 282.8 ± 18.3 kg); vertical jump test (Baseline: 53.5 ± 
4.1 vs. 50.4 ± 2.1 cm – 6 weeks: 55 ± 3.5 vs. 52.4 ± 1.7 cm); 3 km running 
time-trial performance (Baseline: 988.7 ± 68.7 vs. 1040.5 ± 66.3 s – 6 weeks: 
947.5 ± 54.9 vs. 1004.3 ± 70.5 s); isokinetic dynamometry (Baseline: 196.1 ± 
47.3 vs. 184.6 ± 35.0 n.m. – 6 weeks: 179.5 ± 48.9 vs. 195.2 ± 28.9 n.m.); 
and body composition (Baseline: 32.1 ± 13.9 vs. 34.9 ± 10.4 mm – 6 weeks: 
32.4 ± 14.5 vs. 34.5 ± 10 mm) for both the salbutamol group and  the 
placebo group, respectively, over the 6 week period, with no difference 
observed between groups, indicating long-term therapeutic use of 
salbutamol at the WADA upper daily limit has no ergogenic effect. Of note, 
one participant exceeded the urinary threshold, presenting with an adverse 
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analytical finding (AAF) showing that the upper daily limit can lead to AAF’s 
in susceptible individuals. 
Athletes who respond poorly to salbutamol treatment are able to apply 
for the use of the short-acting β2-agonist terbutaline via a therapeutic use 
exemption (TUE) certificate. Urinary upper limits are unknown for terbutaline 
and as such it is prohibited at all times without the presentation of a TUE. 
The purpose of study 2 was to investigate the urinary excretion of terbutaline 
following single and repeated use of inhaled or oral terbutaline. The aim of 
the study was to establish a differential distinction between routes of 
administration which could assist the WADA with regard to anti-doping policy 
and procedure. Results demonstrated a significant difference in urine 
concentration of terbutaline between inhaled and oral administration for 
female Caucasian (670.1 ± 128.3 vs. 361.8 ± 43.8 ng·ml-1; P=0.019; 680.8 ± 
91 vs. 369.9 ± 41.9 ng·ml-1; P=0.006), male Afro-Caribbean (343.18 ± 45 vs. 
231.3 ± 32.95 ng·ml-1; P=0.044; 389.73 ± 67.4 vs. 212.4 ± 50.3 ng·ml-1; 
P=0.008) and male Asian (266.4 ± 23.7 vs. 143.3 ± 22 ng·ml-1; P=0.004; 
379.5 ± 50.4 vs. 197.5 ± 38.6 ng·ml-1; P=0.000) groups for single (5 mg oral 
vs. 2 mg inhaled) and repeated (4 x 5 mg oral vs. 8 x 1 mg inhaled) 
administration trials, respectively. No difference was observed in male 
Caucasians. High intra- and inter-individual variability between samples 
meant that a clear distinction between routes of administration could not be 
established. The study was able to identify an upper urinary threshold 
following inhaled administration of 1284.3 ng·ml-1 and an upper urinary 
threshold following oral use of 2376.3 ng·ml-1 which may inform the process 
of distinguishing between inhaled and oral use. 
Athletes are permitted to use inhaled terbutaline therapeutically 
through the TUE process. The purpose of study 3 was to investigate the 
ergogenic effect of terbutaline at high (2 mg and 4 mg) therapeutic inhaled 
doses on 3 km running time-trial performance in males and females. The 
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study found that inhaled terbutaline, when used at the highest therapeutic 
dose, has no impact upon 3 km time-trial performance in males (956.3 s vs. 
982 s) and females (1249 s vs. 1214.7 s) for placebo vs. 4 mg inhaled 
terbutaline, respectively. 
The majority of studies investigating the ergogenic potential of 
salbutamol have been in healthy individuals. It is not yet understood whether 
the exercise response differs in asthmatic individuals. The purpose of study 
4 was to investigate the use of inhaled salbutamol (400 µg) during a 3 km 
running time-trial in eucapnic voluntary hyperpnoea positive (EVH+ve) and 
negative (EVH-ve) individuals, in a low humidity environment. Results 
demonstrated increased FEV1 in both groups following salbutamol inhalation, 
which did not translate to improved performance. No performance 
differences were found between salbutamol and placebo (Sal: 1012.7 ± 50 
vs. 962.1 ± 37.5 s – Pla: 1002.4 ± 46.5 vs. 962 ± 28.8 s) in the EVH+ve 
group vs. the EVH-ve group, respectively. 
This thesis is the first to investigate the effects of long-term use of 
salbutamol at the WADA upper daily limit on exercise performance. It is also 
the first study to establish upper urinary thresholds for terbutaline use, and 
the effects of therapeutic inhaled terbutaline on exercise performance. The 
effect of salbutamol on exercise performance at low humidity in asthmatic 
individuals has also never previously been investigated. Overall, the findings 
from this thesis support previous research that inhaled β2-agonist use does 
not provide any ergogenic potential. With β2-agonists being an essential 
therapy for the treatment of EIB their current position on the WADA List of 
Prohibited Substances and Methods is appropriate. Further research is 
warranted to fully elucidate the upper urinary threshold for terbutaline to 
inform WADA and support the re-introduction of terbutaline as a therapeutic 
tool in the treatment of EIB in athletes. 
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1.1 Introduction 
 
In 2002 The International Olympic Committee (IOC) established the 
requirement for athletes to present evidence of current asthma, exercise 
induced asthma (EIA), exercise induced bronchospasm (EIB) or airway 
hyper-responsiveness (AHR) through the Therapeutic Use Exception (TUE) 
certificate process. These regulations, guided by the IOC Medical 
Commission (IOC-MC), were based on health and not anti-doping 
(performance enhancing) concerns for athletes in light of a marked increase 
in the notification by athletes for the use of inhaled short acting β2-agonist 
from 3.7% in Atlanta, 1996, to 5.7% in Sydney, 2000 (Fitch et al., 2008). 
Dickinson et al. (2005) provided support for the health justification of adding 
inhaled short acting β2-agonists to the prohibited substances list when 
reporting data from the Sydney, 2000, and Athens, 2004, Great Britain 
Olympic Teams (Team GB; Dickinson et al., 2005).  
 
The data from Dickinson et al. (2005) demonstrated that the establishment of 
a TUE for inhaled short acting β2-agonists had no impact on the proportion of 
Team GB presenting with asthma, EIA, EIB or AHR (c.21% at both Olympic 
Games) however; the use of the TUE identified a number of athletes with 
false positive diagnoses and athletes who had not been previously identified. 
Accordingly, they concluded, as have others, that the requirement of 
demonstrable evidence through the TUE process improves the quality of 
care for athletes. Furthermore, Rundell et al., (2004) has demonstrated the 
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improved diagnostic sensitivity and specificity of objective, bronchial 
provocation tests of airway function as part of the TUE process.  
 
Whilst the weight of evidence supports the improved health care of athletes 
following the introduction of the TUE process for inhaled short acting β2-
agonists (Dickinson et al., 2005) WADA removed the need for a TUE for 
salbutamol in 2010, replacing it with the need for declaration of use (DoU). 
The position of salbutamol was further relaxed in 2012 to allow athletes to 
use salbutamol for the treatment of respiratory symptoms, monitored with a 
urinary concentration threshold limit of 1000 ng.ml-1 (WADA Prohibited List, 
2015). Due to their potential performance enhancing properties (Pluim et al., 
2011), all orally administered β2-agonists are banned for use by athletes in 
and out of competition (WADA, 2015). There are a number of inhaled β2-
agonists that are permitted in the form of salbutamol, salmeterol, and 
formoterol that can be used by athletes who have asthma, EIA, EIB or AHR. 
In contrast, terbutaline remains on the restricted list and can only be used 
through the therapeutic use exemption (TUE) process (WADA 2015), which 
requires the athlete to submit objective evidence of asthma/EIA/EIB/AHR 
and a detailed history of their condition.  The regulations for the use of 
salbutamol, salmeterol and formoterol are relatively relaxed when compared 
with terbutaline.  
 
In contrast to the improved health care of athletes, little is understood of the 
ergogenic effect of inhaled short acting β2-agonists. β2-adrenergic 
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stimulation of various organs plays an important role in adaptation to 
exercise. Increased transport capacity through an increase in cardiac output, 
increased availability of substrates for energy metabolism by increases in 
lipolysis and glycogenolysis and increased skeletal muscle contractility 
associated with increased activity of the sympathetic nervous system are all, 
in part, mediated by β-adrenergic receptor stimulation (Hoffman, 2001). 
Despite this only a small number of studies have examined the ergogenic 
effect of inhaled short acting β2-agonists.   
 
A recent review highlighted there is limited evidence to suggest that short 
acting β2-agonists provide any ergogenic effect (Price et al., 2014). However, 
the majority of previous studies have investigated the impact of inhaled 
salbutamol on endurance running, cycling and swimming performance in 
Caucasian males (Meeuwisse et al., 1992; van Baak et al., 2000; Decorte et 
al., 2008; McKenzie et al., 1983; Koch et al., 2013; Koch et al., 2014; Elers 
et al., 2010). Of the small number of studies that have investigated the 
impact of short acting β2-agonists on sprint/power performance there is 
contrasting evidence for an ergogenic effect (Signorile et al., 1992; Sporer et 
al., 2008; Decorte et al., 2013; Decorte et al., 2008; Kalsen et al., 2013; Van 
Baak et al., 2000). Furthermore, previous research investigating inhaled 
salbutamol has primarily focused on acute administration of a single 
therapeutic and supra-therapeutic dose. Research investigating long-term 
daily administration of salbutamol at the maximum WADA permitted dose, is 
therefore warranted. 
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The majority of available evidence for the ergogenic effect of inhaled β2-
agonists has focused on salbutamol. Very few studies have investigated the 
ergogenic effects of terbutaline (Larsson et al., 1997; Unnithan et al., 1994; 
Sanchez et al., 2013; Kalsen et al., 2014; Hostrup et al., 2014). The study by 
Larsson et al. (1997) reported no significant effect on running time to 
exhaustion performed at 10oC in elite athletes following the administration of 
3 mg of inhaled terbutaline, another study by Sanchez et al. (2013) also 
investigating oral terbutaline found no significant effects on performance. 
Kalsen et al. (2014) and Hostrup et al. (2014) both investigated supra-
therapeutic inhaled terbutaline finding improvements in strength and power 
performance yet no improvements in endurance performance. The lack of 
research on the ergogenic effects of inhaled terbutaline is a key factor in the 
decision by WADA for a full TUE for inhaled terbutaline. 
 
Research investigating the differentiation between oral and inhaled 
salbutamol (Elers et al., 2010; Berges et al., 2000) has managed to 
successfully identify differences between routes of administration. However, 
limited research is available examining the differentiation of inhaled and oral 
administration of terbutaline. Roig, et al. (2002) attempted to distinguish 
between oral and inhaled doses of terbutaline through analysis of terbutaline 
concentration in urine. Although different trends were observed after oral and 
inhaled doses in total terbutaline, total free terbutaline concentrations and in 
ratios between its enantiomers, differences observed were not sufficiently 
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significant to establish cut-off values in order to clearly distinguish between 
routes of administration.  
 
The dosing strategy employed by Roig et al., (2002) has limited ecological 
validity as it failed to replicate the dosing strategy that may be adopted by an 
elite athlete which would be a standardized dose used PRN. More recently 
Elers et al., (2012b) examined terbutaline use via both oral and inhaled 
administration with more ecologically valid dosing strategies. The findings 
indicate that, although there was a significant difference between values, 
they were unable to identify a cut-off value that could distinguish between 
routes of administration. Further research investigating urinary 
concentrations of inhaled and oral terbutaline, along with the ergogenic 
potential of therapeutic doses of inhaled terbutaline are therefore warranted. 
 
This thesis will add to the current body of knowledge associated with the 
ergogenic effect and pharmacokinetics of short acting β2-agonists, and in the 
process assist WADA in the implementation of regulations on the use of 
inhaled short acting β2-agonists and assist in the resolution of contested 
doping violations. Firstly, by investigating the legitimacy of the chronic 
administration of the WADA daily upper limit of 1600 µg salbutamol per day. 
Secondly, by investigating the urinary concentrations of inhaled and oral 
terbutaline to establish cut-off limits for anti-doping purposes. Thirdly, 
investigate the effects of a therapeutic dose of inhaled terbutaline on 
endurance performance. Finally, investigate the potential for ergogenic 
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effects of salbutamol in eucapnic voluntary hyperpnoea (EVH) positive 
individuals along with the effectiveness of salbutamol at offsetting any 
detriment in either lung function or performance that may be experienced by 
mild EVH positive (EVH+ve) individuals, exercising in a low humidity 
environment.  
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2. Review of the 
literature 
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2.1 Asthma 
 
Asthma is a chronic inflammatory disorder of the conducting airways which 
causes airway hyper-responsiveness (AHR) and recurrent episodes of 
wheezing, breathlessness, chest tightness, and coughing, particularly at 
night or in the early morning (Barnes, 2011). These episodes are associated 
with widespread but variable airflow obstruction that is reversible, either 
spontaneously or with treatment. Asthma is heterogeneous with respect to 
immunopathology, clinical phenotypes, response to therapies and natural 
history.   
 
Accordingly, asthma is being redefined as a collection of different endotypes 
rather than a single, specific disease with a unifying pathogenic mechanism 
(Barnes, 2011). Asthma is purported to affect an estimated 300 million 
people worldwide (Braman et al., 2006; Masoli et al., 2004) with recent 
estimates suggesting that around 15% of the UK population (5.4 million 
people) are asthmatic, leading to increasing National Health Service (NHS) 
expenditure of up to 1 billion pounds per annum (Asthma U.K., 
www.asthma.org.uk accessed December 2014).   
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2.1.1 Pathophysiology of asthma 
 
The characteristic mechanisms of asthma include activation of mast cells, 
infiltration of eosinophils and infiltration of T helper 2 (TH2) lymphocytes into 
the airway epithelium (Barnes, 2008). The activation of mast cells in the 
airway epithelium (e.g. by allergens), releases inflammatory mediators into 
the extra-cellular matrix (ECM), including histamine, leukotriene (LT) D4, and 
prostaglandin (PG) D2. The release of these mediators leads to 
bronchoconstriction, microvascular leakage and plasma exudation in 
susceptible individuals (Skidgel et al., 2012). Figure 2.1 depicts the 
downstream cascade of cellular mechanisms caused by activation of the 
mast cell in both a healthy and a damaged airway epithelium, with the latter 
also showing increased eosinophil infiltration and activation.  
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Figure 2.1 The airway epithelium showing the process of exudative inflammation in 
the intact epithelium (left) and damaged epithelium (right). Plasma derived adhesive 
proteins and solutes are contributing to the milieu of the lamina propria, epithelium 
and mucosal surface. MC – Mast Cell, M – Macrophage, E – Eosinophil, N – 
Neutrophil, F – Fibroblast, D – Dendritic Cell, B – B-lymphocyte, T – T-lymphocyte, GM-
CSF – Granulocyte Macrophage Colony Stimulating Factor, LTC – Leukotriene C4, TGF 
– Transforming Growth Factor, TNF – Tumor Necrosis Factor, IL – Interleukin, IgE – 
Immunoglobulin E, PAF, Platelet-activating factor; ECP, eosinophil cationic protein; 
MBP, major basic protein (Anderson & Kippelen 2008) 
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2.1.2 Chronic adaptations in asthma 
 
Chronic features of asthma are; mucus hyperplasia, fibroblast proliferation 
and airway remodelling. The chronic exposure to the stimulus causes 
increased infiltration and activation of eosinophils, neutrophils and mast cell 
degranulation (Figure 2.1). In addition, Holgate, (2008) explains that the 
chronic adaptations with frequent asthma exacerbations include smooth 
muscle cell hyperplasia, epithelial mesenchymal transition and fibroblast 
stimulation via CD34+ cells and transforming growth factor β (TGFβ) in the 
repair of damaged epithelial tissue (Figure 2.2).  
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Figure 2.2: Diagram of the mechanisms for structural changes showing; a) 
Mechanisms for acute and chronic inflammation in asthma and the remodelling 
process; b) Clinical consequences of airway remodelling in asthma; c) Link between 
pathologic mechanisms and clinical consequence in asthma (Bousquet et al., 2000) 
 
a) 
b) 
c) 
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Although historically asthma has been thought to be a TH2 mediated disease 
it is now largely agreed that a number of different phenotypes exist, each 
with differing mechanisms of action and each with differing degrees of 
severity dependent upon the specific mechanism (Boulet et al., 2014). Table 
2.1 highlights the varying phenotypes of asthma, their identification and 
treatment (Wenzel et al., 2012). 
 
Table 2.1: Asthma phenotypes, identification and treatment (Adapted from 
Wenzel et al., 2012) 
 
Asthma phenotypes in relation to characteristics 
Phenotype Natural 
History 
Clinical and 
physiological 
features 
Pathobiology and 
biomarkers 
Genetics Response to therapy 
Early-onset 
allergic 
Early onset; 
mild to 
severe 
Allergic 
symptoms and 
other diseases 
Specific IgE; TH2 
cytokines; thick 
SBM  
17q12; 
TH2-
related 
genes 
Corticosteroid 
responsive; TH2-
targeted 
Late-onset 
eosinophilic 
Adult onset; 
often severe 
Sinusitis; less 
allergic 
Corticosteroid 
refractory 
eosinophilia; IL-5 
 Responsive to 
antibody IL-5 and 
cysteinyl leukotriene 
modifiers; 
corticosteroid 
refractory 
Exercise-
induced 
 Mild; 
intermittent 
with exercise 
Mast cell 
activation; TH2 
cytokines; 
cysteinyl 
leukotrienes 
 Responsive to 
cysteinyl leukotriene 
modifiers, beta-2 
agonists and antibody 
to IL-9 
Obesity-
related 
Adult onset Women are 
primarily 
affected; very 
symptomatic; 
AHR less clear 
Lack of TH2 
biomarkers; 
oxidative stress 
 Responsive to weight 
loss, antioxidants  and 
possibly to hormone 
therapy  
Neutrophilic  Low FEV1; 
More air 
trapping 
Sputum 
neutrophilia; TH17 
pathways; IL-8 
 Possibly responsive to 
macrolide antibiotics 
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2.1.3 Diagnosis of asthma 
 
The predominant feature of asthma is airway smooth muscle contraction, 
resulting in obstructed airways during expiration and reduced forced 
expiratory volume in 1 second (FEV1) due to decreased flow rate through the 
lower airways. The most widely used test for lung function is spirometry 
(Dwyer et al., 2012), where measurements of FEV1, forced vital capacity 
(FVC) and their ratio (FEV1/FVC) are measured. When airway smooth 
muscle constricts there is a marked fall in FEV1, a greater time to FVC, and 
an FVC value that remains relatively unchanged, leading to a disparity 
between FEV1/FVC from resting values (Quanjer et al., 1993).  
 
In order to obtain an accurate diagnosis of asthma, the physician should 
perform a consultation with the patient and obtain a full symptoms history 
and physical examination, only when combined with evidence of airway 
hyper-responsiveness and airway reversibility is this the most effective way 
of diagnosing asthma (Dwyer et al., 2012). Objective evidence of 
bronchoconstriction can be obtained following either direct or indirect 
bronchoprovocation challenges, or the assessment of reversibility to 
bronchodilator medication. These are the most effective methods of 
determining Airway Hyper-responsiveness (AHR). Following the direct or 
indirect bronchoprovocation challenges (Table 2.2) there will be a significant 
reduction in expiratory airflow in susceptible individuals due to bronchial 
smooth muscle contraction, leading to reduced FEV1, which can be reversed 
via the administration of β2-agonists in controlled asthma.  
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Table 2.2: Direct and indirect stimuli used to measure bronchial 
responsiveness. Direct stimuli cause bronchoconstriction through action on 
effector cells, indirect stimuli cause bronchoconstriction through action on 
cells which interact secondarily with effector cells (adapted from Borges et 
al., 2011). 
 
 
Direct Bronchoprovocation Stimuli 
 
 
Methacholine 
 
 
Histamine 
 
Acetylcholine 
Carbachol 
 
Prostaglandin D2 Leukotriene C4/D4/E4 
 
Indirect Bronchoprovocation Stimuli 
 
 
Hypertonic aerosols 
(Saline/Mannitol) 
 
 
Hypotonic aerosols 
 
Exercise 
Eucapnic voluntary 
hyperpnoea 
 
Bradykinin Adenosine 
Propanolol Metabisulphite Tachykinins 
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2.1.4 Management of asthma 
 
A number of therapeutic strategies have been employed in an attempt to 
control the symptoms associated with asthma, including β2-agonists, inhaled 
corticosteroids (ICS), and other anti-inflammatory agents. An overview of 
these current therapies has been summarized in Table 2.3.  The degree of 
airway responsiveness is aided by the administration of corticosteroids to 
reduce airway inflammation and the β2-Agonists allow for airway smooth 
muscle relaxation, therefore bronchodilator therapies and inhaled 
corticosteroids are the preferred first choice of therapy for symptom relief in 
asthmatic individuals (McFadden et al., 1994).  
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Table 2.3: Therapies for control of asthma and their mode of action. 
 
Therapy Mode of Action 
β2 – agonists • Increase levels of cAMP to relax bronchial smooth 
muscle through the inhibition of myosin light chain 
kinase. (Donohue, 2004) 
Corticosteroids • Act upon the glucocorticoid receptor to elicit a 
number of anti-inflammatory mechanisms to aid in 
the reduction of airway inflammation (Barnes & 
Adcock, 2009) 
 
Leukotriene receptor antagonists 
• Inhibit antigen-induced contraction of bronchial 
smooth muscle 
• Inhibit eosinophil activity  
• Reduce sputum eosinophilia 
• Reduce exhaled nitric oxide levels 
• Improve allergen-induced decline in FEV1  
(Horwitz et al, 1998) 
Anti-cholinergic therapies • Inhibit muscarinic receptors (M1, M2 and M3 subtypes, 
respectively) decreasing the effects of vagal 
stimulation on the lung. (Donohue, 2004) 
Mast cell stabilizers • Prevent the release of the mediators of type I allergic 
reactions, such as histamine, from sensitized mast 
cells. (O’Byrne, 2004)  
PDE4 Inhibitors • Prevent the hydrolysis of cAMP, leading to 
bronchodilation and reduced inflammation 
• Inhibition of cell trafficking  
• Activation of inflammatory cells  
(Adcock et al, 2008). 
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2.2 Asthma and the elite athlete: Exercise-induced 
bronchoconstriction 
 
The transient narrowing of the airways, which limits expiration and occurs 
during or following exercise is termed, exercise-induced bronchoconstriction 
(EIB) (Anderson et al., 2005). EIB is reversible either spontaneously or via 
therapeutic intervention (Anderson et al., 2005). According to Anderson et 
al., (2005) EIB is usually classed as a 10% reduction in forced expiratory 
volume in 1 second (FEV1) from the pre-exercise value and is most 
commonly reported in people who are already clinically recognised 
asthmatics, usually stemming from either atopy or increased sputum 
eosinophilia. The term exercise-induced asthma (EIA) is mainly used when 
EIB occurs and there is also a previous history of physician diagnosed 
asthma (e.g. atopic). 
 
2.2.1  Pathophysiology of EIB 
 
According to Parsons et al. (2013) the pathogenesis of EIB occurs following 
a modest period of high-intensity exercise sufficient to markedly increase 
minute ventilation, resulting in a prototypical response consisting of 
bronchoconstriction, occurring predominantly following the cessation of 
hyperpnoea and usually lasting between 30-90 minutes if left untreated.  
Susceptibility to EIB can vary significantly between individuals, occurring 
variably in subsets of individuals with clinically defined asthma (McFadden et 
al., 1994), individuals without a known history of asthma (Molphy et al., 
2014) and also elite athletes (Dickinson et al., 2011).  
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If the environment in which a sporting activity takes place has increased 
numbers of pollutants and is extremely dry/cold, this can lead to increased 
need for the air to be filtered, warmed and humidified. The problem 
therefore, is that due to the high ventilatory demand of these activities, there 
is a loss of the protective effects of nasal breathing as they switch to mouth 
breathing (~ >100 L/min) to achieve higher ventilation (Rundell et al., 2015). 
This places a greater strain on the respiratory system as the lower airways 
are recruited to warm and humidify the air, and pollutants in the air are 
deposited in the airways (Rundell et al., 2014; Anderson et al., 2008).  
 
The overall effect of these stressors is that, in susceptible individuals, 
airways can become hyper-responsive, causing bronchoconstriction and 
airway hyper-responsiveness (AHR), resulting in EIB (Fitch et al., 2012). In 
subjects that are susceptible to EIB, there are increases in levels of exhaled 
nitric oxide (Scollo et al., 2000), leukotrienes (Carraro et al., 2005; Hallstrand 
et al., 2005) mast cell expression (Hallstrand et al., 2010) and epithelial 
shedding into the lumen (Hallstrand et al., 2005). The signalling cascades 
and potential mechanisms for the process of airway smooth muscle 
contraction in response to exercise are described in figure 2.3. 
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Figure 2.3: Schematic showing the proposed cascade of exercise-induced changes 
to the airway epithelium leading to exercise-induced bronchoconstriction in 
susceptible individuals (Adapted from Price et al., 2014c) 
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2.2.2 Prevalence of Exercise-Induced Bronchoconstriction 
 
Exercise induced bronchoconstriction is estimated to occur in up to 90% of 
asthmatics (McFadden et al., 1994) and in up to 10% of people without a 
known history of asthma (Gotshall et al., 2002). It is important that EIB can 
be identified in order to decrease the likelihood of any adverse events 
occurring during exercise (Backer et al., 2007). Recent work has indicated 
that bronchoconstriction induced by hyperpnoea can have prevalence as 
high as 13% in previously undiagnosed individuals (Molphy et al., 2014). 
 
The occurrence of EIB is greater in elite athletes than in the general 
population (Dickinson et al., 2005; Fitch, 2006; Parsons et al., 2007). There 
are certain sports where the prevalence of asthma or EIB is extremely high. 
Sports with high EIB prevalence include swimming (76%), cross-country 
skiing (winter athletes) (42%) and rowing (31%) (Bougalt et al., 2011; 
Pohjantahti et al., 2005; Dickinson et al., 2011). This higher prevalence can 
be due to increased ventilatory demand of the activity (Parsons et al., 2007), 
increased numbers of pollutants in the sporting environment (Rundell et al., 
2013) and harsh low humidity or cold environments (Sue-Chu et al., 2012). 
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2.2.3 Diagnosing EIB 
 
When diagnosing EIB the American Thoracic Society (Parsons et al., 2013) 
state that a diagnosis is made based upon changes in lung function post-
exercise, not based upon the presence of symptoms. This is due to the low 
sensitivity and specificity of self-reported symptoms in establishing EIB 
(Parsons et al., 2007; Hallstrand et al., 2002; Rundell et al., 2001).  
 
In addition to measuring a fall in FEV1 post-exercise it is also accepted that 
an objective bronchoprovocation challenge can be used (Parsons et al., 
2013). There are two methods of challenge testing dependent upon whether 
the bronchial smooth muscle is challenged directly (e.g. methacholine 
challenge) or indirectly (e.g. eucapnic voluntary hyperpnoea challenge, 
mannitol challenge, hypertonic saline) 
 
An indirect airway challenge is a means of provoking the airways in a 
manner which will elicit bronchoconstriction in susceptible individuals. 
Spirometry is performed both pre- and post- an indirect airway challenge, 
with EIB identified following a drop in lung function (FEV1), with the value of 
the drop needed to categorise EIB differing between challenge modalities 
(Holzer et al., 2002). 
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2.2.3.1 Direct airway challenges 
 
Direct airway challenges provoke the airway smooth muscle directly; these 
tests are useful in determining whether an individual is susceptible to airway 
smooth muscle contraction, an example of which is the methacholine 
challenge (Holley et al., 2012). The methacholine challenge involves the 
cumulative inhalation of 5 increasing dosages of methacholine. At each 
stage FEV1 is measured to detect a fall of 20% from baseline levels. 
Methacholine concentrations inhaled consist of 0.0625, 0.25, 1, 4 and 16 
mg·mL-1. Methacholine acts upon airway smooth muscle directly and a fall of 
20% or more will only occur in susceptible individuals who exhibit AHR 
(Holley et al., 2012).   
 
 
2.2.3.2 Indirect airway challenges 
 
Examples of indirect airway challenges used to identify EIB are the 
laboratory based exercise challenge, the sport-specific exercise challenge, 
the eucapnic voluntary hyperpnoea (EVH) challenge and the dry powder 
mannitol challenge. Each of these challenges have varying degrees of 
specificity, sensitivity and validity dependent upon how closely they match 
the original stimulus for EIB in the individual being tested (Anderson et al., 
2010).   
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The exercise challenge involves the completion of a short bout of high 
intensity exercise sufficient to significantly increase minute ventilation to 
roughly 21 x baseline FEV1 (Parsons et al., 2013). It is recommended that 
the air is dry, a nose clip should be worn and that heart rate reaches roughly 
80-90 predicted max (~220-age). It is also recommended that exercise 
should continue at this high level for at least 4-6 minutes and sport-specific 
exercise is preferable.  
 
Anderson et al. (2001) state the EVH challenge consists of baseline 
measurements of FEV1, recorded from three maximal voluntary flow-volume 
manoeuvres. The challenge requires participants to attain target minute 
ventilation (V̇E) of 85% of their predicted maximal voluntary ventilation rate 
(MVV) (FEV1 x30) for 6 minutes. During the 6 minutes, participants breathe 
air from a compressed gas cylinder containing 21% Oxygen, 5% Carbon 
Dioxide and 74% Nitrogen. The gas is delivered to each participant via a gas 
cylinder, reservoir and a two-way valve. V̇E is recorded by calculating the 
volume of air passing through a dry gas meter every minute.  After the 6 
minute EVH challenge, two consecutive maximal voluntary flow-volume 
loops were measured at 3, 5, 7, 10 and 15 minute time-points, with the 
highest of the two FEV1 values recorded. A fall in FEV1 greater than 10% on 
two successive occasions post-challenge results in a positive test. 
 
With reference to Holley et al. (2012) it is noted that EVH is superior to 
methacholine for detecting EIB in non-athletes, this consolidates the findings 
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of Pedersen et al. (2008) who concluded that EVH is preferable to both 
methacholine and exercise challenge in elite swimmers. 
 
EIB can be identified by the individual response to the indirect airway 
challenge and this term denotes the phenomena of the airways constricting 
in association to an exercise-related stimulus (Parsons et al., 2013). An 
individual that has other environmental triggers (e.g. atopy), alongside a 
previous history of associated symptoms would then have sufficient 
information to be accurately diagnosed by a consulting physician of 
exhibiting exercise-induced asthma (EIA).  
 
To further improve the validity of the EIB diagnosis, markers of inflammation 
can be measured. An example of which is the fractional exhaled nitric oxide 
(FeNO) test, which measures the amount of nitric oxide present in exhaled 
air. This value will rise in association with increased inflammatory markers in 
the airway such as eosinophils. Therefore FeNO is an indirect marker of 
airway inflammation. Care is warranted, however, when using FeNO as an 
indirect marker of airway inflammation due to the susceptibility of the test to 
be altered by dietary nitrate consumption (Olin et al., 2001). 
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2.2.4 Treatment of EIB 
 
Treatment for EIB can involve the administration of short-acting β2-agonists, 
long-acting β2-agonists, inhaled corticosteroids or combination therapy. 
Exactly which treatment methods are needed fall at the discretion of the 
consulting physician, given an adequate patient symptoms history and 
broncho-provocation challenge/reversibility test result. In some instances a 
physician may deem it necessary to incorporate other medications into the 
treatment regimen such as leukotriene receptor antagonists, theophyllines or 
chromones. The British Thoracic Society (BTS) recommend that immediately 
prior to exercise, short-acting β2-agonists are the drug of choice, with the 
addition that for most patients, exercise-induced asthma is an expression of 
poorly controlled asthma and that regular treatment including inhaled 
steroids should be reviewed (British Thoracic Society, 2009). These 
recommendations are also supported within the guidelines of the American 
Thoracic Society (ATS) (Parsons et al., 2013). 
 
The most common therapy for the management of EIB in the sporting 
population is via the administration of β2-agonist medications for the rapid 
relief of bronchoconstriction (Fitch, 2006). Short-acting β2-agonists act to 
reverse the bronchoconstriction of the airways through stimulation of the β2 
adrenergic receptor (β2-receptor) present on bronchial smooth muscle, 
allowing the muscle to relax and the airways to dilate restoring airway 
function (Hoffman, 2001).  
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Athletes are more likely to require the use of β2-agonists for the prevention 
and/or relief of bronchoconstriction caused by exercise. According to Fitch, 
(2006) salbutamol use accounted for around 6% of all athletes competing at 
the 2000 Sydney Olympic Games. Fitch, (2006) also identified that 
salbutamol was used c.5% of all athletes competing at the 2004 Athens 
Olympic Games. Indeed, Dickinson et al. (2005) identified that around 21% 
of British athletes used inhaled β2-agonists to protect against 
bronchoconstriction at the 2000 Sydney Summer Olympic Games and the 
2004 Athens Summer Olympic Games. It is notable that the disparity 
between the figure presented by Fitch (2006) and those of the British cohort 
may be due, in part, to selection criteria of certain countries which can rule 
out asthmatic individuals. Other countries may also prefer to treat asthmatic 
symptoms with herbal remedies or mechanical strategies and finally, the 
type of sports in which the British team have the highest number of 
representatives, are potentially more asthmogenic in terms of ventilatory 
demand and environmental pollutants. 
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2.3  β2-adrenergic receptors 
 
Adrenergic receptors are cell surface proteins which pick up signals from the 
sympathetic and parasympathetic nervous system and respond by altering 
the actions of the cell in which the receptor is located. The adrenergic 
receptors are G-Protein Coupled Receptors (GPCRs) that link onto 
heterotrimeric G proteins (Westfall et al., 2011). Overall, there are three main 
types α1, α2 and β each with three subtypes of adrenergic receptor including; 
α1A, α1B, α1D, α2A, α2B, α2C, β1, β2 and β3 receptor. Each of these adrenergic 
receptors are localised to different tissues within the body and act via 
signalling cascades following G-protein coupled activation, these signalling 
cascades occur to a varying extent and to differing physiological effects 
(Westfall et al., 2011).  
 
The β2-adrenergic Receptor (β2-receptor) is a subtype of the adrenergic 
receptors which, when activated by adrenaline and noradrenaline in the 
sympathetic nervous system, can exert their effects on muscle function 
and/or neurotransmitter release, dependent upon tissue localisation (Lynch 
et al., 2008). The principal sites of the β2-receptor are the: heart; lung; blood 
vessels; bronchial smooth muscle; gastro-intestinal (GI) smooth muscle; 
kidney; skeletal muscle; olfactory bulb; piriform cortex; cortex; and 
hippocampus. The predominant effects of β2-receptor activation are smooth 
muscle relaxation and increased skeletal muscle contractility (Westfall et al., 
2011). Figure 2.4 illustrates the signalling cascade induced by β2-receptors 
present on airway smooth muscle. 
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Figure 2.4: Schematic representation of the signalling cascade of β2 adrenergic 
activation showing how this activates G-protein, stimulating adenylate cyclase, 
which in turn converts ATP to the second messenger cAMP, this then activates 
PKA which acts upon a number of mechanisms to cause downstream effects which 
include inhibition of mechanisms responsible for smooth muscle contraction.  
β2R – β2 Receptor; Gs – G-Protein s α subunit; AC – Adenylate Cyclase; ATP – Adenosine Tri-Phosphate; cAMP – 
cyclic Adenosine Mono-Phosphate; PKA – Protein Kinase A;  MLCK – Myosin Light Chain Kinase; PDE – 
Phosphodiesterase; HSP-20 – Heat Shock Protein-20; SR – Sarcoplasmic Reticulum ; RyR – Ryanodine Receptor; 
Gq – G Protein q; Gi – G Protein i α subunit; (Adapted from Pierce et al., 2002) 
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The adrenergic receptors of the sympathetic nervous system can be 
activated by compounds that mimic the effects of adrenaline and 
noradrenaline (NA), such as catecholamine and sympathomimetic amines. 
These substances can be classified according to their mode of action which 
are: direct-acting; indirect-acting; or mixed-acting sympathomimetics (Lynch 
et al., 2008). These classifications are dependent upon whether they actively 
stimulate the adrenergic receptor; whether they release NA from the synaptic 
nerve and block NA transport or block metabolising enzymes; or whether 
they act upon both mechanisms, respectively.  
 
Sympathomimetic amines, which can be synthesized according to their 
molecular characteristics to exert their effects upon specific receptors, are 
important contributors to pharmacotherapy.  These synthetic molecules can 
be used to stimulate or block signalling cascades to promote downstream 
actions on skeletal or smooth muscle (Bowman et al., 1969). The key feature 
of the β2-receptor is that it is present in bronchial smooth muscle and is 
responsible for bronchial smooth muscle relaxation, making the β2-receptor 
agonist the ideal compound for the treatment of respiratory distress caused 
by bronchial smooth muscle contraction (bronchoconstriction) (Westfall et 
al., 2011).  
 
The β2-agonists are similar in structure to adrenaline with a single benzene 
ring and an amino group side-chain. Figure 2.5 provides examples including 
clenbuterol, salbutamol (albuterol) and terbutaline (Lynch et al., 2008). 
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Figure 2.5: Chemical structures of the β2-agonists clenbuterol, salbutamol 
and terbutaline. (Fan et al., 2013) 
 
The long-acting β2-agonists such as formoterol and salmeterol have an 
additional benzene ring attached to the amino-group, which likely accounts 
for their longer duration of action (Waldeck et al., 1996).  
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2.4  β2-agonists and their effects 
 
Whilst traditionally used for the relief of respiratory distress caused by 
bronchoconstriction, it is widely known that some β2-agonists are able to 
increase lean mass whilst also decreasing fat mass (Lynch et al., 2008). This 
effect is commonly known as the repartitioning effect (Emery et al., 1984) 
with the benefits of the β2-agonists’ anabolic properties being utilized 
significantly in the livestock industry to improve meat quantity and quality 
(Sillence et al., 2004). Not surprisingly the use of β2-agonists such as 
clenbuterol, with well-known repartitioning properties became frequently 
used in competitive bodybuilding (Prather et al., 1995) for athletes hoping to 
increase lean mass and decrease fat. This then led to the use of β2-agonists 
in athletes competing in sports that involve strength and power performance 
(Prather et al., 1995) in the hope of increasing muscle mass, decreasing fat 
mass and improving power to bodyweight ratio.  
 
Lynch and Ryall (2008) explain that acute administration of adrenaline has 
the ability to increase fast-twitch muscle fibre force production but not that of 
slow-twitch muscle fibre.  With the β2-agonists being similar in structure to 
adrenaline it has been suggested that β2-agonists  are able to also improve 
muscle force production, however a study by Ha et al. (1999) examining the 
effects of the acute administration of the β2-agonist terbutaline on muscle 
force production in rats, found that the proposed improvement in muscle 
contractility was due to changes in the amount of sarcoplasmic reticulum 
(SR) Calcium (Ca2+) released and the speed of SR Ca2+ re-uptake rather 
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than changes in Ca2+ sensitivity or the ability of the muscle contractile 
proteins to generate force. This proposed mechanism is in agreement with 
Brodde and Michel (1999) when describing the effects of β2-receptor 
activation in the mammalian heart, which results in improved Ca2+ influx in 
the SR through phosphorylation of L-type Ca2+ channels and increased Ca2+ 
uptake in the SR through phosphorylation of phospholamban.  
 
With chronic high-dose administration of β2-agonists there can be an 
increase in muscle mass associated with increased protein synthesis (Choo 
et al., 1989) and decreased protein degradation (Benson et al., 1991). The 
extent of the anabolic effects of β2-agonists largely depend upon: type of β2-
agonist; mode of administration; dosage; frequency of administration; and 
duration of treatment, with animal models also exhibiting the largest 
increases in muscle mass following β2-agonist administration (Lynch et al., 
2008).  
 
β2-agonists have been proven to have powerful lipolytic properties due to 
their ability to increase thermogenesis (Arch et al., 1984) and impact upon 
adipose tissue. Adrenoreceptors present upon adipose tissue, when 
stimulated, can increase lipolysis and when combined with the increased 
energy expenditure that is associated with β2-agonist use, results in an 
overall increase in fat burning potential (Mills et al., 2000). 
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Along with these purported mechanisms for so-called advantageous effects 
of β2-agonist administration for athletes, there are also a large range of 
deleterious side-effects of their use. These have far-reaching implications for 
the health and well-being of the athlete, who may take these substances in 
supra-therapeutic doses for performance enhancement. According to Lynch 
and Ryall (2008) since 1990 the use of β2-agonists for the purpose of 
performance enhancement has become increasingly prevalent and many of 
these athletes are unaware of the adverse side-effects of taking these drugs.  
 
Some of the side-effects of β2-agonists in the treatment of respiratory 
symptoms are their ability to exert their effects upon skeletal muscle and 
cardiac smooth muscle leading to undesirable side-effects such as 
tachycardia and fine tremor (Prather et al., 1995). When used via inhalation 
at therapeutic doses for topical administration in the lower airways, these β2-
agonists can have minimal side-effects, however when taken orally or intra-
venously they can exert greater systemic effects which can have the 
potential to cause more notable side-effects as mentioned by Lynch and 
Ryall (2008) in their review of the effects of  β2-agonists on skeletal muscle, 
whereby high dose β2-agonist administration produced an increase in 
skeletal muscle mass and a concomitant decrease in body fat in animal 
models. Prather et al. (1995) explain that acute side-effects associated with 
β2-agonist use include: nausea; headaches; and insomnia. With more severe 
side-effects resulting in muscle tremor, palpitations, muscle cramps, 
headache and peripheral vasodilatation. Interestingly, as highlighted by 
Salpeter et al., (2004) in a meta-analysis of the effects of prolonged β2-
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agonist use, there is an increased tolerance following as little as 1 week of 
consistent use, leading to the deleterious side effect of being unresponsive 
to treatment during an adverse event. 
 
A study by Ingalls et al. (1996) looking at the effects of chronic high-dose 
administration of the β2-agonist clenbuterol on exercise performance in mice 
over a period of 8 weeks, found that although clenbuterol increased muscle 
mass, it had a negative effect on endurance exercise performance. 
Alongside decreased exercise performance there are also many studies that 
highlight the negative effects that the β2-agonist clenbuterol has on cardiac 
muscle hypertrophy, leading to instances of sudden death in both animal 
models (Duncan et al., 2000) and human case studies (Kierzkowska et al., 
2005). In addition, chronic high dose oral administration of clenbuterol and 
salbutamol in rats has been shown to result in cardiac hypertrophy (Duncan 
et al., 2000; Cepero et al., 2000). 
 
Brodde and Michel (1999) state that the relative abundance of β2-receptors 
in the heart is about 40% with the predominant receptor being the β1-
receptor, however they also outline that drugs with a relative affinity for β2-
receptors lose that preferential affinity with increasing concentrations and 
bind less selectively. They highlight that in contrast to cardiac muscle, the 
sino-atrial node (SAN) has a 2.5 fold higher concentration of β2-receptors 
than β1-receptors. These findings could be the reason why high-dose studies 
involving β2-agonists have a large correlation with cardiac abnormalities 
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(Duncan et al., 2000; Kierzkowska et al., 2005), especially with dosages that 
result in high systemic bioavailability of the β2-agonist (Duncan et al., 2000; 
Kierzkowska et al., 2005; Cepero et al., 2000). 
 
The type, dose, mode of administration and systemic bioavailability of a 
given β2-agonist all affect its mode of action and duration of action, which in 
turn affect its potential to cause unwanted side-effects (Lynch et al., 2008). 
With the primary desired mode of action for β2-agonists in healthcare being 
bronchial smooth muscle relaxation, in the prevention of obstructive airways 
disease, it is crucial that athletes are informed about the potential for 
adverse events following supra-therapeutic use. It is essential that governing 
bodies ensure strict guidelines to oversee the legitimate use of β2-agonists in 
and out of competition, with the primary concern being the health and well-
being of the athlete, with the hope of deterring potential supra-therapeutic 
use in the hope of gaining a competitive advantage. 
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2.5  Status of short-acting β2-agonists on the WADA Prohibited List 
of Substances and Methods 
 
Throughout the past 40 years the International Olympic Committee (IOC) 
has changed their regulations regarding the use of short-acting β2-agonists 
in competition on a number of occasions. The constantly changing scientific 
literature regarding the ergogenic properties of the β2-agonists through 
differing routes of administration (oral vs. inhaled) has influentially shaped 
these regulations (Martineau et al., 1992; Collomp et al., 2010; Pluim et al., 
2011; Decorte et al., 2008; Larsson et al., 1997; Meeuwisse et al., 1992; Le 
Panse et al., 2006; Caruso et al., 2005; McKenzie et al., 1983; Van Baak et 
al., 2000). The regulations imposed have been largely due to increasing 
concerns over possible unnecessary use of these medications by athletes 
and also due to health concerns regarding β2-agonist use (Fitch, 2006; 
Dickinson et al., 2005; Lynch et al., 2008). The specific changes in the status 
of the β2-agonists are described in table 2.4. 
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Table 2.4: The history of the β2-agonists and their guidelines for use in the athletic 
population since 1972 (Adapted from Fitch, 2006). 
 
History of β2-Agonists Guidelines for use in athletes 
1972 Permission to administer inhaled salbutamol refused by IOC-MC  
1975 Inhaled salbutamol and terbutaline permitted with prior notification  
1976 Olympic team doctors notified IOC-MC of intended use of salbutamol or 
terbutaline 
 
1980 Permission to use fenotorol by inhalation granted prior to the Moscow 
Olympics 
 
1984 Fenotorol prohibited at the Sarajevo winter games because of metabolism 
to p-hydroxyamphetamine 
 
 
1984 
Because of concerns of the effect of air pollution on bronchial airways in 
Los Angeles, team doctors are permitted to notify β2-agonists post-
administration 
 
1985 Biltolterol, orciprenaline (isoprotenerol) and rimiterol added as permitted 
β2-agonists. 
 
1986 Notification of administration of β2-agonists to IOC-MC no longer required; 
oral β2-agonists reconfirmed to be prohibited. 
 
 
1992 
Clenbuterol prohibited. Two athletes disqualified in Barcelona for using 
clenbuterol, β2-agonists listed as anabolic agents when administered 
systemically (orally or by injection) 
 
 
1993 
Biltolterol, orciprenaline, and rimiterol no longer permitted β2-agonists. 
Notification of administration of permitted inhaled β2-agonists re-
introduced. 
 
1994 Permission to administer inhaled salmeterol refused by IOC-MC.  
1996 Salmeterol permitted to provide prolonged protection from exercise-
induced asthma. 
 
2001 Formoterol permitted  
 
2001 
Because of concerns at the large and increasing number of athletes inhaling 
β2-agonists, as a health measure, the IOC-MC introduces the necessity for 
demonstrating that an athlete has asthma and/or EIB and is given a 
therapeutic use exemption certificate (TUE). 
 
2009 The World Anti-Doping Agency establishes regulations for all athletes to 
obtain a TUE for the use of β2-agonists. 
 
2010 Salbutamol and Salmeterol permitted via inhalation with a declaration of 
use. 
 
 
2012 
Salbutamol, Salmeterol and Formoterol permitted via inhalation without 
declaration of use. Monitoring of salbutamol and formoterol in the urine 
within threshold limits. 
 
2012 Terbutaline remains prohibited except when used with a TUE certificate  
 
IOC-MC – International Olympic Committee Medical Commission; EIB – Exercise-Induced Bronchoconstriction 
- Stricter guidelines for β2-agonist use        - Relaxation of guidelines for β2-agonist use 
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In 2002 the International Olympic Committee (IOC), guided by the 
International Olympic Committee – Medical Commission (IOC-MC) set 
guidelines for all athletes to provide objective evidence of 
bronchoconstriction via the performance of an objective bronchoprovocation 
challenge. These guidelines were later adopted by WADA in the 2009 
Prohibited List of Substances and Methods (WADA, 2009). This was set due 
to increasing prevalence of β2-agonist use amongst athletes, which was not 
in correlation with the number of athletes using inhaled corticosteroids, 
leading to fears that athletes were not receiving adequate care and may 
have been over-using β2-agonists, leading to increased tolerance of the β2-
agonist medication (Fitch, 2006; Anderson et al., 2006a).  
 
The exact increases are outlined by Fitch, (2006) who highlights that 
between the 1984 Los Angeles Olympic Games and the 1996 Atlanta 
Olympic Games there was a 212% increase in the use of β2-agonists by 
athletes. This figure increased by a further 151% between the Atlanta games 
and the 2000 Sydney Olympic Games, leading ultimately to the IOC-MC 
decision to change from the requirement for declared use through to the 
requirement for objective evidence of bronchoconstriction in 2001, with the 
health and wellbeing of the athlete being the main influencing factor for the 
decision (Fitch, 2006).  This decision by the IOC-MC for the provision of 
demonstrable evidence of EIB led to the decision by WADA to place inhaled 
β2-agonists on the prohibited substance list in 2009, whereby their use could 
only be granted via a therapeutic use exemption (TUE) certificate. 
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The decision by the IOC-MC in 2002 to provide objective evidence of 
bronchoconstriction did not significantly affect the number of athletes 
requiring the use of short-acting β2-agonists at the following Olympic cycle 
(Fitch et al., 2006; Dickinson et al., 2005). The requirement to undertake a 
bronchoprovocation challenge was able to successfully identify previously 
undiagnosed individuals with bronchoconstriction and was able to 
successfully identify individuals that were falsely diagnosed with EIB 
(Dickinson et al., 2005; Ansley et al., 2012).  
 
The advantages of EIB testing were evidenced in a study by Dickinson et al., 
(2005) where the British Olympic team athletes who were currently using 
inhalers or were referred for screening, were tested for EIB prior to the 2004 
Athens Olympic Games, via either a reversibility test, an exercise challenge 
or via a eucapnic voluntary hyperpnoea (EVH) challenge, which is the IOC-
MC preferred method of screening for EIB (Anderson et al., 2000; Holzer et 
al., 2002; Anderson, et al., 2003). The findings of the study highlight that in 
this cohort of elite athletes 20.7% presented with demonstrable evidence of 
EIB. This figure did not differ from the proportion of British athletes using β2-
agonists (21.2%) at the previous Olympic cycle where demonstrable 
evidence was not required. The study concluded that screening of athletes is 
warranted, as it is able to maintain standards of care by highlighting 
previously undiagnosed individuals and also identifying any false positive 
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diagnoses, allowing for better control of asthmatic symptoms during training 
and competition. 
 
WADA changed the status of the short-acting β2-agonists in 2010 to allow for 
the use of inhaled salbutamol and salmeterol via declaration of use (DoU) 
which was then relaxed further in 2012 when salbutamol, salmeterol and 
formoterol were permitted to be taken within recommended dosages without 
the requirement for a DoU (WADA 2010; WADA 2012). Further to this 
requirement existing urinary thresholds for salbutamol (1000 ng.mL-1) and 
formoterol (30 ng.mL-1) were outlined with the aim of distinguishing between 
legitimate therapeutic inhaled use and prohibited oral use (Ventura et al., 
2000; Elers et al., 2011; Eibye et al., 2013). No threshold levels were 
outlined for Salmeterol mainly due to the absence of any oral equivalent. 
Terbutaline is permitted for use by athletes only through the TUE process. 
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2.6 Salbutamol and the elite athlete 
 
Salbutamol is a short-acting β2-agonist that is effective in the treatment of 
bronchoconstriction.  It is predominantly administered via an inhaled dose of 
100 µg per actuation; however it can also be administered orally via a 2 mg 
tablet.  
 
Salbutamol is currently permitted for use by athletes and is the only short-
acting β2-agonist permitted by WADA without TUE. Guidelines for use 
indicate that athletes are allowed to up to 1600 µg pro re nata (PRN). Urinary 
threshold limits for salbutamol have been established in which a 
concentration above 1000 ng·mL-1 constitutes an adverse analytical finding 
(AAF). Above this there is also a decision limit of 1200 ng·mL-1 (WADA, 
2015; Elers et al., 2011). 
 
The use of salbutamol amongst the athletic population is around 5% of all 
athletes (Fitch, 2006). Until recently there have been mixed reports 
regarding the use of salbutamol and its ergogenic potential (Van Baak et al., 
2000; Decorte et al., 2013; McKenzie et al., 1983; Le Panse et al., 2006; 
Caruso et al., 1995; Caruso et al., 2005). More recent findings indicate that 
inhaled salbutamol up to 1600 µg taken in either acute or accumulative 
doses over a one-off or 24 hour period does not improve endurance or 
strength and power performance (Pluim et al., 2011; Dickinson et al., 2014a; 
Dickinson et al., 2014b; Decorte et al., 2008; Sporer et al., 2008).  
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Further to these studies, a study by Elers et al. (2012a) suggests inhaling an 
acute dose of up to 4000 µg of salbutamol results in no improvement in 
cycling time to exhaustion or oxygen kinetics. Accordingly, from a 
performance perspective the current WADA guidelines permitting athletes to 
inhale up to 1600 µg in a 24 hour period are appropriate as there appears to 
be no resultant improvement in performance in non-asthmatic athletes.  
However, more recent work by Kalsen et al. (2013) has highlighted 
performance improvement following combined short- (1600 µg salbutamol) 
and long-acting β2-agonists (200 µg salmeterol; 36 µg formoterol).  
 
Decorte et al. (2013) have shown performance improvement in quadriceps 
fatigability following a supra-therapeutic (800 µg salbutamol) dose of β2-
agonist. Interestingly the findings of Decorte et al. (2013) are in contrast to 
the findings of the same research group (Decorte et al., 2008) who 
previously found no performance enhancement when assessing quadriceps 
force and fatigability with the same supra-therapeutic (800 µg salbutamol) 
dose of β2-agonist. Possible reasons for performance enhancement 
following higher doses is a greater systemic availability of the β2-agonist 
leading to greater activation of the β2-receptors, to date no study has 
investigated the effects of continuous daily use of β2-agonist at the maximum 
WADA daily limit, which may lead to greater systemic availability of the β2-
agonist due to a cumulative effect of repeat administration. 
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In a meta-analysis of the acute performance enhancing effects of β2-agonists 
with regard to oral salbutamol, Pluim et al. (2011) concluded there was weak 
evidence to suggest acute doses of oral salbutamol would significantly 
improve athletes’ anaerobic capacity and strength. A recent study by 
Sanchez et al. (2012) examined the impact of oral salbutamol on maximal 
power from either a single, acute dose (6 mg) or a daily dose (12 mg·day-1) 
for three weeks. The study reported that oral salbutamol resulted in 
significantly improved maximal power with the one-off dose resulting in 
greater gains than three weeks daily intake (14% vs. 8%). The authors 
concluded that acute doses led to greater gains and that long term use of 
oral salbutamol may lead to down regulation of muscle β2-Adrenoreceptors 
resulting in a dampening of the effect of salbutamol on strength gains. The 
study by Sanchez et al. (2012) involved long-term use of oral β2-agonists, 
yet it has also been demonstrated that the same potential for dampening 
down of the β2-receptor occurs following long-term use of inhaled salbutamol 
(Hancox et al., 2002; Salpeter et al., 2004). 
 
The main action of inhaled salbutamol is to act as a bronchodilator to 
reverse the bronchoconstriction of airway smooth muscle. This results in the 
asthmatic airway becoming dilated leading to a reduced airway resistance 
and improvements in minute ventilation (V̇E) and exercise performance 
(Fitch, 2006; Haverkamp et al., 2007). One of the proposed ergogenic 
mechanisms for inhaled salbutamol is a significant bronchodilation in non-
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asthmatic athletes resulting in an improved V̇E during exercise and increases 
in oxygen uptake. Previous research has reported improvements in V̇E 
following acute doses of up to 1600 µg of salbutamol in the absence of an 
improvement in 5 km running time-trial performance in endurance athletes or 
repeated sprint performance in football players (Dickinson et al., 2014a; 
Dickinson et al., 2014b). Prior to this, studies have demonstrated non-
significant improvements in FEV1 of 0.2 L following inhalation of 800 µg 
salbutamol, which did not result in greater V̇E or improved endurance 
performance (Decorte et al., 2008). 
 
Previous studies that have focused on oral salbutamol have primarily 
demonstrated performance gains in strength and power variables (Pluim et 
al., 2011; Sanchez et al., 2012; Caruso et al., 1995; Martineau et al., 1992), 
there remains a possibility that athletes who use oral salbutamol will benefit 
from improved performance. WADA have established threshold limits in the 
urine for the use of salbutamol, such threshold limits should act as a 
deterrent to any athlete that would wish to use oral salbutamol in the hope of 
improved performance, for fear of presenting with an AAF, which may occur 
following the higher oral dose. 
 
Salbutamol is used by individuals who present with bronchoconstriction, in 
athletes this is predominantly exercise-induced bronchoconstriction 
(Anderson, 2001). Many of the studies investigating the effects of 
salbutamol, however, have investigated its effects in healthy individuals 
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(Sanchez et al., 2012; Caruso et al., 1995; Martineau et al., 1992; Decorte et 
al., 2008; Decorte et al., 2013; Kalsen et al., 2013). Within the athletic 
population any ergogenic potential has to be examined within those 
individuals who exhibit with EIB, a recent study by Koch et al. (2013), 
investigated the effects of salbutamol on cycling performance in both healthy 
individuals and EVH positive (EVH+ve) individuals, finding that salbutamol 
significantly increased lung function in both groups but that this improvement 
did not translate to any improvements in exercise performance. The study 
was repeated by the same research group (Koch et al., 2014) investigating 
any performance improvements in females with the same findings. Given 
that exercise in cold, dry environments is known to be most provocative to 
the respiratory system (Sue-Chu et al., 2012) it would be interesting to 
investigate the effects of salbutamol on exercise performance in both healthy 
and EVH+ve individuals in a low humidity environment to determine any 
ergogenic effects, but also to investigate the potential disadvantage that may 
occur in EVH+ve individuals, exercising at low humidity without the broncho-
protective effects of β2-agonists. 
 
Although salbutamol is the only short-acting β2-agonist that is permitted for 
use by athletes, there are also two long-acting β2-agonists salmeterol and 
formoterol that are currently permitted. If an athlete suffers from more severe 
asthma and is unresponsive to salbutamol, or if an athlete suffers from 
adverse side-effects of salbutamol use, then there is currently no other 
available short-acting β2-agonist permitted for use by athletes. It is possible 
however, that if an athlete provides demonstrable evidence of EIB they can 
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be permitted a TUE certificate for the use of the alternative short-acting β2-
agonist terbutaline (WADA, 2015). 
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2.7  Terbutaline and the elite athlete 
 
The majority of athletes treat symptoms of EIB through the use of 
salbutamol, however other β2-agonists, such as terbutaline, are available 
through the therapeutic use exemption (TUE) process. Terbutaline is 
purported to have fewer adverse side-effects than salbutamol (Sanchez et 
al., 2013). Indeed, Sanchez et al. (2013) indicate that due to fewer reported 
side-effects than other β2-agonists, terbutaline may be of benefit to athletes 
for the relief of EIB. Terbutaline is also a fast-acting β2-agonist that is active 
for a maximum of 12 hours whereas salbutamol is active for a maximum of 6 
hours, making terbutaline a desirable treatment option for the athletic 
population (Sanchez et al., 2013). 
 
Unlike the permitted β2-agonists salbutamol, formoterol and salmeterol, 
terbutaline is prohibited during competition except for those athletes who 
have a TUE (WADA, 2015). This prohibited status is largely due to the 
inability to distinguish between inhaled and oral use, with oral use being 
banned for all β2-agonists (WADA, 2015). Whilst investigations into threshold 
limits that can distinguish between inhaled and oral use of terbutaline are 
ongoing, it is important to outline whether there are any performance 
enhancing properties when taken at the therapeutic dose. Certainly there 
have been recent investigations into the performance enhancing effects of 
supra-therapeutic doses of terbutaline which have highlighted an ergogenic 
potential (Kalsen et al., 2014; Hostrup et al., 2014), yet athletes with TUE 
that require the use of terbutaline should only be taking a therapeutic dose 
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for the relief of symptoms, therefore it is this dose (0.5 – 4 mg) that warrants 
investigation for any ergogenic effect. 
 
The highest acute therapeutic dose of inhaled terbutaline that is 
recommended, is up to 4 mg (8 x 0.5mg inhalations) (Prior et al., 1982).  
However the dose required for therapeutic effects can be as low as a single 
inhalation of 0.5mg (Simpson et al., 2014). With a large variation in what 
could be considered the ideal therapeutic dose, athletes that are using 
terbutaline with a TUE may feel the need to take doses towards the higher 
end of the spectrum in order to obtain adequate protection from the 
symptoms of EIB. In a study by Elers et al. (2012b) when trying to distinguish 
between inhaled and oral administration of terbutaline, a therapeutic dose of 
2 mg inhaled terbutaline was chosen and compared against a supra-
therapeutic dose of 10 mg oral terbutaline in order to establish differences in 
urinary concentrations, with a finding that no differences were apparent. With 
no standardised therapeutic dose outlined for the use of inhaled terbutaline 
in athletes with a TUE it is reasonable to assume that athletes would use 
single inhaled doses of either 0.5 mg, 2 mg, or 4 mg.  
 
Hostrup et al. (2014) highlight the ergogenic potential of inhaled terbutaline 
by examining the effects of 15 mg inhaled terbutaline on muscle strength, 
maximal sprint performance and endurance performance in cycling. The 
group found significantly improved muscle strength and sprint performance 
but not endurance performance in trained males. Conversely, Kalsen et al. 
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(2014) also investigated the effects of 15 mg inhaled terbutaline on 
performance, during 300 kcal cycling time-trial, finding no significant 
difference in performance compared to placebo, the study did highlight that 
terbutaline inhalation promotes a shift towards carbohydrate metabolism 
during exercise.  
 
With the requirement of a TUE for the use of inhaled terbutaline during 
competition being largely due to the inability to distinguish between an 
inhaled dose and a prohibited oral dose in urine, investigations into the urine 
concentrations following route of administration have been warranted (Elers 
et al., 2012b). In a recent study by Elers et al. (2012b) investigating the 
blood and urinary concentrations of terbutaline following either an inhaled or 
an oral dose, it was highlighted that although significant differences were 
found between the doses, no cut-off value could be established between the 
two modes of administration.  
 
If a cut-off value were able to be established then it is possible that inhaled 
terbutaline would be able to be monitored in much the same way as both 
salbutamol and formoterol, where an adverse analytical finding (AAF) would 
indicate possible supra-therapeutic use or oral administration which may 
have ergogenic potential (Hostrup et al., 2014). Indeed a recent study by 
Sanchez et al. (2013) investigating the effects of a supra-therapeutic (8mg) 
oral dose of terbutaline on aerobic performance found no significant 
difference versus placebo, highlighting the lack of ergogenic potential of 
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terbutaline even at high doses. In the study by Hostrup et al. (2014) the main 
findings were improved muscle strength and sprint performance. It is 
possible therefore, that terbutaline is only ergogenic in these types of 
performance tasks.  
 
A recent study by Simpson et al. (2013) highlights the protective effect of a 
single inhaled dose of 0.5 mg terbutaline. It is possible that many athletes 
would only need to inhale 0.5 mg terbutaline for effective protection against 
EIB, however it is likely that they may choose higher doses if they thought it 
would be more beneficial for the prevention or relief of symptoms. Further 
research is warranted that could establish a cut-off threshold permitting 
athletes to use a single inhaled dose of 0.5 mg terbutaline, providing 
effective protection against EIB for the elite athlete and allowing the use of a 
broader range of β2-agonists, which would be beneficial for athletes who 
suffer side-effects of currently permitted medications (Sanchez et al., 2013). 
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2.8 Summary 
 
The use of β2-agonists in sporting competition has been a constant matter of 
debate for doping authorities. The decision to permit or restrict the use of 
these bronchodilating agents has been regularly altered. Athletes who 
experience respiratory symptoms during exercise should have adequate 
therapies available to prevent adverse events during training and 
competition. Research examining the ergogenic properties of acute 
administration of the β2-agonist salbutamol at therapeutic doses has so far 
been unable to ascertain any performance enhancing properties, leading to 
permission being granted by the IOC-MC and WADA for athletes to use 
inhaled salbutamol. For athletes that may have unwanted side-effects from 
salbutamol it is important that another short-acting β2-agonist is available to 
use during competition, such as terbutaline. The IOC-MC and WADA 
currently do not permit the use of terbutaline without a TUE (WADA, 2015).  
 
The difficulty distinguishing between inhaled and oral use of terbutaline is a 
possible factor leading to its inclusion on the Prohibited List (WADA, 2015). 
The β2-agonist literature supports the hypothesis that the use of orally 
administered β2-agonists is potentially ergogenic due to the high systemic 
bioavailability following this route of ingestion. Studies that could highlight 
the difference between route of administration of terbutaline and the 
ergogenic properties of therapeutic dosages are required. This will establish 
a better understanding of terbutaline as a potential addition to the current 
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asthma medications available to the elite athlete, with the healthcare of the 
elite athlete being the main priority. 
 
2.9 Statement of purpose 
 
The purpose of the studies contained in this thesis are to assist WADA in the 
implementation of regulations on the use of inhaled short acting β2-agonists 
and assist in the resolution of contested anti-doping rule violations.  The 
initial study will aim to determine the effects of chronic high-dose salbutamol 
on endurance, strength and power performance. Furthermore, this study 
aims to highlight the pharmacokinetics of long-term use.  The second study 
aims to investigate the urinary excretion of varying dosages of terbutaline 
through different routes of administration. It also aims to provide a clear 
distinction between oral and inhaled routes and varying dosages of 
terbutaline through analysis of urinary concentration. Furthermore, the study 
will aim to look at a wider cross-section of individuals examining potential 
differences between gender and race.  The third study will investigate the 
effect of varying therapeutic inhaled dosages of terbutaline on exercise 
performance, aiming to highlight the potential ergogenic properties of inhaled 
terbutaline. The final study will investigate whether inhaled salbutamol 
provides a health and/or 3 km time-trial performance benefit in a low 
humidity environment in individuals with and without a positive EVH 
challenge.  
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2.10 Hypotheses 
 
Hypothesis 1: Long-term use of 1600 µg inhaled salbutamol per day for 6 
weeks does not significantly improve performance compared to placebo. 
Hypothesis 2: Long-term (1600 µg.day-1 for 6 weeks) inhaled salbutamol 
does not lead to urinary concentrations above the WADA urinary threshold. 
Hypothesis 3: An acute therapeutic dose (2 mg) of inhaled terbutaline will 
lead to significantly lower urine concentrations than an acute therapeutic 
dose (5 mg) of oral terbutaline. 
Hypothesis 4: Repeated therapeutic dose (8 x 1 mg over 36 hours) inhaled 
terbutaline will lead to significantly lower urine concentrations than repeated 
therapeutic dose (4 x 5 mg over 36 hours) oral terbutaline. 
Hypothesis 5: Inhaled terbutaline at two different therapeutic dosages of 2mg 
and 4mg does not lead to improved 3km running time-trial performance. 
Hypothesis 6: EVH positive individuals exercising in a low humidity 
environment will have decreased 3 km running time-trial performance and 
decreased lung function compared to pair matched EVH negative controls. 
 Hypothesis 7: EVH positive individuals exercising in a low humidity 
environment will have improved lung function and 3 km running time-trial 
performance following salbutamol intervention, compared to pair matched 
EVH negative controls.  
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3. General Methods 
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3.1 Physical Activity Readiness Questionnaire (PARQ)  
 
All participants were free from chest infection for at least 4 weeks prior to 
assessment; they were not taking any medication and there were no other 
health or medical contraindications to them taking part in the study (such as 
history of any cardiovascular or metabolic disease) as confirmed by 
information provided on a physical activity readiness questionnaire 
(Appendix A). 
 
3.2 Respiratory Symptoms History Questionnaire 
 
Inclusion criteria required participants to have no history of physician 
diagnosed asthma as confirmed subjectively by the respiratory symptoms 
history questionnaire, previously used by Dickinson et al. (2011) (Appendix 
B). 
 
3.3 Spirometry 
 
All participants undertook maximal flow-volume manoeuvres using a 
spirometer (Microlab ML3500, Cardinal Health, Basingstoke, UK). 
Participants sat upright in a chair, wore a nose clip to prevent nasal 
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breathing and were instructed to reach maximum inhalation before placing 
the spirometer mouthpiece in the mouth and forcefully exhaling as hard as 
possible. Exhalation continued for a minimum of 6 seconds and also until 
they had completely emptied their lungs, indicated by a plateau in the 
volume/time graph on the spirometer, at which point the experimenter would 
signal the participant to breathe in as fast as possible to maximum 
inspiration, completing the maximal flow-volume manoeuvre.  
 
A minimum of three maximum flow-volume loops were required for baseline 
measurements, flow-volume measurements were rejected if: the participant 
was deemed not to have reached maximum inspiration prior to the 
manoeuvre (indicated by the same start and end point of the flow-volume 
loop); the participant was deemed to have coughed during the manoeuvre; 
the participant was deemed to have performed a slow start or to have not 
maintained the pressure of expiration for the duration of exhalation and also 
if the values were not consistent (i.e. less than 5% or 150 mL variation 
between all three baseline values). 
 
Flow-volume measures recorded from each maximal flow-volume loop were; 
Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity 
(FVC), FEV1 to FVC ratio (FEV1/FVC %), Peak Expiratory Flow (PEF) and 
forced expiratory flow between 25% and 75% of FVC (FEF25–75).  
Individual maximal flow-volume loops were accepted in accordance with 
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European Respiratory Society American Thoracic Society criteria (Quanjer et 
al., 1993; Miller et al., 2005). Acceptability criteria are outlined in table 3.1. 
 
 
Table 3.1: Maximal flow-volume loop acceptance and rejection criteria for 
individual efforts and for reliability between efforts (Adapted from Miller et al., 
2005) 
 
 
Summary of within- and between- manoeuvre acceptability criteria 
 
Within-manoeuvre criteria 
Individual spirograms are acceptable if: 
    They are free from: 
         Cough during the first second of exhalation 
         Glottis closure that influences the measurement 
         Early termination or cut-off 
         Effort that is not maximal throughout 
         Leak 
         Obstructed mouthpiece 
   They have good starts: 
         Extrapolated volume <5% of FVC or 0.15 L, whichever is greater 
   They show satisfactory exhalation: 
        Duration of > 6 s, a plateau in the volume-time curve or if they cannot or should not  
        continue to exhale 
Between-manoeuvre criteria 
After three acceptable spirograms have been obtained apply the following tests: 
    The two largest values of FVC must be within 0.15 L of each other  
    The two largest values of FEV1 must be within 0.15 L of each other 
If both of these criteria are met the test session may be concluded 
If both of these criteria are not met, continue testing until: 
    Both of the criteria are met with analysis of additional acceptable spirograms 
    A total of 8 tests have been performed (optional) 
    The patient/participant cannot or should not continue 
Save, as a minimum, the three satisfactory manoeuvres  
FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 second 
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3.4 Eucapnic Voluntary Hyperpnoea Challenge 
 
All participants underwent a eucapnic voluntary hyperpnoea (EVH) challenge 
in accordance with the methods described by Anderson et al. (2001) 
Participants were instructed to avoid exercise and caffeine consumption on 
the day of the EVH challenge. Baseline FEV1 was recorded from three 
maximal voluntary flow-volume manoeuvres. If the participant had an FEV1 
less than 80% of the predicted value or if they had an FEV1/FVC ratio less 
than 70% they were deemed unsuitable to participate in the EVH challenge 
for health and safety reasons and were excluded from participation in any 
studies. 
 
Participants were asked to attain target minute ventilation (V̇E) of 85% of 
their predicted maximal voluntary ventilation rate (MVV) (FEV1 x 30) for 6 
minutes (Anderson et al., 2001). During the 6 minutes, participants breathed 
air from a compressed gas cylinder containing 21% oxygen, 5% carbon 
dioxide and 74% nitrogen. The gas was delivered to each participant via a 
gas cylinder, reservoir and a two-way valve. ?̇?E was recorded by calculating 
the volume of air passing through a dry gas meter every minute. Participants 
were verbally encouraged to reach MVV, however, the minimum acceptable 
ventilation rate for an acceptable test was 60% of the predicted MVV, if the 
participant failed to reach this value they were required to perform the test 
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again on a separate occasion. After the 6 minute EVH challenge, two 
maximal voluntary flow-volume loops were measured at 3, 5, 7, 10 and 15 
minute time-points, with the highest of the two FEV1 values recorded. A fall 
in FEV1 greater than 10% on two successive occasions post-challenge 
resulted in a positive test.  The data collection sheet for the EVH challenge is 
provided in appendix C. 
 
3.5 Peak Oxygen Consumption (VO2peak) 
 
Participants performed a standardised incremental running test to volitional 
exhaustion to establish peak oxygen consumption (V̇O2peak; Withers et al., 
2000) on a motorised treadmill (Pulsar, h/p/cosmos, Germany). The protocol 
consisted of one minute stages starting at 8 km·h-1 and increasing every 
minute until a maximum speed of 16 km·h-1 was attained, the gradient then 
increased by 1% every minute until a maximum of a 10% incline was 
attained. Each test was conducted under controlled laboratory conditions 
(temperature 20oC, relative humidity 40%), participants performed a 5 minute 
standardised warm-up on a motorized treadmill (10 km·h-1) before 
performing the test. Prior to starting, the participants were fitted with a heart 
rate monitor (Polar RS400; Polar Electro Oy, Kempele, Finland) and 
connected to a breath-by-breath online gas analyser via a face mask 
(Oxycon Pro, Jagear, Wuerzberg, Germany). At the end of every stage and 
upon trial cessation the following were measured: time (s), heart rate (HR), 
oxygen consumption ( V O2), carbon dioxide production ( V CO2), minute 
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ventilation ( V E), respiratory exchange ratio (RER) and rating of perceived 
exertion (RPE). The trial ended when the participant was no longer able to 
continue at the desired speed or when the participant voluntarily ended the 
test protocol. 
 
3.6 Three Km Time-Trial 
 
The 3 km time-trials were conducted on a non-motorised curved treadmill 
(Woodway Curve, Woodway, USA). Participants were familiarised to running 
on a non-motorised treadmill prior to initiating their recorded 3 km time-trials.  
Familiarisation runs took place over a distance of 3 km on at least two 
occasions. Participants progressed to the recorded 3 km time-trials once 
they felt comfortable pacing themselves on the non-motorised treadmill over 
a 3 km distance. 
Each time-trial was conducted under controlled laboratory conditions (20oC, 
relative humidity 40%). Prior to starting the time-trial participants were fitted 
with a heart rate monitor (Polar RS400; Polar Electro Oy, Kempele, Finland) 
and connected to a breath-by-breath gas analyser via a face mask (Oxycon 
Pro, Jagear, Wuerzberg, Germany). Over the course of the 3 km time-trial 
the following were measured: time (s), average heart rate (HR), oxygen 
consumption ( V O2), carbon dioxide production ( V CO2), minute ventilation (V
E), respiratory exchange ratio (RER) and rating of perceived exertion (RPE). 
Two minutes following the completion of the 3 km time-trial a finger-tip 
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capillary blood sample was collected to measure blood lactate concentration 
(Lactate Pro, Arkray KDK, Japan).  
During the 3 km time-trial participants were only given feedback on the 
distance they had covered. They were blinded to all other feedback such as 
time and HR. Participants were encouraged to complete the time-trial as fast 
as possible. 
 
3.7 Isokinetic Dynamometry 
 
Prior to performing isokinetic dynamometry all participant were required to 
perform a familiarisation session to determine repeatability of 
measurements, at this familiarisation session differences between repetitions 
were required to be below the criterion value of 7.5% co-efficient of variation, 
familiarisation sessions continued until this value was met. Before 
completing isokinetic dynamometry participants completed a standardised 5 
minute warm-up on a cycle ergometer. Participants completed peak torque 
assessments of knee extension and knee flexion in order to assess 
quadriceps and hamstrings strength. Measurements were obtained using a 
Biodex Dynamometer (Biodex Medical Systems, Shirley, NY, USA) in 
accordance with methods outlined by Wrigley and Strauss (2000). 
Participants were instructed to perform flexion and extension at the following 
rotational speeds 60o.s-1 or 240o.s-1.  All participants completed a protocol 
consisting of 3 repetitions at 60o.s-1 followed by 45 seconds rest and a further 
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single repetition at the same speed, participants then had a further 45 
second rest then completed 3 repetitions at 240o.s-1, then again a further 45 
seconds rest and a single repetition at the same speed, range of motion 
parameters were set at the start of every test, this range of motion was 
required for every extension and flexion in order for the acceptance of a valid 
test.  Co-efficient of variation below 7.5% between repeated repetitions was 
required to ensure familiarisation with the technique, if this criterion was not 
met the protocol was repeated at a later date.  
 
3.8 One Repetition Maximum (1RM) Bench Press and Leg Press  
 
All participants were required to perform 1 repetition maximum (1 RM) tests 
during the second week of training to allow familiarisation with the equipment 
and lifting technique. On 1 RM testing days participants were required to 
have been free from strenuous strength training for at least 48 hours.  All 
participants were required to complete a standardised 5 minute warm-up 
prior to the testing.  All participants were tested for 1 RM Bench Press and 
Leg Press using the methods outlined by Beachle, Earle and Wathen (2008).  
Participants performed warm-up repetitions of 6, 4 and 2 repetitions at self-
selected weights.  Following this the participants moved on to 1 RM attempts 
with a minimum rest of between 3-5 minutes.  Participants continued to 
perform 1RM lifts until failure, an attempt was deemed as a failure if the 
participant either, did not manage to meet the required range of motion (i.e. 
a 90° angle at the knee during leg press and the barbell within 1 cm of the 
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chest during bench press) or was unable to lift the weight to its original 
position, on two separate occasions. 
   
3.9 Vertical Jump Test  
 
Vertical jump height was measured using a Jump Mat (Probotics Inc, 
Alabama, USA) in accordance with the methods of Hatze, (1998). The 
participant was instructed to stand on the jump mat. From a standing 
position with feet shoulder width apart and arms straight out in front, the 
participant then performed a countermovement jump, first flexing the legs at 
the knee at the same time as a down-swinging arm motion, which was 
immediately followed by extension to push off the mat and an upward 
swinging motion of the arm. The participant then landed with both feet back 
on the mat in a standing position, if the participant landed in a squat position 
the measurement was rejected. Time in the air and jump height were 
recorded. The best of three efforts was recorded during each assessment, 
for reliability purposes all three jumps were required to be within 10%. 
 
3.10 Skinfold Measurements 
 
Skin fold measurements were taken in accordance with methods outlined by 
Norton et al. (2000). Skin fold measurements were taken at the following 
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recognised sites on the right hand side of the body: triceps, biceps, 
subscapular and supraspinale. All measurements were taken by the same 
technician using a single set of Harpenden skinfold callipers (Baty 
International, Sussex, UK). Skin fold measurements were taken from each 
site consecutively a total of two times. The sum of four skin folds was then 
calculated for both totals, the criterion for a valid measurement was a 
difference of less than 1 mm between the two totals.  If this was not the case 
then the cycle of measurements was repeated until the criterion was met. 
The average of the two totals for the sum of four skin folds was then 
calculated and this average was taken as the final value.  
 
3.11 Muscle Girth 
 
Muscle girth measurements were taken in accordance with methods outlined 
by Norton et al. (2000) by a single, trained technician using an 
anthropometric tape measure. Muscle girths were measured at the arm, 
thigh and calf. Relaxed arm girth was measured with the right arm by the 
side and the participant in the anatomical position, the circumference was 
recorded at the radiale triceps landmark.  Tense arm girth was measured 
with the participant holding their right arm straight out in front at shoulder 
height, with an angle of 45° at the elbow, the circumference was measured 
along the arm until the widest point was met, the participant was then 
instructed to bring their fist as far as possible toward the shoulder, the tense 
arm circumference was then measured.  Calf girth was measured with the 
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participant in the anatomical position and the calf relaxed, measurements 
were taken down the calf until the widest point was met.  Thigh girth was 
measured at the mid trochanterion–tibiale laterale landmark.  
 
3.12 Salbutamol Urinalysis  
 
All urinalysis was performed at HFL Sport Science (Fordham, UK) an 
independent drug surveillance laboratory and former WADA-accredited 
laboratory. Sample preparation involved the addition of 200 ng of 
Salbutamol-D3 (NMI) as an internal standard to 1 ml of urine. Following the 
addition of 2 ml of 0.1M phosphate buffer pH 6.8 and 100 μl of E. Coli 
enzyme (β-glucuronidase) solution the mixture was incubated overnight at 
37oC. Strata XC 60 mg solid phase extraction cartridges (Phenomenex, 
Macclesfield, UK ) were conditioned with 3 ml of methanol followed by 3 ml 
of reagent grade water. Following centrifugation at 3500 rpm for 5 min the 
samples were applied to the cartridges. The cartridges were then washed 
with 3 ml of 0.1M acetate buffer pH 9.0 followed by 3 ml of reagent grade 
water, 3 ml of 0.1M HCl, 3 ml of methanol and 3 ml of diethyl ether. The 
cartridges were then dried for 5 min under vacuum and samples were eluted 
into glass vials with two, 1 ml of basic drug elution solvent (160 ml ethyl 
acetate, 34 ml propan-2-ol and 6 ml 34% ammonia solution). Samples were 
then evaporated to dryness at ambient temperature using a centrifugal 
vacuum concentrator (Genevac Ltd, Ipswich, UK) and reconstituted in 10 μl 
of isopropanol followed by 200 μl of basic reconstitution solution (495 ml of 
0.1 acetic acid mixed with 5 ml Benzyldimethylphenyl Ammonium). Samples 
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were centrifuged at 3000 rpm for 10 min prior to LCMS submission. Samples 
were injected onto a Thermo Scientific Accela HPLC system coupled to a 
Thermo Scientific LTQ Orbitrap Discovery Mass Spectrometer (Thermo 
Fisher Scientific, Waltham, USA). Chromatographic separation was 
performed on a Waters Atlantis T3 column (2.1 x 100 mm, particle size 3 um; 
Waters Ltd, Elstree, UK) at 35oC. The mobile phase was a gradient system 
of 0.1% acetic acid aqueous solution containing uracil (300 ng.ml-1) and 
0.1% acetic acid in acetonitrile containing uracil (300 ng.ml-1) set at a flow 
rate of 0.4 ml.min-1.  
 
The urine salbutamol concentrations reported correspond to the sum of the 
free and glucuronide conjugates. The samples were analysed over the 
calibration range of 10-2000 ng.ml-1. Samples with salbutamol 
concentrations greater than the upper limit of quantification were diluted with 
blank human urine prior to analysis. The lower limit of quantification was 
accepted as the lowest standard on the calibration curve (10 ng.ml-1). 
 
3.13 Terbutaline Urinalysis 
 
Each urine-sample was measured for pH and osmolality before 30 ml of 
each sample was distributed into a Nalgene bottle (Thermo Fisher Scientific, 
Leicestershire, UK) prior to freezing the sample at -80 ºC until urinalysis. All 
urinalysis was performed at HFL Sport Science (Fordham, United Kingdom), 
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an independent drug surveillance laboratory and former WADA-accredited 
laboratory. All samples were packaged in dry ice during transportation to 
prevent thawing. The laboratory used a validated proprietary analytical 
method. In brief, urine samples were thawed, centrifuged and subaliquotted 
prior to addition of a deuterated internal standard (Terbutaline D3; CDN 
Isotopes via QMX Laboratories Ltd, Thaxted, UK). Following overnight 
enzymatic hydrolysis with β glucuronidase from E. Coli (type 1X-A; Sigma 
Aldrich, Dorset, UK), sample clean-up was performed using solid phase 
extraction (Strata XC 30 mg 96-well plate; Phenomenex, Macclesfield, UK). 
After elution, samples were evaporated to dryness, reconstituted and 
analysed using an AB Sciex 4000 QTrap mass spectrometer (AB Sciex, 
Warrington, UK), with a Waters Acquity UPLC system (Waters Ltd, Elstree, 
UK). Chromatographic separation was achieved using a Waters Acquity 
HSS T3 Column (2.1 x 100 mm, particle size 1.8 µm) and gradient solvent 
programme using methanol and water, both containing 10 mM ammonium 
formate.  
 
Sample concentrations were measured using a calibration line containing 
terbutaline at different concentrations (10 to 3000 ng·ml-1) which were 
extracted and analysed in the same batch. Quality control samples were 
tested along with samples to confirm assay performance. 
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4. The ergogenic effect of 
long-term use of high-
dose salbutamol 
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4.1  Background 
 
Between 2002 and 2010 the International Olympic Committee (IOC) 
established the requirement for athletes to present evidence of current 
asthma or exercise induced bronchoconstriction (EIB) through the 
Therapeutic Use Exemption (TUE) process in order to use the short acting 
β2-agonist, salbutamol. These regulations were guided by health and not 
anti-doping (performance enhancing) concerns (Fitch et al., 2006). Previous 
reports have provided demonstrable evidence that the TUE process 
improves the quality of care for athletes (Dickinson et al., 2005; Parsons et 
al., 2007). Furthermore, it has been demonstrated that there is improved 
diagnostic sensitivity and specificity of incorporating indirect airway 
challenges into the process of diagnosing an athlete with asthma and/or EIB 
(Anderson et al., 2003; Rundell et al., 2004; Dickinson et al., 2006a; 
Dickinson et al., 2006b; Parsons et al., 2007).  
 
The weight of evidence supports the improved health care of athletes 
following the introduction of the TUE process for inhaled short acting β2-
agonist. In contrast, there is limited evidence to suggest inhaled β2-agonists 
(200 – 800 µg) have an ergogenic effect. The small numbers of studies that 
do exist have focused mainly on endurance performance and have reported 
no performance effect with up to 800 µg of inhaled short acting β2-agonist 
(Pluim et al., 2011). It has been demonstrated that large (up to 4000 µg) 
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acute doses of inhaled salbutamol do not significantly improve endurance 
(Dickinson et al., 2014a; Elers et al., 2012a), simulated association football 
(soccer) or repeated sprint performance (Dickinson et al., 2014b). Whilst 
there appears to be no performance gain from acute administration of 
salbutamol there is limited data available investigating the ergogenic effect of 
chronic, daily use of salbutamol.  
 
Sanchez et al. (2012) observed an improved sprint performance following 3 
week daily use of oral salbutamol (12 mg.day−1) however; they note that 
sprint performance was greater following an acute oral dose of salbutamol (6 
mg) when compared with the 3 week chronic use. To date, no study has 
examined the ergogenic impact following the chronic use of inhaled 
salbutamol. Furthermore, WADA (WADA Prohibited List 2013) currently 
recommends a daily upper limit of 1600 μg of salbutamol pro re nata (as 
required); a dose rarely examined in the literature. A possible mechanism for 
the improvement in performance following prolonged use may be due to 
repeated dose accumulation of the β2-agonist in the system. If there is not 
sufficient time for full clearance of the β2-agonist then there will be an 
accumulation in the system, which may be able to stimulate the β2-receptors 
more potently due to higher availability than would be observed with single 
administration (Hoffman, 2001).  
 
Accordingly, the purpose of this study is to contribute to the understanding of 
the ergogenic effect of prolonged use of the inhaled short acting β2-agonist 
 95 | P a g e  
 
salbutamol at daily doses of 1600 μg on measures of endurance, strength 
and power performance in athletes.  
 
It is hypothesized that therapeutic use of inhaled salbutamol has no effect on 
performance following 6 weeks use of the WADA maximum permitted (1600 
µg per day) therapeutic dose for athletes. 
 
It is also hypothesized that prolonged use of salbutamol at the WADA 
maximum permitted daily dose does not lead to any urinary concentrations 
that would present as an adverse analytical finding. 
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4.2 Methods 
 
Ethical approval was obtained from Liverpool John Moores University Local 
Ethics Committee (ethics no: P09SPS031). Sixteen recreationally trained 
male athletes provided written consent and agreed to take part in the study 
(mean + SD: age 20.1 ± 1.6 years; height 179.9 ± 8.2 cm; weight 74.6 ± 9.1 
kg). All participants were free from asthma, EIB and AHR confirmed by no 
previous history of disease and presenting with a negative Eucapnic 
Voluntary Hyperpnoea (EVH) challenge (Anderson et al., 2001). All 
participants were free from chest infection for at least 4 weeks prior to 
assessment. Participants completed baseline performance challenges for 
endurance, power and strength. Each assessment was conducted under 
controlled laboratory conditions (temperature 20oC, relative humidity 40%). 
Following the baseline measures participants were pair-matched according 
to their ?̇?O2peak, then randomly assigned to one of two groups in a double 
blind design: 
 
Placebo Group (PLA): 4 inhalations of placebo inhaler, via pocket chamber, 
4 times per day for 6 weeks. 
 
Salbutamol Group (SAL): 4 x 100 μg inhaled Salbutamol (Sandoz Ltd. 
Bordon, UK), via pocket chamber, 4 times per day for 6 weeks.   
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Participants used their inhaler as instructed daily at 08.00, 12.00, 16.00 and 
20.00 hours and kept a record of their inhaler use. Over the six week 
intervention participants attended four (two endurance and two strength 
training) personal trainer led gym sessions per week. The performance tests 
for endurance, power and strength included 3 km running time-trial, 1RM 
bench press and leg press, vertical jump height and knee extension and 
flexion using isokinetic dynamometry, these assessments were repeated at 
week three and also at week six. 
 
4.2.1 Endurance performance assessments  
 
4.2.1.1 Peak Oxygen Consumption (?̇?O2peak) 
 
As described in general methods section 3.5. 
 
4.2.1.2 3 km Time-Trial 
 
As described in general methods section 3.6. 
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4.2.2 Strength and Power Assessments 
 
4.2.2.1 Isokinetic Dynamometry 
 
As described in general methods section 3.7. 
 
4.2.2.2 One Repetition Maximum (1 RM) Bench Press and Leg Press  
 
As described in general methods section 3.8. 
 
4.2.2.3 Vertical Jump Test  
 
As described in general methods section 3.9. 
 
4.2.3 Training Protocol  
 
Participants trained four times per week, consisting of two resistance based 
sessions and two endurance based sessions.  Using the baseline measures 
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of the strength and power assessments a personalised, incremental 
resistance training programme was provided and weight lifted was recorded. 
The resistance training programme consisted of leg press, Romanian dead 
lift, bench press, bench pull/bent over dumbbell row, biceps curl (preacher 
and hammer), bench triceps dips and box jumps. The endurance sessions 
lasted 40 minutes and consisted of two 20 minutes steady state exercise 
episodes on: a treadmill; cycle ergometer; or cross-trainer. All endurance 
distances were recorded and a progressive increase in endurance distances 
was prescribed across the six weeks. Participants used HR zones to 
regulate the intensity of each endurance session. Typical HR zones during 
each session were 70-80% heart rate max for the duration of the exercise. 
 
4.2.4 Anthropometric Measurements 
 
4.2.4.1 Skinfold measurements 
 
As described in general methods section 3.10. 
 
4.2.4.2 Muscle girth measurement 
 
As described in general methods section 3.11. 
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4.2.5 Urine collection 
 
Urine samples were provided midway through the administration period.  
Subjects were asked to collect samples following the final daily dose of 
salbutamol at 20:00 h. A 20 ml aliquot was collected and stored initially 
overnight at 4oC and subsequently at -80oC until analysis. 
 
4.2.6 Salbutamol Urinalysis 
 
As described in general methods section 3.12. 
 
4.2.7 Statistical Analysis 
 
Changes in the performance and physiological measurements recorded in 
the endurance, strength and power assessments between groups (PLA or 
SAL) over the course of the 6 week training programme were analysed using 
a mixed model repeated measures ANOVA with a Bonferroni correction for 
multiple analyses. A p-value of <0.05 was deemed significant for all analysis.  
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4.3 Results 
 
All 16 participants completed 6 weeks of either SAL or PLA and completed 
all endurance, strength and power assessments, there were no adverse 
events reported. Participant characteristics are presented in table 4.1. 
 
4.3.1 Endurance Performance Assessments 
 
4.3.1.1 Peak Oxygen Consumption (?̇?O2peak) 
 
Over the course of 6 week training programme ?̇?O2peak improved significantly 
(p=0.02) in both PLA and SAL groups (Figure 4.1). There was no significant 
interaction between group and time in ?̇?O2peak and HR. The SAL group had a 
significantly greater (p=0.02) change in ?̇?E from baseline (139.3 + 22.6 l.min
-
1) to 6 week follow-up (155.25 + 22.0 l.min-1) when compared with PLA 
change from baseline (145.3 + 40.9 l.min-1) to 6 week follow-up (147.13 + 
38.1 l.min-1).  
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Table 4.1 Mean (±SD) Participant demographics and lung function values Pre- and Post- EVH challenge for: Salbutamol (SAL) and 
Placebo (PLA) groups. 
 
Group Height Weight Age Baseline FEV1 % Predicted FEV1 Post EVH FEV1 
SAL (n=8) 180.3 (7.7) 73.6 (11.6) 20 (1.1) 4.95 (0.5) 108.1 (4.3) 4.69 (0.5) 
PLA (n=8) 179.4 (9.2) 75.6 (6.2) 20.25 (2.2) 4.79 (0.7) 108 (11) 4.61 (0.7) 
FEV1 - Forced Expiratory Volume in 1 Second; EVH - Eucapnic Voluntary Hyperpnoea; MC – Male Caucasian; 
MAC – Male Afro-Caribbean; FC – Female Caucasian; MA – Male Asian 
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Figure 4.1: Mean (+SE) a) V O2peak, b) peak HR, c) V E and d) V CO2 during the V O2peak assessment at baseline and at 6 week 
follow-up in PLA and SAL groups. (* = SAL significant increase (p=0.02) from baseline to 6 week follow-up). 
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4.3.1.2 3 km Time Trial 
 
All participants significantly improved 3 km running time over the course of 
the 6 week period. There was no difference in the amount of improvement 
between PLA (1057.8 ± 234.1 s vs. 1005.3 ± 255.3 s) and SAL (909.2 ± 86.1 
s vs. 885.8 ± 61.6 s) groups for baseline and 6 week completions times, 
respectively (Figure 4.2). No significant differences were noted for HR, ?̇?O2, 
?̇?CO2, ?̇?E or blood lactate (Figure 4.2). 
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Figure 4.2: a) Mean (+SE) 3km completion time, b) individual completion 
time, c) oxygen consumption (?̇?O2), d) carbon dioxide production (?̇?CO2), e) 
heart rate (HR), f) minute ventilation (?̇?E), g) rating of perceived exertion 
(RPE) and h) blood lactate during the 3 km time-trial between SAL and PLA 
at baseline, 3 weeks and 6 weeks. 
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4.3.2 Strength and Power Assessments 
 
There were no significant improvements in peak torque for any peak torque 
measurements between baseline and 6 week follow-up tests (see Figure 
4.3.). There was a significant interaction for peak torque 1RM leg extension 
at 60o.s-1 between PLA and SAL (p=0.03) from baseline (184.6 + 35.0 vs. 
196.1 + 47.3 n.m.) to six week follow up (195.2 + 28.9 vs. 179.5 + 48.9 n.m.). 
All other peak torque measurements for knee extension and knee flexion did 
not change significantly between groups. Over the course of the 6 weeks 
bench press and leg press 1 RM improved in both SAL and PLA (p<0.01). 
No significant changes in bench press or leg press 1 RM were observed 
between groups (Figure 4.3). Vertical jump height did not significantly 
change over the 6 week period in either PLA or SAL groups (Figure 4.4). 
 
 
 
 
 
 
 
 
107 | P a g e  
 
 
Figure 4.3: Mean (+SE) Peak Torque for a) 60o.s-1 extension b) 240o.s-1 extension c) 60o.s-1 flexion and d) 240o.s-1 flexion 1RM 
efforts between SAL and PLA at pre- and post-6 week treatment and training phase. 
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Figure 4.4: Mean (+SE) leg press (a) bench press (b) and vertical jump 
height (c) at baseline, 3 weeks and 6 weeks in PLA and SAL groups.  
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4.3.3 Urinary salbutamol 
 
The mean (+SD) urinary salbutamol concentration at the 3 week stage of the 
administration period was 347.5 (+361.4) ng.ml-1. Whilst seven of the eight 
subjects from group 1 (SAL) produced samples significantly lower than the 
1000 ng.ml-1 threshold established by WADA one subject produced a sample 
slightly higher (1071 ng.ml-1) (Figure 4.5).    
 
4.3.4 Anthropometric Measurements 
 
There were no significant differences in any of the anthropometric 
measurements assessed at either the 3 week or the 6 week assessment 
stages (Figure 4.6). 
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Figure 4.5: Urinary Salbutamol concentrations for the SAL group showing 
individual concentrations and the group mean. 
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Figure 4.6: Anthropometric measurements for a) skinfolds b) relaxed arm 
circumference c) tensed arm circumference d) calf circumference e) thigh 
circumference. 
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4.4 Discussion 
 
This is the first study to examine the impact of chronic, daily accumulated 
doses of 1600 µg of inhaled salbutamol on endurance, strength and power. 
The results indicate no significant performance improvement in 3 km running 
time-trial, 1RM bench and leg press, vertical jump height or isokinetic 
dynamometry when compared with placebo.  
 
This study supports to previous research that has demonstrated inhaled 
salbutamol up to 1600 µg taken in either acute or accumulative doses over a 
one-off or 24 hour period does not improve endurance or strength and power 
performance (Pluim et al., 2011; Dickinson et al., 2014a; Dickinson et al., 
2014b; Decorte et al., 2008, Sporer et al., 2008). Further to the data in the 
present study and previous research, Elers et al. (2012a) suggests inhaling 
an acute dose of up to 4000 µg of salbutamol results in no improvement in 
cycling time to exhaustion or oxygen kinetics. Accordingly, from a 
performance perspective the current WADA guidelines permitting athletes to 
inhale up to 1600 µg in a 24 hour period are appropriate as there does not 
appear to be a resultant improvement in performance in non-asthmatic 
athletes following acute or chronic inhalation. 
 
The findings from the present study contradict findings from studies 
investigating oral salbutamol. In a meta-analysis of the acute performance 
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enhancing effects of oral salbutamol, Pluim et al. (2011) concluded there 
was weak evidence to suggest an acute dose of oral salbutamol would 
significantly improve athletes’ anaerobic capacity and strength. A recent 
study by Sanchez et al. (2012) examined the impact of oral salbutamol on 
maximal power from either a single, acute dose (6 mg) or a daily dose (12 
mg.day-1) for three weeks. They reported that oral salbutamol resulted in 
significantly improved maximal power with the one-off dose resulting in 
greater gains than three weeks daily intake (14% vs. 8%). The authors 
concluded that acute doses lead to greater gains and that long-term use of 
oral salbutamol may lead to down regulation of muscle β2-adrenoreceptor 
function leading to a dampening of the effect of salbutamol on strength 
gains, these findings are supported by Hancox et al., (2002) who assessed 
the use of salbutamol for one week between repeat EVH challenges, finding 
that response to therapy was diminished in the salbutamol group compared 
to placebo in the follow up EVH challenge. The potential down regulation of 
muscle β2-adrenoreceptors from daily doses of salbutamol may be why the 
data from our study demonstrated a reduction in 1 RM peak torque leg 
extension at 60o.s-1 in the SAL group compared to an improvement in the 
PLA group.  
 
The main action of inhaled salbutamol is to act as a bronchodilator to 
reverse the bronchoconstriction of airway smooth muscle. This results in the 
asthmatic airway becoming dilated leading to a reduced airway resistance 
and improvements in ?̇?E and exercise performance (Collomp et al., 2010). 
One of the proposed ergogenic mechanisms for inhaled salbutamol is a 
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significant bronchodilation in non-asthmatic athletes resulting in an improved 
?̇?E during exercise and increases in oxygen uptake. In the present study we 
observed significant increases in ?̇?E during the ?̇?O2peak assessment from the 
SAL group when compared against PLA which may have been attributable 
to a slight familiarization effect in the SAL group, however; this increase in 
?̇?E did not result in an improved ?̇?O2peak. Previous research has reported 
similar improvements in ?̇?E following acute doses of up to 1600 µg of 
salbutamol in the absence of an improvement in 5 km running time-trial 
performance in endurance athletes or repeated sprint performance in football 
players (Dickinson et al., 2014a; Dickinson et al., 2014b). Previous studies 
have demonstrated non-significant improvements in FEV1 of 0.2 L following 
inhalation of 800 µg, which did not result in greater ?̇?E or improved 
endurance performance (Decorte et al., 2008). 
 
Previous studies that have focused on oral salbutamol have primarily 
demonstrated performance gains in strength and power variables (Pluim et 
al., 2011; Sanchez et al., 2012; Caruso et al., 1995; Martineau et al., 1992). 
In addition to strength and power this study focused on endurance 
performance. This had an impact on the prescribed training programme as 
participants completed two strength and power sessions and two endurance 
sessions per week. If the focus had been on strength and power 
assessments the participants could have received greater training gains from 
a greater training volume (i.e. 4 sessions/week vs. 2 sessions/week). Future 
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studies could employ a greater strength and power training load allowing 
results from oral salbutamol studies to be more comparable.  
 
Whilst dosing to the recommended maximal levels according to WADA 
(WADA Prohibited List 2015) produced no benefit in terms of enhanced 
performance, urinalysis results demonstrated a distinct possibility that an 
individual may contravene the anti-doping regulations as a consequence of a 
positive drugs test. Whilst all but one subject produced a negative test result 
(<1000 ng.ml-1) there is a concern that a single subject produced a sample 
which was greater than the current threshold as a result of the study’s dosing 
regimen. This positive test highlights the large inter-individual variability for 
urinary thresholds, however the difference between the WADA threshold and 
the WADA decision limit appears to be sufficient as the positive responder 
did not exceed the decision limit of 1200 ng.ml-1. Nevertheless, this does 
suggest that administration of an acute, high dose of salbutamol may lead to 
a breach of the threshold and thus result in an adverse analytical finding 
(AAF), which is supported by Dickinson et al., (2014d) who found AAF’s 
following acute doses of 1600 µg salbutamol with varying levels of 
dehydration. Further research is clearly needed to establish the variability 
surrounding urinary salbutamol levels amongst individuals dosing up to and 
including 1600 µg in a single acute dose, the present study would have also 
benefitted from investigations into the hydration status of the participants. 
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In conclusion, there is no improvement in endurance, strength and power 
performance following the inhalation of 1600 µg of salbutamol per day for six 
weeks in non-asthmatic recreationally trained males. This would suggest that 
the current WADA list of banned substances (WADA List of Prohibited 
Substances, 2015), which allows athletes to inhale up to 1600 µg is sufficient 
given the findings from this and previous studies. Future research should 
focus on establishing the variability surrounding urinary salbutamol levels 
amongst individuals dosing up to and including 1600 µg in a single acute 
dose. 
Salbutamol is the preferred choice of treatment for athletes, however 
athletes with a TUE are permitted to use the alternative short-acting β2-
agonist terbutaline. Terbutaline currently has no established thresholds for 
use to distinguish between route of administration and is potentially more 
ergogenic than salbutamol in supratherapeutic dosages. It is important 
therefore that urinary thresholds for terbutaline are established in order for 
athletes with a TUE to be effectively monitored. 
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5.  Urinary 
concentrations of single 
and multiple 
administration of inhaled 
and oral terbutaline: 
influence of gender and 
race 
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5.1  Background 
 
Short-acting β2-agonists act to reverse bronchoconstriction of the airways 
through stimulation of the β2-receptors present on bronchial smooth muscle, 
allowing the muscle to relax and the airways to dilate restoring airway 
function (Anderson et al., 1997; Hoffman, 2001; Driessen et al., 2013). 
These short-acting β2-agonists are the preferred immediate/acute treatment 
for EIB, in athletes this is via salbutamol administration (Fitch, 2006). 
Sanchez et al. (2013) have indicated that terbutaline is a fast-acting β2-
agonist that is active for a maximum of 12 hours whereas salbutamol is 
active for a maximum of 6 hours. Sanchez et al. (2013) also state that 
terbutaline, with fewer reported side-effects than other β2-agonists, may be 
of benefit to athletes for the relief of EIB.  
 
The World Anti-Doping Authority (WADA) Prohibited List of Substances and 
Methods (WADA Prohibited List, 2010-2014) has permitted the use of the 
short-acting β2-agonist salbutamol and the long acting β2-agonist salmeterol 
for inhalation in therapeutic doses since the removal of the need for a 
therapeutic use exemption (TUE) in 2010. Furthermore, the inhaled long 
acting β2-agonist formoterol has been permitted in therapeutic doses since 
2012. However, despite the absence of evidence that therapeutic doses of 
inhaled terbutaline have an ergogenic effect on athletic performance (Kalsen 
et al., 2014), terbutaline remains on the prohibited substances list (WADA 
prohibited List 2015) (UEFA Guide to the WADA Prohibited List, 2015) 
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except for those athletes with a therapeutic use exemption (TUE). A 
threshold for terbutaline would be useful in the fight against doping in sport 
and also in maintaining standards of healthcare for the elite athlete, as it 
would allow for a broader range of inhaled β2-agonists to be used by athletes 
and also allow for successful identification of the prohibited use of oral 
terbutaline that could potentially be ergogenic. 
 
The inclusion of terbutaline on the WADA List is primarily due to the inability 
to distinguish between oral and inhaled use (Elers et al., 2012b). Studies 
have been performed for salbutamol investigating the differences between 
oral and inhaled use that have successfully established concentration limits 
in the urine, included in the WADA Prohibited List (Elers et al., 2012a; 
Berges et al., 2000; Elers et al., 2010; Pichon et al., 2006). There is a large 
disparity between the amount of inhaled salbutamol (200 µg) and the amount 
of oral salbutamol (4 mg) that is used therapeutically with an inhaled-oral 
ratio of roughly 1:20, yet this is not as apparent for terbutaline where normal 
dosing regimens for individuals with a TUE permit up to 2 mg inhaled 
terbutaline prophylactically for the relief of symptoms (Elers et al., 2012b) 
and the therapeutic oral dose is a 5 mg tablet where the inhaled-oral ratio is 
1:2.5, this is potentially the reason that it is difficult to distinguish between 
route of administration. 
 
Recent work has highlighted that in order to improve measures for doping 
control hydration status is a factor that can affect the outcome of a test 
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(Dickinson et al., 2014c). Other factors such as ethnic background can 
influence urine concentrations of metabolites, Kim et al., (2004) state that 
there is inter-ethnic variability between male Caucasians and male Asians, 
highlighting that potential genetic difference between different ethnic groups 
could result in differences in the urinary concentrations of metabolites. The 
differences in metabolism between ethnicities is supported by Deshmuck et 
al., (2010) who highlight that there are varying degrees of gene 
deletion/insertion/substitution polymorphisms between individuals of different 
ethnic backgrounds, in particular they highlight the reduced glucuronidation 
of steroids through a gene deletion polymorphism in uridine diphosphate 
glucuronosyl transferase 2B17 (UGT2B17) in individuals of Asian origin.  
Guo et al., (2010) indicate also that variability in urinary concentrations of 
metabolites, occurring between males and females, are largely due to weight 
differences between individuals, in the study by Guo et al., (2010) values in 
females were roughly 20% higher than that of males, equivalent to the 
weight differences between the two groups. 
 
The purpose of the present study was to measure the urine concentrations 
of terbutaline following single and repeated doses of oral and inhaled 
terbutaline in male Caucasians, female Caucasians, male Afro-Caribbeans 
and male Asians to allow for comparisons between gender and race to better 
inform WADA with regard to doping policy and procedure relating to 
terbutaline use. 
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It is hypothesized that an acute therapeutic dose (2 mg) of inhaled 
terbutaline will lead to significantly lower urine concentrations than an acute 
therapeutic dose (5 mg) of oral terbutaline. 
 
It is also hypothesized that a repeated therapeutic dose (8 x 1 mg over 36 
hours) inhaled terbutaline will lead to significantly lower urine concentrations 
than repeated therapeutic dose (4 x 5 mg over 36 hours) oral terbutaline. 
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5.2  Methods 
 
Prior to the initiation of the study ethical approval was obtained from 
Liverpool John Moores University Local Research Ethics Committee (Ethics 
no. P11SPS044). Twenty-two male and eight female subjects (8 male 
Caucasian, 8 female Caucasian, 6 male afro-Caribbean, 6 male Asian) 
provided written informed consent and were recruited for the study. All 
participants were free from asthma, EIB and AHR confirmed by no history of 
disease and a negative eucapnic voluntary hyperpnoea (EVH) challenge 
(Anderson et al., 2001). All participants were non-smokers, were free from 
chest infection for 4 weeks prior to assessment and had no history of any 
pulmonary, cardiovascular or metabolic disease. 
 
5.2.1 Oral and Inhaled Doses of Terbutaline 
 
To enable close monitoring of participants responses to increasing doses of 
terbutaline it was deemed necessary to systematically order the trials, a 
schematic of study progression is shown in figure 5.1.  During visit 1 all 
participants received a single therapeutic dose of 5 mg oral terbutaline 
(Bricanyl, AstraZeneca, UK), single oral administration (SOA).  During visit 2 
all participants received a therapeutic dose of 4 inhalations of 0.5 mg 
terbutaline (Bricanyl Turbohaler, AstraZeneca, UK) totalling 2mg inhaled, 
single inhaled administration (SIA). During visit 3 all participants inhaled the 
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therapeutic dosing regimen of 1 mg (2 x 0.5 mg inhalations) of terbutaline 
(Bricanyl Turbohaler, AstraZeneca, UK) at 08:00h, 12:00h, 16:00h and 
20:00h for 2 days, repeated inhaled administration (RIA). During visit 4 all 
participants received the therapeutic dosing regimen of 5 mg oral terbutaline 
(Bricanyl, AstraZeneca, UK) at 10:00h and 18:00h for 2 days, repeated oral 
administration (ROA). There was a minimum of 7 days between the 
cessation of one trial and the commencement of the next trial to ensure 
complete washout of terbutaline which has a terminal half-life of ~17h 
(Kalsen et al., 2014). 
 
 
 
Figure 5.1: Timeline schematic of study progression 
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5.2.2 Urine Sample Collection 
 
Following the final dose of terbutaline during each trial, participants were 
required to provide urine samples at 1h, 3h, 6h and 12h time-points. 
Participants were asked to record the volume and time of each sample 
provided. Each urine-sample was measured for pH and osmolality before 30 
ml of each sample was distributed into a Nalgene bottle (Thermo Fisher 
Scientific, Leicestershire, UK) prior to freezing the sample at -80 ºC until 
urinalysis (see below). Where samples were provided off-site participants 
were required to freeze immediately at -20ºC until the next day when they 
were returned to the laboratories for pH and osmolality assessment prior to 
freezing at -80 ºC. 
 
5.2.3 Terbutaline Urinalysis 
 
As described in general methods section 3.13. 
 
5.2.4 Sample Correction 
 
All urine concentrations of terbutaline were corrected to urine specific gravity 
of 1.020 prior to analysis using the following equation (Elers et al., 2012b):  
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Corrected urine concentration = measured urine concentration x (0.02/(urine 
specific gravity -1)). 
 
 
5.2.5 Statistical Analysis 
 
Statistical analyses were performed using the statistical package for the 
social sciences SPSS (SPSS v20.0, IBM, New York, USA). All data were 
normally distributed and presented as mean and standard deviation unless 
otherwise stated.  A mixed-model analysis of variance (ANOVA) was 
performed to compare between groups within each trial and to compare 
between trials within each group, 2-way ANOVA was used to compare 
between groups and between trials at all time-points. A post-hoc Bonferroni 
correction was applied to adjust for multiple comparisons. Statistical 
significance was set at p<0.05 for all analyses. 
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5.3  Results 
 
Twenty-eight participants successfully completed all trials, subject 
demographics and lung function screening values are shown in Table 5.1, 
two subjects reported fine tremor following both oral administration trials, 
which diminished within four hours of ingestion. No other adverse side-
effects were reported. 
 
Comparisons were performed examining differences between oral and 
inhaled terbutaline for single-dose administration (Figure 5.2) and for 
repeated administration (Figure 5.3). Comparisons between groups were 
performed examining differences between male and female Caucasians for 
gender related differences and differences between male Caucasian, Afro-
Caribbean and Asian for ethnic differences (Figure 5.4). Finally, comparisons 
were performed between the highest individual peak values obtained within 
each group for each trial condition (Figure 5.5).  
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Table 5.1: Mean (±SD) Subject Demographics and Lung Function Values Pre- and Post EVH Challenge for: Male Caucasians 
(MC), Female Caucasians (FC), Male Afro-Caribbean's (MAC) and Male Asians (MA) 
 
 
Group Height Weight Age Baseline FEV1 % Predicted FEV1 Post EVH FEV1 
MC (n=8) 181.05 (4.5) 78.48 (7.9) 23.38 (2.1) 5.03 (0.4) 110.63 (6.9) 4.81 (0.4) 
MAC (n=6) 183.72 (6.5) 81.36 (9.3) 21.5 (3.5) 4.24 (0.7) 100.67 (12.7) 4.1 (0.8) 
FC (n=8) 167.59 (5.7) 58.12 (6) 21.63 (1.9) 3.50125 (0.4) 100.63 (9.6) 3.31 (0.4) 
MA (n=6) 170.83 (4.9) 69.35 (2.9) 31.5 (4) 4.08 (0.6) 111.34 (11.8) 4.01 (0.6) 
FEV1 - Forced Expiratory Volume in 1 Second; EVH - Eucapnic Voluntary Hyperpnoea; MC – Male Caucasian; 
MAC – Male Afro-Caribbean; FC – Female Caucasian; MA – Male Asian 
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5.3.1 Single Administration 
 
Following the single dose (5 mg) of oral terbutaline the urinary terbutaline 
concentration was significantly greater when compared to the single dose (2 
mg) of inhaled terbutaline in the female Caucasian group (670.1±128.3 vs. 
361.8±43.8 ng·ml-1; P=0.019), the male afro-Caribbean group (343.18±45 
vs. 231.3±32.95 ng·ml-1; P=0.044) and the male Asian group (266.4±23.7 vs. 
143.3±22 ng·ml-1; P=0.004), respectively with no difference in the male 
Caucasian group (Figure 5.2). Of note, the peak concentrations following 
inhaled doses occurred at the 1 hour time-point and the peak concentrations 
following the oral doses occurred at the 3 hour time-point in all groups 
except the male Caucasians, where the peak for oral terbutaline was also at 
the 1 hour time-point. 
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Figure 5.2: Mean ±SE urine concentrations between single inhaled administration and single oral administration of terbutaline for a) male 
Caucasians; b) male Afro-Caribbeans; c) female Caucasians; d) male Asians. The area under the curve (AUC) for oral and inhaled trials has 
also been presented. 
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5.3.2 Repeated Administration 
 
There were significant differences between urinary terbutaline 
concentrations for repeated dose oral vs. repeated dose inhaled terbutaline 
in the female Caucasian group (680.8 ± 91 vs. 369.9 ± 41.9 ng·ml-1; 
P=0.006) the male afro-Caribbean group (389.73 ± 67.4 vs. 212.4 ± 50.3 
ng·ml-1; P=0.008) and the male Asian group (379.5 ± 50.4 vs. 197.5 ± 38.6 
ng·ml-1; P<0.005) for oral vs. inhaled terbutaline, respectively (Figure 5.3). 
There were no differences between trials for either single or repeated dose 
terbutaline in the male Caucasian group. Following repeated administration 
peak levels of urinary terbutaline occurred at the 1 hour time-point as 
expected in all groups except for the female Caucasian group. 
 
 
 
 
 
131 | P a g e  
 
  
Figure 5.3: Mean (±SE) urine concentrations between repeated inhaled administration and repeated oral administration of 
terbutaline for a) male Caucasians; b) male Afro-Caribbean; c) female Caucasians; d) male Asians. The area under the curve 
(AUC) has also been presented 
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5.3.3 Gender Differences 
 
There was a significant difference between male and female Caucasians for 
the repeated dose oral administration trial (406.9 ± 45.4 vs. 678.8 ± 94.8 
ng·ml-1; P=0.018), respectively. There were no gender differences between 
trials in any other conditions (Figure 5.4). 
 
5.3.4 Ethnicity Differences 
 
There was a significant difference between male Caucasians and male 
Asians for the single dose inhaled administration trial (372.14 ± 69.7 vs. 
131.8 ± 19.7 ng·ml-1; P=0.005), respectively.  
 
5.3.5 Peak Values 
 
There was a large inter-individual variation in the urinary concentrations of 
terbutaline. Figure 5.5 demonstrates the highest individual peak values 
obtained within each group for each trial condition. Values were generally 
higher following oral administration however there was a large crossover in 
values whereby a definitive cut-off value was not identified. Peak values after 
inhaled use barring one exception were all below 1284.3 ng·ml-1 and apart 
from one exception peak values after oral use were all below 2376.3 ng·ml-1.  
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5.3.6 Upper limits following inhaled and oral use 
 
To calculate the upper limits the means for all participants in each trial were 
calculated. The upper limit was established as being two standard deviations 
above the mean. This was done for both the inhaled trial condition (1284.3 
ng.ml-1) and the oral trial condition (2376.3 ng.ml-1). These values were then 
included in figure 5.5 to ascertain the sensitivity and specificity of the upper 
limits. These upper thresholds proved to have a specificity of 98.44% for 
both conditions but a sensitivity of only 14.1% to distinguish between oral 
and inhaled use.  
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Figure 5.4: Highest individual peak urine concentration between groups for: a) single oral administration; b) single inhaled 
administration; c) repeated inhaled administration; d) repeated oral administration. 
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Figure 5.5: Peak values obtained during trials for each group with a proposed upper threshold for inhaled use and upper threshold for oral use; 
MC – Male Caucasian; MAC – Male Afro-Caribbean; FC – Female Caucasian; MA – Male Asian 
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5.4 Discussion 
 
The findings of the present study demonstrate that there is no clear 
distinction between urinary concentrations of inhaled and oral terbutaline. 
The study did highlight, however, an upper threshold following therapeutic (2 
mg) inhaled use of 1284.3 ng·ml-1 and an upper threshold following 
therapeutic (5 mg) oral use of 2376.3 ng·ml-1. 
 
There are a number of asthmatic athletes currently using terbutaline through 
the therapeutic use exemption (TUE) process (Elers et al., 2012b), therefore 
it is important to be able to distinguish between legitimate inhaled use and 
prohibited oral use in these athletes. The findings of the present study 
indicate that the urinary concentrations of terbutaline via oral and inhaled 
administration cannot be easily distinguished. The current status of 
terbutaline on the WADA List is appropriate until a cut-off threshold can be 
established, care is warranted for athletes using terbutaline through the TUE 
process in order to prevent athletes from illegally using supra-therapeutic 
doses of inhaled/oral terbutaline in the hope of gaining a competitive 
advantage (Kalsen et al., 2014; Hostrup et al., 2014).  
 
The results from the present study show significant inter-individual variation 
in the urinary levels of terbutaline, dependent upon mode of administration, 
gender and race. In the female Caucasian group, the male Afro-Caribbean 
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group and the male Asian group there were significantly higher urinary 
concentrations of terbutaline in oral administration trials vs. inhaled trials but 
this was not apparent in the male Caucasian group.  A recent study by Elers 
et al., (2012b) reported similar findings when examining the levels of 
terbutaline in the plasma and urine following oral and inhaled administration 
(Elers et al., 2012b). The study was able to find significant differences 
between the mode of administration of terbutaline, however they were 
unable to establish any thresholds due to the high variability between 
samples. In line with Elers et al., (2012b) the present study was also able to 
highlight significant differences between dose and mode of administration, 
yet due to the large range in concentrations observed it has not been 
possible to distinguish between inhaled and oral use. However, our data 
suggest an upper threshold of 1284.3 ng.ml-1 for inhaled use and 2376.3 
ng.ml-1 for oral use, however these results were not sensitive enough to 
distinguish fully between inhaled and oral use of terbutaline.  
 
Recently Hostrup et al., (2014) observed that a supra-therapeutic inhaled 
dose of terbutaline resulted in an improvement in muscle strength and 
maximal sprint performance. This was, however, an extremely high supra-
therapeutic dose of 15mg inhaled terbutaline (30 x 0.5mg inhalations) which 
resulted in serum levels of terbutaline (23.6 ± 1.1 ng·ml-1) roughly four times 
higher than that recorded by Elers et al., (2012b) after a 10 mg oral dose (~6 
ng·ml-1). Such high dose inhalations of terbutaline would be easily 
distinguishable from the maximal therapeutic dose of 2 mg inhaled 
terbutaline which is permitted for athletes with a TUE (WADA 2015). In 
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contrast to the findings of Hostrup et al., (2014), Sanchez et al., (2013) 
reported 8 mg of oral terbutaline had no ergogenic effect during force-
velocity, sprint and endurance cycling tests. This finding may be associated 
with a lower systemic availability of terbutaline (Sanchez et al., 2013). 
Indeed, the oral dose that was administered by Sanchez et al., (2013) would 
probably have elicited serum levels similar to those attained by Elers et al., 
(2012b), which were around four times lower than that attained by Hostrup et 
al., (2014). The present study would have benefitted from the analysis of 
blood plasma levels of terbutaline, yet the emphasis of the study was to 
replicate the procedures utilised during doping control tests, which currently 
only test urinary levels of β2-agonists. 
 
The dose required for effective protection against EIB can be as little as one 
inhalation (0.5 mg) of terbutaline (Simpson et al., 2013), which is the dose 
recommended by the manufacturer. The present study investigated a 
therapeutic dose at the upper recommended limit (Prior et al., 1982), even 
though the present study was unable to detect a difference between the 
highest therapeutic inhaled dose and the therapeutic oral (5 mg) dose, it is 
possible that a difference in urinary concentration could exist between the 
minimum therapeutic (0.5 mg) inhaled dose and the 5 mg oral tablets.  
Future research that could investigate a cut-off threshold based upon the 
minimum dose required for a therapeutic effect (0.5 mg inhaled terbutaline) 
would provide useful information regarding the urinary levels attained 
following low dose inhaled terbutaline, these urinary levels may then be 
distinguishable from those of oral terbutaline.  
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Care is warranted when assessing differences between gender due to 
weight differences between males and females as found by Guo et al., 
(2010) who noted that females exhibited urinary levels of fluconazole roughly 
20% higher than males, which correlated with the average weight of the 
females being ~20% lighter, resulting in a higher volume distribution of the 
drug. Also of note is the possible difference in the metabolism of different 
substances, which can vary highly between individuals. Kim et al. (2004) 
suggested that an individual can be either an extensive metaboliser or a 
poor metaboliser. Variation in metabolism may also be due to inter-ethnic 
variation associated with genetic variations (Kim et al., 2004; Deshmuck et 
al., 2010)). Such a variation in the metabolism of terbutaline between ethnic 
groups could be a possible explanation as to why both Asian and Afro-
Caribbean urinary concentrations appear lower than Caucasian values, 
conclusive evidence of this could only be obtained by identifying the enzyme 
responsible for metabolizing terbutaline and comparing gene variants across 
ethnicities.  It cannot be discounted that these variations could simply be due 
to variations between inhalation technique, despite every effort to 
standardize this it may still have been a factor that allowed for variability 
between results.  Further research examining gender and ethnic variations in 
urinary concentrations of metabolites, standardizing for weight differences 
and investigation enantiomers along with genetic variants in metabolizing 
enzymes, is needed in order to better inform anti-doping policy and 
procedure. 
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As previously mentioned, a limitation to the current study was the absence of 
an investigation of the ratio of enantiomers in the urine and calculation of the 
metabolic ratio (parent drug/metabolite) (Roig et al., 2002), which would 
have further evidenced any possible gender or ethnic differences with regard 
to the metabolism of terbutaline and its excretion in the urine. The 
establishment of a correction equation which could standardise for body 
weight would also have been an advantage to allow for direct comparisons 
across the board. A further limitation was the absence of a direct comparison 
between a standardised inhaled dose and a standardised oral dose of equal 
proportion, however it would have been unethical to administer an inhaled 
dose equivalent to the minimum available oral dose of 5 mg. 
 
In conclusion, the present study identified significant differences in the urine 
concentration of terbutaline following inhaled and oral administration, 
however due to high inter-individual variability a cut-off value was not 
identified. The study was able to identify upper thresholds following oral use 
and inhaled use, which could be used to identify supra-therapeutic use of 
terbutaline. Gender differences were identified between male and female 
Caucasians during the multiple oral administration trial. Ethnic differences 
were identified between male Caucasians and male Asians during the single 
inhaled administration trial. Further research incorporating both female 
Asians and female Afro-Caribbeans is required to fully elucidate inter-ethnic 
gender differences. Future research should also examine urine 
concentrations following a minimum therapeutic dose of inhaled terbutaline 
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versus oral terbutaline and also establish differences in enantiomers in the 
urine to provide further support for anti-doping cut-off limits. 
 
Athletes that use terbutaline therapeutically through the TUE process may 
experience ergogenic effects during endurance performance. Following on 
from this study we wanted to test the ergogenic effect of therapeutic dosing 
of terbutaline (2 mg; 4 mg) on endurance exercise performance through 3 
km running time-trials.  
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6.  The impact of inhaled 
terbutaline on 3 km 
running time-trial 
performance in males and 
females 
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6.1 Background 
 
As an alternative to salbutamol another short-acting β2-agonist, terbutaline, 
is available which is purported to have fewer adverse side-effects (Sanchez 
et al., 2013) and is protective against bronchoconstriction following single-
dsoe administration (Simpson et al., 2013). Accordingly, terbutaline may 
provide a more desirable treatment option for the athletic population 
(Sanchez et al., 2013). The findings from Chapter 5 indicate that therapeutic 
inhaled doses of terbutaline can lead to urinary terbutaline concentrations 
that do not exceed 1500 ng·ml-1 which may be useful in establishing between 
oral and inhaled use. It is still unclear, however, as to whether a therapeutic 
inhaled dose of terbutaline can lead to performance enhancement. 
 
Unlike the permitted β2-agonists salbutamol, formoterol and salmeterol, 
terbutaline is prohibited during competition except for those athletes who 
provide demonstrable evidence of EIB sufficient for the issuing of a 
therapeutic use exemption (TUE) certificate (WADA Prohibited List 2015). 
This prohibited status is largely due to the inability to distinguish between 
inhaled and oral use, with oral use being banned for all β2-agonists (WADA 
Prohibited List 2015). Whilst investigations into threshold limits that can 
distinguish between inhaled and oral use of terbutaline are ongoing 
(including results from Chapter 5 of this thesis), it is important to evaluate 
whether there are any performance enhancing properties when taken at the 
therapeutic dose. Recent investigations examining the performance 
enhancing effects of supra-therapeutic doses of terbutaline have highlighted 
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an ergogenic potential during sprint cycling performance (Hostrup et al., 
2014) but not in endurance cycling performance (Kalsen et al., 2014). A 
possible mechanism for the improved sprint cycling performance may be due 
to enhanced systemic availability of terbutaline following such high-dose 
inhalation, which may have had a more potent effect on skeletal muscle 
receptors than would occur following a therapeutic dose. However, athletes 
with a TUE that require the use of terbutaline should only be taking a 
therapeutic dose for the relief of symptoms, therefore it is this dose that 
warrants investigation for any possible ergogenic effect. 
 
The highest acute therapeutic dose of inhaled terbutaline in the literature has 
been as high as 4 mg (8 x 0.5 mg inhalations) (Prior et al., 1982) however, 
the dose required for therapeutic effects can be as low as a single inhalation 
of 0.5mg (Simpson et al., 2013). With a large variation in what could be 
considered the ideal therapeutic dose, athletes with a TUE may feel the 
need to take doses towards the higher end of the spectrum in order to obtain 
adequate protection from the symptoms of EIB. With no standardised 
therapeutic dose outlined for the use of inhaled terbutaline in athletes with a 
TUE it is reasonable to assume that athletes would use single inhaled doses 
ranging from 0.5 mg to 4 mg.  
 
Accordingly, the aim of the present study was to examine the effects of 2 mg 
and 4 mg inhaled terbutaline on 3km running time-trial performance. 
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6.2 Methods 
 
6.2.1 Participants 
 
Following ethical approval from the Liverpool John Moores University 
research ethics committee (Ethics No. P11SPS044), 8 males (age: 24.3 ± 
2.4 years; weight: 77.6 ± 8 kg; height: 179.5 ± 4.3 cm) and 8 females (age: 
22.4 ± 3 years; weight: 58.6 ± 6 kg; height: 163 ± 9.2 cm) volunteered to 
participate in the study providing their written informed consent. All 
participants were in good health, non-smokers and took part in recreational 
sport and exercise activities for at least 3 hours per week. No participant had 
previously been diagnosed with asthma and/or EIB, all participants were free 
from chest infection for at least two weeks prior to testing. Subjects were 
informed about the nature and the risks of the experimental procedures 
before giving their informed consent.  
 
6.2.2 EVH Challenge 
 
As described in general methods sections 3.3 and 3.4. A negative EVH 
challenge was required in order to participate in the study. Criteria for 
progression into the study are outlined in figure 6.1. 
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Figure 6.1: Schematic diagram of study progression 
 
6.2.3 Three km Time-Trial 
 
As described in general methods section 3.6. 
 
Following familiarisation each participant was required to perform a 3km 
time-trial on three occasions in a randomised, single blind, repeated 
measures design with a minimum of 7 days between trials. Participants were 
instructed to follow the same 24 hour dietary intake prior to each trial. 
Participants were assigned to one of the following groups: 
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(1) Eight inhalations (via pocket chamber) of a non-active inhalant 
(placebo); 
(2) Four inhalations of non-active inhalant plus four inhalations of 0.5 mg 
terbutaline (2mg);   
(3) Eight inhalations of 0.5 mg terbutaline (4mg)  
 
All inhalers looked identical and were kept out of view of the participants 
during dosing to ensure sufficient blinding. The 3km time-trials were 
performed under controlled laboratory conditions of 18°C and 40% humidity. 
 
Following baseline spirometry, subjects were administered their treatment 
dependent upon trial condition, 10 minutes post-inhalation spirometry was 
repeated, before the completion of a standardised warm-up (5 minutes on a 
motorized treadmill at 10 km.h-1); subjects then began the performance time-
trial on the curve treadmill (Woodway, Wisconsin). Two minutes following the 
completion of the 3 km time-trial a finger-tip capillary blood sample was 
collected to measure blood lactate concentration (Lactate Pro, Arkray KDK, 
Japan) followed by final spirometry and the provision of a urine sample.  
 
During the 3 km time-trial participants were only given feedback on the 
distance they had covered. They were blinded to all other feedback such as 
time and HR. Participants were encouraged to complete the time-trial as fast 
as possible. Time-trial progression is shown in figure 6.2. 
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Key: S – Spirometry, A – Trial Administration, W – Warm-Up, TS – Time-Trial Start, TF – Time-Trial 
Finish, L – Blood Lactate, U – Urine Sample 
 
 
Figure 6.2. Schematic of the protocol used for each laboratory visit 
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6.2.4 Terbutaline Urinalysis 
 
As described in general methods section 3.13. 
 
6.2.5 Sample Correction 
 
All urine concentrations were corrected to urine specific gravity of 1.020 prior 
to analysis using the following equation (Elers et al., 2012b):  
Corrected urine concentration = measured urine concentration x (0.02/(urine 
specific gravity -1)). 
 
6.2.6 Statistical Analysis 
 
Statistical analysis incorporated two-way repeated measures analysis of 
variance (ANOVA) to compare between trial conditions during time-trial 
performance, a Bonferroni correction was applied to correct for multiple 
comparisons. Spirometry measurements were also analysed to compare 
between conditions and between time-points using a mixed model repeated 
measures ANOVA. Significance was set at P<0.05 for all analyses. All data 
were reported as mean (±SD) unless otherwise stated. Statistical analysis 
was performed using the statistical package for the social sciences (SPSS 
v21.0, IBM, New York). 
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6.3 Results 
 
All sixteen participants successfully completed all trials. Participant 
demographics and lung function screening values are shown in Table 6.1. 
No side-effects were reported following terbutaline administration in any of 
the participants. 
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Table 6.1: Mean (±SD) Subject Demographics and Lung Function Values Pre- and Post EVH Challenge for Males and 
Females 
 
Group Height (cm) Weight (kg) Age (yrs.) Baseline FEV1 (L) % Predicted FEV1 Post EVH FEV1 % Fall 
Males (n=8) 179.5 (4.3) 77.6 (8) 24.3 (2.4) 5.2 (0.2) 114 (4.6) 5.1 (6.1) 
Females (n=8) 163 (9.2) 58.6 (6) 22.4 (3) 3.6 (0.5) 108.9 (13.4) 2.8 (11.4) 
FEV1 - Forced Expiratory Volume in 1 Second; EVH - Eucapnic Voluntary Hyperpnoea;  
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6.3.1 Urinalysis 
 
There was no difference in urine concentration of terbutaline following either 
2 mg inhalation or 4 mg inhalation post time-trial in males or females (Figure 
6.3). The failure to record a difference between trials may largely be due to a 
high individual variation in urine concentration within each group. The 
highest individual peak value measured was 1244.4 ng.ml-1 in the female 
group and 1244.4 ng.ml-1 in the male group, with both occurring following the 
4 mg inhaled dose (Figure 6.3). 
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Figure 6.3: a) Individual peak and b) Mean ±SD urinary concentrations of 
terbutaline between trials in males and females.  
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6.3.2 Three km Running Time-Trial Performance 
 
There was no significant difference in completion time between trials in 
either males or females (Figure 6.5). Heart rate values were not significantly 
different between trial conditions yet did significantly increase over time 
during the 3km time-trial performances. Rating of perceived exertion values 
were also not significantly different between trials at any time-point during 
performance, indicating that all trials were performed with equal effort 
(Figure 6.4). In the female group there was a significant difference in lactate 
values between the placebo trial (8.6 ± 0.5 mmol·L-1) compared to the 4 mg 
inhaled terbutaline trial (11.4 ± 0.8 mmol·L-1) (P=0.02), yet this difference did 
not translate to a change in performance or perceived exertion, there were 
no significant differences in lactate values in males, no differences were 
observed between VO2, VCO2 and RER in either group (Figure 6.6). 
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Figure 6.4: Heart rate during each of the three trials for a) Females and b) Males alongside Ratings of Perceived Exertion during 
each of the three trials for c) Females and d) Males including mean values for e) Heart rate and f) RPE. 
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Figure 6.5: Mean (±SD) and individual 3km time-trial completion times for a) Female mean completion b) Female individual 
completion c) Male mean completion d) Male individual completion 
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Figure 6.6: VCO2, VO2, RER and Lactate values post 3km running time-trial between conditions in males and females.  
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6.3.3 Respiratory Measurements 
 
No differences were seen between any parameters in females. In males 
there was a significant difference in FEV1 between conditions (P=0.028). 
There were no differences between FEV1 values in the placebo trial at any 
time point. There was a significant difference between baseline and both 
post inhalation (P=0.003) and post time-trial (P=0.014) FEV1 values in the 2 
mg inhaled trial (4.84 ± 0.2 L; 5.08 ± 0.2 L; 5.07 ± 0.2 L), respectively. There 
was a significant difference between baseline and both post inhalation 
(P<0.001) and post time-trial (P=0.028) FEV1 values in the 4 mg inhaled trial 
(4.8 ± 0.2 L; 5.07 ± 0.2 L; 5.04 ± 0.2 L), respectively (Figure 6.7). There was 
no difference in baseline values between conditions. There was a significant 
difference in post inhalation FEV1 values between placebo and both 2 mg 
(P=0.011) and 4 mg (P=0.026) inhalation trials (4.83 ± 0.2 L; 5.08 ± 0.2 L; 
5.07 ± 0.2 L), respectively. There was a significant difference in post time-
trial FEV1 values between placebo and the 2 (P=0.04) mg inhalation trial but 
not the 4 mg inhalation trial (4.87 ± 0.2 L; 5.07 ± 0.2 L; 5.04 ± 0.2 L), 
respectively (Figure 6.7). 
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Figure 6.7: FEV1 following inhaler administration for all trials for change in 
FEV1 from baseline levels 
* - Significantly different from baseline 
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6.4 Discussion 
 
The aim of the present study was to investigate the effects of 2 and 4 mg 
inhaled terbutaline on 3 km running time-trial performance in males and 
females. This study demonstrated that inhaled terbutaline does not improve 
3 km running time-trial performance in males or females. Terbutaline did 
result in a significantly increased resting lung function in healthy males and 
females similar to that observed with other short-acting β2-agonists i.e. 
salbutamol. The maximum observed urinary concentration of terbutaline was 
1244.4 ng/ml-1 following the inhalation of 4 mg terbutaline. This data is able 
to support the therapeutic use of terbutaline in those individuals with a TUE. 
 
In contrast to the findings of this study Hostrup et al., (2014) reported 15 mg 
inhaled terbutaline significantly improved muscle strength and sprint cycling 
performance but not 300 kcal cycling time-trial performance in trained males. 
Conversely, Kalsen et al., (2014) also investigated the effects of 15 mg 
inhaled terbutaline on performance, during a 300 kcal cycling time-trial, 
finding no significant difference in performance compared to placebo. 
Hostrup et al., (2014) in agreement with Sanchez et al., (2012) explain that a 
possible mechanism for improved strength and power performance could be 
due to improved Ca2+ handling from the sarcoplasmic reticulum of skeletal 
muscles, mediated by cAMP-dependent phosphorylation of proteins 
associated with the sarcoplasmic reticulum.   Of note, Kalsen et al., (2014) 
suggested that inhaled terbutaline promotes a shift towards carbohydrate 
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metabolism during exercise. This conclusion could support the higher lactate 
values observed in the female participants in the present study following 4 
mg of inhaled terbutaline despite no differences in performance or perceived 
exertion during the trial. 
 
In the present study, therapeutic inhaled doses of terbutaline were 
investigated in order to ascertain their effects on endurance performance. 
The findings indicate no ergogenic effect of inhaled terbutaline and support 
the use of inhaled terbutaline for those athletes with a TUE.  Currently a TUE 
is needed for the use of inhaled terbutaline during competition, largely due to 
the inability to distinguish between an inhaled dose and a prohibited oral 
dose (Elers et al., 2012b). In a recent study by Elers et al., (2012b) 
investigating the blood and urinary concentrations of terbutaline following 
either an inhaled or an oral dose, it was highlighted that although significant 
differences were found between the doses, no cut-off value could be 
established between the two modes of administration. If a cut-off value were 
able to be established then it is possible that inhaled terbutaline would be 
able to be monitored in much the same way as both salbutamol and 
formoterol, where an adverse analytical finding would indicate possible 
supra-therapeutic use or oral administration which may have ergogenic 
potential (Hostrup et al., 2014). Therefore providing an accessible alternative 
to salbutamol in athletes who suffer with adverse side-effects or are 
unresponsive to salbutamol treatment. 
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In addition to the paucity of data at present examining the impact of inhaled 
terbutaline on performance there is a paucity of data examining the 
ergogenic impact of oral terbutaline. A recent study by Sanchez et al., (2013) 
investigating the effects of a supra-therapeutic (8mg) oral dose of terbutaline 
on aerobic performance, found no significant difference versus placebo, 
highlighting the lack of ergogenic potential of terbutaline even at higher 
doses. Accordingly, further research examining the ergogenic impact of 
inhaled and oral terbutaline on strength and power performance is 
warranted.  
 
In conclusion, inhaled doses of up to 4 mg of terbutaline do not improve 3 
km running time-trial performance in males or females. The finding that the 
highest individual peak value measured was 1244.4 ng.ml-1, is in agreement 
with the findings from Chapter 5 suggesting that terbutaline concentrations 
following inhaled use do not exceed 1284 ng.ml-1. Further research is 
needed to investigate upper cut-off limits of terbutaline in the urine and the 
ergogenic effect of terbutaline on strength and power performance following 
therapeutic inhaled doses and supra-therapeutic oral doses. 
 
With salbutamol being the most widely used medication for athletes with 
respiratory symptoms the next chapter will investigate the use of salbutamol 
in individuals exercising in a bronchoprovocative environment to assess the 
protective effects of salbutamol and also the potential to offset a decrement 
in performance in EVH+ve individuals compared to healthy controls. 
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7.1 Background 
 
The majority of previous research investigating the effects of salbutamol use, 
with regard to possible performance enhancement, has used participants 
who are free from asthma or EIB (Meeuwisse et al., 1992; Van Baak et al., 
2000; Sporer et al., 2008).  As such, it is still relatively unclear what effect 
this medication has at offsetting the potential decrement in performance or 
fall in lung function, that may be experienced in individuals who exhibit with 
EIB, who also regularly exercise in bronchoprovocative environments. No 
performance enhancing effects have been shown for either short-term or 
chronic administration of inhaled salbutamol in healthy individuals (see study 
1 from the present thesis; Dickinson et al., 2014d; Koch et al., 2013).   
 
With salbutamol now the sole permitted β2-agonist for use during competition 
for the treatment of asthma symptoms it is important to investigate the 
effects of this medication on performance in asthmatic individuals. Whilst 
historically, the majority of research investigating salbutamol has used 
healthy male participants, more recently, there have been investigations into 
the effects of salbutamol in both healthy and asthmatic individuals during 
cycling time-trial performance (Koch et al., 2013; Koch et al., 2014; Koch et 
al., 2015), finding no difference between groups in either males (Koch et al., 
2013) or females (Koch et al., 2014) following 400 µg salbutamol, and males 
following 1600 µg salbutamol (Koch et al., 2015) 
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Dickinson et al. (2011) reported a large number of athletes presented with a 
positive EVH challenge with no previous history of asthma or EIB. A positive 
EVH challenge is indicative that the individual has some form of EIB and 
would benefit from inhaler therapy (e.g. salbutamol) to protect against 
bronchoconstriction during or post-exercise, especially in environmental 
conditions which could be potentially more provocative to the respiratory 
system (Sue-Chu et al., 2012). It is hypothesized that exercise without 
salbutamol would be detrimental to performance and/or lung function in 
asthmatic athletes during performance, justifying the use of short-acting β2-
agonists for maintaining standards of performance and for the 
prevention/relief of the symptoms of EIB in susceptible individuals.  
 
Previous work investigating acute doses of salbutamol in athletes with EIB 
has indicated it does not improve cycling time-trial performance compared to 
placebo (Koch et al., 2013; Koch et al., 2014; Koch et al., 2015). However 
the environments that these time-trials took place in were relatively 
unprovocative (Hum ~60% temp ~ 18°C). Therefore the impact of an acute 
dose of salbutamol on exercise performance in athletes with EIB in 
bronchoprovocative environments is unknown. The present study 
investigated the effect of using salbutamol in both healthy individuals and 
eucapnic voluntary hyperpnoea (EVH) positive individuals on 3 km running 
time-trial performance in a low humidity environment.  
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7.2 Methods 
 
7.2.1 Participants 
 
Following ethical approval from the Liverpool John Moores University 
research ethics committee (Ethics No. P13SPS041), 7 mild (ΔFEV1 >-10% 
<-25%)  EVH+ve males (age: 22.7 ± 1.9 years; weight: 71.7 ± 6.6 kg; height: 
175.0 ± 6.0 cm) and 7 EVH-ve males (age: 22.1 ± 1.1 years; weight: 81.1 ± 
8.1 kg; height: 184.3 ± 4.0 cm) volunteered to participate in the study 
providing their written informed consent. All participants were in good health, 
non-smokers and took part in recreational sport and exercise activities for at 
least 3 hours per week. No participant had previously been diagnosed with 
asthma and/or EIB, all participants were free from chest infection for at least 
two weeks prior to testing. Participants were informed about the nature and 
the risks of the experimental procedures before their informed consent was 
obtained.  
 
All participants undertook maximal flow-volume manoeuvres using a 
spirometer (Microlab ML3500, Cardinal Health, Basingstoke, UK). Flow-
volume measures recorded from each maximal flow-volume loop were; 
Forced Expiratory Volume in one second (FEV1), forced vital capacity (FVC), 
FEV1:FVC ratio (FEV1/FVC%), peak expiratory flow (PEF) and forced 
expiratory flow between 25% and 75% of FVC (FEF25–75).  Individual 
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maximal flow-volume loops were accepted in accordance with European 
Respiratory Society/ American thoracic society criteria (Miller et al., 2005). 
 
7.2.2 EVH Challenge 
 
As described in general methods sections 3.3 and 3.4. 
 
7.2.3 ?̇?O2 peak Test 
 
As described in general methods section 3.5. 
 
7.2.4 Three km Time Trial 
 
Once recruited participants were required to familiarise themselves with the 
3 km running time-trial on the Woodway Curve non-motorised treadmill 
(Woodway, Wisconsin) on a minimum of two occasions.  Each participant 
was required to perform a 3km time-trial on a further three occasions in a 
randomised, double blind, repeated measures design with a minimum of 7 
days between trials. Participants were required to inhale (via pocket 
chamber) either 4 inhalations of non-active inhalant (placebo), Salbutamol 
(400μg) or control (nothing inhaled) prior to each 3km time-trial. The 3km 
time-trials were performed in an environmental chamber (Training with 
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Altitude, Sporting Edge UK, England) at 18°C and 21% O2, 20%-25% 
humidity. 
 
Following baseline spirometry, participants were administered their treatment 
dependent upon trial condition, 10 minutes post-inhalation spirometry was 
repeated, before the completion of a standardised warm-up (5 minutes on a 
motorized treadmill at 10 kph); subjects then began the performance time-
trial on the curve treadmill (Woodway, Wisconsin). 3 km time-trials were 
performed as described in general methods section 3.6. Time-trial 
progression is shown in figure 7.1. 
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Figure 7.1: Schematic of the protocol used for each laboratory visit 
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7.2.5 Statistical Analysis 
 
Two-way repeated measures analysis of variance (ANOVA) was used to 
compare time-trial performance between groups and trial conditions, a 
bonferroni correction was applied to correct for multiple comparisons. 
Spirometry measurements were also analysed to compare between groups, 
between condition and between measurements using a mixed model 
repeated measures ANOVA. Significance was assumed at P<0.05 for all 
analyses. All data were reported as mean (±SD) unless otherwise stated. 
Statistical analysis was performed using the statistical package for the social 
sciences (SPSS v21, IBM, New York). 
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7.3 Results 
 
7.3.1 Participant Characteristics 
 
Fourteen participants (7 EVH+ve; 7 EVH-ve) successfully completed all 
trials, participant demographics and lung function screening values are 
shown in Table 7.1. 
Table 7.1: Mean (±SD) Subject Demographics and Lung Function Values 
Pre- and Post-EVH Challenge for: EVH Positive Individuals (EVH+ve) and 
EVH Negative Individuals (EVH-ve) 
Group 
Height 
(cm) 
Weight 
(kg) Age (yrs) 
Baseline 
FEV1 
% Predicted 
FEV1 
Post EVH 
% ΔFEV1 
EVH+ve 
(n=7) 175 (6) 71.7 (6.6) 22.7 (1.9) 4.13 (0.8) 92.9 (13.1) -14.4 (1.5) 
EVH-ve 
(n=7) 184.3 (4) 81.1 (8.1) 22.1 (1.1) 4.94 (0.5) 102.6 (6.3) -6.02 (0.9) 
FEV1 - Forced Expiratory Volume in 1 Second; EVH - Eucapnic Voluntary Hyperpnoea 
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7.3.2 Lung Function Values 
 
Overall there was a significant difference in post-administration FEV1 
between the Salbutamol trial (4.66 ± 0.60 L) and both the Placebo trial (4.46 
± 0.60 L) and Control trial (4.44 ± 0.60 L) (P<0.01) (Figure 7.2). During the 
Salbutamol trial there was a significant increase in FEV1 from baseline to 
post-salbutamol administration (Δ FEV1 0.25 ± 0.07 L) (P<0.01) and post 
time-trial (Δ FEV1 0.24 ± 0.12 L) (P=0.016) (Figure 7.3). There was a 
significant difference in FEV1 between groups  at baseline with mean (±SD) 
values of 4.1 ± 0.8 L and 4.8 ± 0.4 L for the EVH+ve group and the EVH-ve 
group, respectively (P=0.032).  There was no significant difference between 
groups for the change in FEV1 during the Salbutamol trial (Figure 7.3). 
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Figure 7.2: Lung Function Values for: a) EVH-ve FEV1 values for each condition b) 
EVH+ve FEV1 values for each condition c) EVH –ve FVC values d) EVH+ve FVC 
values e) EVH-ve ratio values f) EVH+ve ratio values 
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Figure 7.3: Change in FEV1 from baseline in both groups during the three conditions 
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7.3.3 Performance Variables 
 
There were no significant differences between completion times either 
between groups or between trials (Figure 7.4). There were no significant 
differences between post-exercise lactate concentrations or RPE highlighting 
that individual effort for each trial was the same. There were no differences 
between groups for minute ventilation (?̇?E) and this was also not significantly 
higher in the Salbutamol trial despite higher values for FEV1 post-Salbutamol 
inhalation. There was no difference between groups or between conditions 
for ?̇?O2. 
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Figure 7.4: Performance Variables for a) Completion Time; b) Post Time-Trial Lactate Values; c) Peak Minute Ventilation; d) Mean V̇O2 Values 
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7.3.4 Heart Rate 
 
There was a significant difference in heart rate (HR) between the Salbutamol 
trial and the control trial, HR was higher in both groups during the 
Salbutamol trial at the start of exercise (171.5 ± 11.3 and 174.3 ± 6.6 bpm) 
compared to the control trial at the start of exercise (169.5 ± 11 and 166.3 ± 
8.9 bpm) for the EVH+ve group and the EVH-ve group, respectively 
(P=0.047). There was also a significant difference in average HR throughout 
the trials in the Salbutamol trial (182.5 ±8.4 and 183.5 ±8.2 bpm) compared 
to the control trial (179.7 ±9.8 and 179.5 ±8.3 bpm) for the EVH+ve group 
and the EVH-ve group, respectively (P=0.05) as can be seen in figure 7.5. 
There was a significant difference in HR between groups during the placebo 
trial (P<0.01) yet there was no difference in either lactate, RPE or completion 
time between groups during this trial indicating that the lower heart rates did 
not affect performance and were not due to lesser effort in those trials.  
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Figure 7.5: Heart Rate and Ratings of Perceived Exertion for: a) Salbutamol Trial; b) 
Placebo Trial; c) Control Trial. 
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7.4 Discussion  
 
The aim of the present study was to investigate the effect of salbutamol use 
on performance in EVH+ve and EVH-ve individuals in a bronchoprovocative 
environment. The study found no significant improvements in 3 km running 
time-trial performance following 400 µg inhaled salbutamol in mild EVH+ve 
individuals and also EVH-ve controls. 
 
Despite the exercise environment being more provocative to induce AHR no 
significant falls in FEV1 were seen post time-trial in the EVH+ve group, nor 
were there any differences in exercise performance. The results are in 
agreement with the findings of Koch et al. (2014) who examined the effects 
of Salbutamol inhalation on cycling performance in both asthmatic and non-
asthmatic males. The results highlighted a significant increase in FEV1 in 
both groups post-bronchodilator in the absence of any improvement in 
performance. Koch et al. (2014) found the same effects in female athletes 
where FEV1 was significantly increased in both asthmatic and non-asthmatic 
individuals. Of note, their findings also highlighted that there was a 
significant decrease in cycling mean power output during the salbutamol 
time-trials in this female cohort (Koch et al., 2014). The results of chapter 7 
add to the findings of Koch et al., (2013) by investigating the role of 
salbutamol in a low humidity environment, finding no differences in 
performance or lung function post performance in asthmatic individuals 
compared to healthy controls. 
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Lung-function values post-exercise in the EVH+ve group did not significantly 
fall as expected through the broncho-provocation which occurred during 
exercise at low humidity.  This may highlight that although some individuals 
were mild EVH+ve they may have been negative to EIB due to the high 
sensitivity of the EVH challenge, a factor that is highlighted by Rundell et al. 
(2004) where 7 out of 38 (18%) athletes exhibited with mild to moderate falls 
in FEV1 following EVH challenge, these falls were not apparent following an 
exercise challenge. Further research (Price et al., 2014a) has also 
highlighted that participants with mild falls (-10% to -20%) following EVH 
challenge did not show reproducibility during follow-up EVH challenge tests. 
Therefore mild EVH+ve athletes may have transient AHR that does not 
occur following every exercise effort, alternatively the EVH challenge may be 
too sensitive and therefore individuals who are mild EVH+ve may not exhibit 
with EIB at all. The participants in the present study may also have been 
negative to any form of asthma due to the lack of full reversibility (>12% 
increase in FEV1) to salbutamol. The post-exercise changes in lung function 
would have benefitted from flow-volume loops at 10 and 15 minutes post-
exercise to fully elucidate this finding. 
 
The present study found no effects on exercise performance in line with 
previous research (Koch et al., 2013; Koch et al., 2014). This is in contrast to 
the findings of Kalsen et al. (2014) and Decorte et al. (2013) who used 
higher doses of inhaled β2-agonists and also looked at muscle contractility 
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performance variables, possible reasons for the differences are due to 
higher systemic availability of the drug.  
 
In addition, the hypothesis that exercising in a broncho-provocative 
environment (low humidity in this study) would adversely affect performance 
in individuals who were mild EVH+ve was also investigated. Previous studies 
examining the effects of exercise in broncho-provocative environments have 
found that dry, cold air adversely affects lung function values during high-
intensity exercise (Rundell et al., 2004). It is not yet known how much of an 
effect this can have on performance, many elite athletes that experience EIB 
would be reluctant to exercise without the broncho-protective effects of β2-
agonists. In the interests of safety the current study was only able to recruit 
participants with no previous history of asthma and/or AHR, who exercised 
regularly without the use of β2-agonists yet exhibited a mild positive 
response (ΔFEV1 <10% >25%) to the EVH challenge. However, given that 
an estimated 13% of individuals are exercising with previously unrecognized 
AHR/EIB, with some individuals experiencing moderate-severe falls in FEV1 
post-challenge (Molphy et al., 2014), it is important to highlight the potential 
adverse effects of exercise in different environments to help inform these 
individuals of the need for the protective use of bronchodilators. 
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7.4.1 Conclusions 
 
The findings of the present study highlight that there is a significant increase 
in resting and exercise FEV1 with inhaled salbutamol in both healthy and 
mild EVH+ve individuals. However, this increase in FEV1 does not translate 
to improved performance during a 3 km running time-trial. Finally, the low 
humidity environment (20-25%) did not induce a fall in FEV1 in mild EVH+ve 
individuals.  
 
It is possible that asthmatic athletes who are using salbutamol alongside a 
corticosteroid may get more beneficial effects from the short-acting β2-
agonist medication, a recent study by Spiteri et al. (2014) was able to show a 
non-significant but greater improvement in rugby fitness within a subset of 
EVH+ve rugby players whilst using a combination of salbutamol and 
corticosteroid continuously for 8 weeks. Haverkamp et al. (2007) were able 
to successfully identify improved performance and alveolar ventilation in 
steroid naïve asthma patients following 6 weeks ICS use, it would be useful 
to see the effects of similar studies conducted on athletes with EIB. 
 
There is not sufficient evidence for either an ergogenic effect of salbutamol 
on performance or a decline in performance without salbutamol in asthmatic 
individuals, this does not mean that an athlete should avoid salbutamol use 
however, due to its bronchoprotective effects. The long-term effects of using 
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inhalers is still relatively unknown (Price et al., 2014b) and further work is 
warranted looking into chronic use of inhaled asthma medications. 
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8 . Synthesis of Findings 
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8.1  Reflection of Aims and Objectives 
 
Currently only one short-acting β2-agonist (salbutamol) is available for use 
by athletes (WADA Prohibited List, 2015), and until recently it has been 
unclear whether prolonged (chronic) use has any ergogenic potential. The 
findings from the current thesis indicates that the WADA regulations stating a 
maximum of 1600 µg inhaled salbutamol per day (24 hour period) appear to 
be sufficient given that this dose failed to induce performance enhancement 
following long-term (6 weeks) use.  
 
It has been previously suggested that terbutaline offers an alternative short-
acting β2-agonist for athletes suffering adverse side-effects from salbutamol 
(Sanchez et al., 2013). This thesis confirms the findings of a small number of 
previous studies demonstrating that terbutaline, when taken at high 
therapeutic doses of 2 mg and 4 mg does not have any ergogenic effect on 
endurance performance. Of note, the present thesis is the first to 
demonstrate the potential for an upper urinary concentration threshold for 
terbutaline following therapeutic inhaled administration which could be used 
to distinguish between therapeutic inhaled and oral use.  
 
It is unknown whether the ergogenic potential of salbutamol would be greater 
in asthmatic athletes compared to placebo. Previous work investigating 
salbutamol on cycling performance in mild EVH+ve individuals has found no 
ergogenic effect (Koch et al., 2013; Koch et al., 2014; Koch et al., 2015). To 
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date there has been no research into the ergogenic potential of salbutamol in 
asthmatic athletes exercising in a bronchoprovocative environment (low 
humidity), compared to placebo. This thesis found that in mild EVH+ve 
individuals there was no ergogenic potential of salbutamol during 3 km 
running time-trial performance at ~20-30% humidity, compared to placebo. 
  
8.2  General Discussion 
 
8.2.1 Do short-acting β2-agonists have ergogenic effects? 
 
In Chapter 4 the impact of chronic (6 week), daily accumulated doses of 
1600 µg of inhaled salbutamol on endurance, strength and power 
performance was examined. The results indicate there is no significant 
performance improvement in any marker of endurance, strength or power 
performance compared with placebo. This unique study is the first training 
study to investigate prolonged salbutamol use, at the maximum permitted 
therapeutic dose (1600 µg in a 24 hour period), on athletic performance.  
 
The findings from Chapter 4 add to the current body of literature 
investigating the maximum therapeutic dose of inhaled salbutamol. Previous 
work has highlighted that inhaled salbutamol up to the WADA recommended 
daily limit of 1600 µg, either acutely or cumulatively, does not lead to 
 187 | P a g e  
 
improvements in endurance, strength or power performance (Pluim et al., 
2011; Dickinson et al., 2014a; Dickinson et al., 2014b; Decorte et al., 2008, 
Sporer et al., 2008). Work investigating the supra-therapeutic use of inhaled 
salbutamol (up to 4000 µg in a single-dose; Elers et al., 2012a) 
demonstrated no improvements in either cycling time to exhaustion or 
cycling oxygen kinetics at a sub-maximal work-rate equivalent to 75% of 
maximal exertion. In accordance with these findings the WADA guidelines, 
which permit athletes to inhale up to 1600 µg over a 24 hour period, are 
sufficient to avoid any performance improvements in non-asthmatic athletes.  
 
The findings from Chapter 4 indicating no greater improvement in any 
performance variable in the salbutamol group compared to placebo are in 
contrast to the findings from studies investigating oral salbutamol. In a meta-
analysis of the effects of β2-agonists Pluim et al. (2011) concluded that the 
performance enhancing effects of an acute dose of oral salbutamol showed 
weak evidence to suggest an improvement in anaerobic capacity and 
strength. Le Panse et al. (2007) demonstrated an increased cycling peak 
power following an acute dose of 4 mg oral salbutamol and earlier work by 
the same group (Le Panse et al., 2006) reported that the chronic ingestion of 
supra-therapeutic oral salbutamol (12 mg.day-1 for 4 weeks) resulted in 
significantly increased peak power and decreased time to peak power. 
Further support for the ergogenic effect of oral salbutamol was provided in a 
recent study by Sanchez et al. (2012) who examined the impact of oral 
salbutamol on maximal sprint cycling power from either a single, acute dose 
(6 mg) or a daily dose (12 mg.day-1) for three weeks. They reported that oral 
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salbutamol resulted in significantly improved maximal power with the one-off 
dose resulting in greater gains than three weeks daily intake (14% vs. 8%). 
Of note, the authors concluded that an acute oral dose led to greater gains 
and that long-term use of oral salbutamol may lead to a down regulation of 
muscle β2-adrenoreceptors leading to a dampening of the effect of 
salbutamol on strength gains. The potential down regulation of muscle β2-
adrenoreceptors from daily doses of salbutamol may offer an explanation for 
the reduction in 1 RM peak torque leg extension at 60o.s-1 in the SAL group 
compared to an improvement in the PLA group in Chapter 4 of this thesis. 
Overall, the findings from Chapter 4 and previous studies support the WADA 
upper daily limit of 1600 µg inhaled salbutamol whilst previous studies 
examining oral salbutamol supports the maintenance of oral salbutamol on 
the WADA restricted list. 
 
The main action of inhaled salbutamol is to act as a bronchodilator to 
reverse the bronchoconstriction of airway smooth muscle. This results in the 
asthmatic airway becoming dilated leading to a reduced airway resistance 
and improvements in V̇E and exercise performance (Haverkamp et al., 2007; 
Anderson & Kippelen., 2008). One of the proposed ergogenic mechanisms 
for inhaled salbutamol is a bronchodilation in non-asthmatic athletes 
resulting in an improved V̇E and an increased oxygen uptake during exercise. 
Findings in Chapter 4 provide, in part, support for this hypothesis with 
significant increases in  V̇E during the  V̇O2peak assessment in the SAL group 
when compared to PLA, however; this increase in  V̇E did not result in an 
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improved  V̇O2peak. Previous research has reported similar improvements in  
V̇E following acute doses of up to 1600 µg of salbutamol in the absence of an 
improvement in 5 km running time-trial performance in endurance athletes or 
repeated sprint performance in football players (Dickinson et al., 2014a; 
Dickinson et al., 2014b). Furthermore, similar studies have demonstrated 
non-significant improvements in FEV1 of 0.2 L following inhalation of 800 µg, 
which did not result in greater V̇E or improved endurance performance 
(Decorte et al., 2008). 
 
Previous oral salbutamol studies have demonstrated performance gains in 
strength and power variables (Pluim et al., 2011; Sanchez et al., 2012; 
Caruso et al., 1995; Martineau et al., 1992; Le Panse et al., 2006; Le Panse 
et al., 2007). In addition to strength and power Chapter 4 focused on 
endurance performance. This had an impact on the prescribed training 
programme as participants completed two strength and power sessions and 
two endurance sessions per week. Research supporting the efficacy of 
combined strength and endurance training has been presented by Hakkinen 
et al. (2003) investigating the impact of combined strength and endurance 
training (2 days strength, 2 days endurance per week) compared to strength 
training alone (2 days per week). Their findings demonstrated no differences 
between variables in either group. However, if the present study had focused 
solely on strength and power assessments the participants may have 
experienced greater strength gains from four days a week of strength 
training compared with two days per week. Future studies could employ a 
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greater strength and power training load allowing greater comparisons with 
oral salbutamol studies.  
 
The findings of Chapter 6 demonstrate that terbutaline, when taken in 
therapeutic doses (2 mg and 4 mg), does not improve 3 km running time-trial 
performance in either males or females. Terbutaline did result in a 
significantly increased resting lung function in healthy males and females 
similar to that observed with other short-acting β2-agonists i.e. salbutamol.  
 
Recently the ergogenic potential of inhaled terbutaline has been examined. 
Hostrup et al. (2014) observed that a supra-therapeutic inhaled dose of 
terbutaline allowed for an improvement in muscle strength (8.4 ± 3.0 %) 
during maximal voluntary contractions, as well as maximal sprint peak power 
(2.2 ± 0.8 %) and mean power (3.3 ± 1.0 %) during the Wingate test on a 
cycle ergometer. Interestingly, these power improvements did not translate 
to any improvements in time-trial performance. Of note, the power 
improvements in this study may be attributed to the increased systemic 
availability of the drug with peak plasma concentrations of 23.6 ± 1.1 ng·ml-1. 
Additionally, Kalsen et al. (2014) investigated the effects of 15 mg inhaled 
terbutaline on endurance performance during a 300 kcal cycling time-trial 
finding no significant difference in performance compared to placebo. The 
findings reported in Chapter 6 are in line with Kalsen et al. (2014) and 
Hostrup et al. (2014) suggesting no improvement in endurance time-trial 
performance following terbutaline inhalation in both males and females. Of 
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note, Kalsen et al. (2014) suggested that inhaled terbutaline promotes a shift 
towards carbohydrate metabolism during exercise. This conclusion could 
support the higher lactate values observed in the female participants in the 
present study following 4 mg of inhaled terbutaline, despite no differences in 
performance or perceived exertion during the trial.  
 
The findings of Chapter 6 and others (Kalsen et al., 2014; Hostrup et al., 
2014; Larsson et al., 1997; Sanchez et al., 2013) have concluded that 
terbutaline administration has no significant effect on endurance 
performance however, it is important to note that the effects of a supra-
therapeutic dose of terbutaline on increased strength and power 
performance has been clearly indicated (Hostrup et al., 2014). There have 
been very few studies on terbutaline and exercise performance, according to 
a review by Kindermann, (2007) and supported by Pluim et al., (2011) only 
two studies investigating terbutaline on exercise performance (Unnithan et 
al., 1994; Larsson et al., 1997) had been performed prior to 2011. Since 
2011, there have been three studies investigating terbutaline on exercise 
performance (Sanchez et al., 2013; Hostrup et al., 2014; Kalsen et al., 
2014), none of which have investigated any ergogenic potential of a 
therapeutic dose. Future work should focus on the effects of therapeutic 
doses of inhaled terbutaline on strength and power performance. 
 
Chapter 7 investigated the effects of either 400 µg or 800 µg inhaled 
salbutamol during 3 km running time-trial performance on the Woodway 
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curve non-motorised treadmill in a low-humidity environment, finding an 
increased FEV1 with no significant improvements in time-trial performance. A 
recent study by Koch et al. (2013) examined the effects of salbutamol 
inhalation (400 µg) on 10 km time-trial cycling performance in both asthmatic 
and non-asthmatic males. The same research group (Koch et al., 2014) went 
on to examine the effects of inhaled salbutamol (400 µg) in female athletes 
finding that FEV1 was also significantly increased in both asthmatic and non-
asthmatic individuals. Of note, Koch et al. (2014) reported a significant 
decrease in cycling mean power output during the salbutamol time-trials 
which the group explained could have been due to a possible over-
stimulation of the β2-adrenergic system impairing athletic performance, yet 
the exact mechanism for this was not provided. 
 
The administration of a single acute dose of inhaled β2-agonist does not 
appear to affect exercise performance in either healthy individuals or 
individuals with mild EIB in a low humidity environment. Recently, however, 
a study performed by Kalsen et al. (2013) examined the acute administration 
of multiple inhaled β2-agonists simultaneously at the WADA maximum 
permitted daily limit, in healthy and airway hyper-responsive (AHR) 
individuals. The findings from this study demonstrated a significant increase 
in FEV1 post-inhalation in both groups and significantly greater swim 
ergometer sprint performance and maximal voluntary contraction (MVC) with 
β2-agonists, where no improvement in performance was seen in time to 
exhaustion during swimming. The findings that force of muscular contraction 
is improved during exercise is in contrast to the findings of Decorte et al. 
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(2013) who found that there was an increased time to fatigue during 
isokinetic dynamometry contractions of the quadriceps following salbutamol 
inhalation with no improvement in MVC. These differences could be 
explained due to the administration of multiple β2-agonists in the Kalsen et 
al. (2013) study which may have had a greater effect on the β2 adrenergic 
receptors due to greater systemic availability of the drugs. There may have 
also been more potent stimulation due to structural differences between the 
different β2-agonists, leading to greater force of contraction and higher 
muscular fatigue resistance (Hoffman 2001). 
 
In addition, Chapter 7 hypothesized that exercise in a broncho-provocative 
environment would adversely affect performance in individuals who were 
mild EVH+ve. Previous studies examining the effects of exercise in broncho-
provocative environments have found that dry, cold air adversely affects lung 
function values during high-intensity exercise (Dickinson et al., 2006). It is 
not yet known how much of an effect this can have on performance as many 
elite athletes that experience EIB would be reluctant to exercise without the 
broncho-protective effects of β2-agonists. In the interests of safety the 
current study was only able to recruit participants with no previous history of 
asthma and/or AHR, who exercised regularly without the use of β2-agonists 
yet exhibited a mild positive response (Δ FEV1 >10% <25%) to an EVH 
challenge. However, around 13% of individuals that are exercising without 
any previous identification of AHR/EIB, can experience moderate to severe 
falls in FEV1 post-challenge (Molphy et al., 2014). Therefore, it is important 
to highlight the potential adverse effects of exercise in different environments 
 194 | P a g e  
 
to help better inform these individuals of the need for the protective use of 
bronchodilators. 
 
The findings in Chapter 7 highlight that salbutamol significantly increases 
FEV1 in both healthy and mild EVH+ve individuals however, this difference 
has no impact upon either minute ventilation or exercise performance. This 
finding is in line with Koch et al. (2013) who reported a significant increase in 
FEV1 in both groups post-bronchodilator in the absence of an improved 
performance.  Lung-function values post-exercise in the EVH+ve group did 
not significantly fall as expected through the broncho-provocation which 
occurred during exercise at low humidity.  This suggests that some EVH+ve 
individuals may be negative for EIB due to the highly aggressive nature of 
the EVH challenge. Furthermore, they may also have been negative for any 
form of asthma due to the lack of full reversibility (>12% increase in FEV1) to 
salbutamol. The post-exercise changes in lung function would have 
benefitted from flow-volume loops at 10 and 15 minutes post-exercise to fully 
elucidate this finding. 
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8.2.2 Urinary concentrations of β2-agonists following 
therapeutic and supra-therapeutic use.  
 
Dosing to the WADA recommended maximal daily levels of salbutamol 
produced no benefit in terms of enhanced performance; however urinalysis 
results demonstrate the possibility that an individual may contravene anti-
doping regulations. Whilst all but one subject produced a negative test result 
(<1000 ng.ml-1) there is a concern that a single subject produced a sample 
which was greater than the current threshold as a result of the study’s dosing 
regimen. This positive test result highlights the large inter-individual 
variability for urinary thresholds and supports previous findings reporting  
adverse analytical findings (AAF) following the legitimate use of inhaled 
salbutamol (McKenzie, 2004; Schweizer et al., 2004).  
 
The difference between the WADA threshold and the WADA decision limit 
however, appears to be sufficient to differentiate legitimate and illegitimate 
use as the positive responder in Chapter 4 did not exceed the decision limit 
of 1200 ng.ml-1. Nevertheless, Chapter 4 does suggest the administration of 
the WADA upper daily limit of salbutamol may lead to a breach of the 
threshold and thus result in an AAF, which is supported by Dickinson et al., 
(2014d) who found AAF’s following acute doses of 1600 µg salbutamol with 
varying (2 – 5%) levels of dehydration. Dickinson et al. (2014b) also highlight 
the instance of an athlete presenting with an AAF following 1600 µg 
salbutamol prior to 5 km running time-trial performance. Further research is 
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clearly needed to establish the variability surrounding urinary salbutamol 
levels amongst individuals dosing up to and including 1600 µg in either a 
daily accumulated or single dose. 
 
There is ambiguity regarding the optimal therapeutic dose of salbutamol, 
with guidelines that promote its use pro re nata (when required) with a 
maximum of 1600 µg over 24 h. Dickinson et al. (2014b) state that dosing 
over and above this guideline may happen either intentionally or 
inadvertently, indeed a case of such inadvertent misuse has been described 
by Chester et al. (2015) in a professional rugby league player, which led to a 
subsequent AAF. Dickinson et al. (2014b) indicate that athletes feeling the 
need to dose up to and above the 1600 µg limit are clearly experiencing 
uncontrolled asthma which, combined with high-dose β2-agonist use, may 
lead to desensitisation and tolerance to the medication, increasing the 
likelihood of unsuccessful treatment in an emergency and further overdosing 
in an attempt to control EIB. In line with current anti-doping practice Chapter 
4 did not normalise drug concentrations for urine specific gravity. Elers et al. 
(2012a) highlight that urine samples corrected for specific gravity showed no 
urine samples breaching the WADA threshold of 1000 ng·ml-1 following 
inhalation of 800 μg salbutamol. Normalising urine samples for specific 
gravity may be a potential doping control measure for WADA in the future. 
 
The purpose of Chapter 5 was to examine differences in urine 
concentrations of terbutaline dependent upon dose (single/multiple), mode of 
administration (inhaled/oral), according to gender and race, within 
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therapeutic limits. The therapeutic use exemption (TUE) process (WADA, 
2015; UEFA, 2015) permits athletes to use inhaled terbutaline (Elers et al., 
2012b), therefore it is important to be able to distinguish between legitimate 
inhaled use and prohibited oral use in athletes. Furthermore, it is important 
to distinguish between oral and inhaled terbutaline to allow a more informed 
approach to the inclusion of terbutaline on the WADA prohibited List of 
substances and methods. 
 
WADA have established thresholds for the use of salbutamol and the long-
acting β2-agonist formoterol, allowing for the legitimate inhaled use of these 
substances to be successfully monitored via an upper-limit and a decision 
limit (WADA Prohibited List 2014). Such threshold levels for the alternative 
long-acting β2-agonist salmeterol are not required as there is no oral 
equivalent. A threshold for terbutaline would be useful in the fight against 
doping in sport and also in maintaining standards of healthcare for the elite 
athlete as it would allow for a broader range of inhaled β2-agonists to be 
used by athletes and also allow for successful identification for the use of 
oral terbutaline, which, as with every orally administered β2-agonist, is 
prohibited due to the potential for ergogenic effects. 
 
The findings of Chapter 5 indicate that there is no clear distinction between 
urinary concentrations of inhaled terbutaline and oral terbutaline which could 
be used to categorize the different routes of administration. The current 
status of terbutaline on the WADA List is appropriate until a clear cut-off 
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threshold can be established and prevent athletes from illegally using supra-
therapeutic doses of inhaled/oral terbutaline to gain a competitive advantage 
(Kalsen et al., 2014; Hostrup et al., 2014). Care is warranted for athletes 
using terbutaline through the TUE process (Elers et al., 2012b) as it is still 
difficult to identify between legitimate inhaled and prohibited oral use of 
terbutaline. Chapter 5 did identify ceiling urinary thresholds that did not 
exceed 1284 ng·ml-1 following inhaled administration and that did not exceed 
2376 ng·ml-1 following oral administration. Such upper thresholds could 
identify possible anti-doping limits that would be useful in highlighting 
possible prohibited oral use that would then require further investigation 
through a controlled administration trial. 
 
 
A study by Elers et al. (2012b) reports similar findings when examining the 
levels of terbutaline in the plasma and urine following oral and inhaled 
administration (Elers et al., 2012b). Their study was able to find significant 
differences between inhaled (2mg) and oral (10mg) doses of terbutaline, 
however they were unable to establish any clear thresholds due to the high 
variability between samples. In line with Elers et al. (2012b) Chapter 5 was 
also able to highlight significant differences between dose and mode of 
administration, yet due to the large range in observed concentrations, the 
present study was unable to clearly distinguish between inhaled and oral 
use.  With reference to the study by Elers et al. (2012b) it is necessary to 
note that following corrections for urine specific gravity, upper thresholds for 
urinary terbutaline concentrations were lower than 1500 ng·ml-1 following 2 
 199 | P a g e  
 
mg inhaled terbutaline. No differences were apparent in systemic availability 
of terbutaline in plasma serum following the different routes of administration 
(median concentration 6 ng·ml-1), yet differences were apparent in the time 
to peak concentration, which was delayed following oral administration.  
Results from Chapter 5 highlight the high variability between urinary values 
following terbutaline administration, yet also highlight the potential for oral 
terbutaline to exceed the 1284 ng·ml-1 threshold seen following inhaled 
administration. 
 
Recently Hostrup et al. (2014) examined an extremely high supra-
therapeutic dose of 15mg inhaled terbutaline (30 x 0.5mg inhalations) which 
resulted in serum levels of terbutaline roughly four times higher (23.6 ± 1.1 
ng·ml-1) than that recorded by Elers et al. (2012b) after a 10 mg oral dose 
(~6 ng·ml-1). It can be presumed that such high dose inhalations of 
terbutaline would be easily distinguishable from the maximal suggested 
therapeutic dose of 2 mg inhaled terbutaline which is permitted for athletes 
with a TUE. The dose required for effective protection against EIB can be as 
little as one inhalation (0.5 mg) of terbutaline (Simpson et al., 2013), which is 
the dose recommended by many of the manufacturers. The present study 
investigated a maximum therapeutic dose (Prior et al., 1982), therefore it is 
possible that a difference in urinary concentration could exist between 0.5 
mg inhaled and 5 mg oral tablets that could allow for a threshold to be 
established. Future research that could distinguish a cut-off threshold based 
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upon the minimum dose required for a therapeutic effect (0.5 mg inhaled 
Terbutaline) is needed.  
 
The results from Chapter 5 also demonstrated significant inter-individual 
variation in the urinary levels of terbutaline, dependent upon mode of 
administration, gender and race. In the female Caucasian group, the male 
afro-Caribbean group and also the male Asian group there were significantly 
higher urinary concentrations of terbutaline in the oral administration trials 
vs. the inhaled trials but this difference was not apparent in the male 
Caucasian group.  Care is warranted when assessing differences between 
gender due to weight differences between males and females. A study by 
Guo et al., (2010) highlighted that the plasma concentrations of the 
medication fluconazole were roughly 20% higher in females compared to 
males, which is in direct correlation to the average weight difference (~20%) 
between each group (Guo et al., 2010). These findings were attributed to a 
higher volume distribution of the drug in lighter individuals.  Also of note is 
the difference in the rate at which different substances can be metabolised, 
which can vary highly between individuals. Kim et al., (2004) hypothesised 
that a person can be categorized as either an extensive metaboliser or a 
poor metaboliser through inter-individual variation. They went on to state that 
variations in the rate of metabolism can also be due to inter-ethnic 
differences and can be caused by genetic variations between individuals 
from different ethnic backgrounds (e.g. gene deletion/insertion/substitution 
polymorphisms).  
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Such variations in the metabolism of terbutaline between ethnic groups could 
provide a possible explanation as to why both Asian and Afro-Caribbean 
urinary concentrations appear lower than Caucasian values, however it 
cannot be discounted that variations between inhaler technique could also 
have been a factor that allowed for variability between results.  Further 
research examining gender and ethnic variations in urinary concentrations of 
short-acting β2-agonist metabolites is needed in order to better inform WADA 
with regard to doping policy and procedure. In addition, Chapter 6 
demonstrated that the highest urinary concentration of terbutaline following 
the inhalation of 4 mg terbutaline was 1244 ng·ml-1. This finding provides 
further justification for the proposed upper urinary threshold discussed in 
Chapter 5. 
 
8.3  Limitations of thesis 
 
Following data collection and analysis some limitations of the present 
research were highlighted. Firstly, the long-term use of salbutamol at the 
WADA daily limit would have benefitted from an emphasis on strength and 
power based performance in which participants were able to train four 
sessions of strength and power per week instead of two. This would have led 
to potentially better gains in strength and power performance and the 
possibility of greater adaptations in either the SAL group and/or the PLA 
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group. Secondly, when analysing the urinary concentrations of terbutaline it 
would have been valuable to add a further arm to the study to examine the 
impact of a lower therapeutic dose of inhaled terbutaline to try to distinguish 
between inhaled and oral use. This may have led to lower urinary values of 
terbutaline in the inhaled trials which may have then identified clear cut-off 
thresholds to determine routes of administration.  
 
A further limitation to chapter 5 was the absence of an investigation into the 
ratio of enantiomers in the urine and calculation of the metabolic ratio (parent 
drug/metabolite) (Roig et al., 2002), which would have further evidenced any 
possible route of administration, gender or ethnic differences with regard to 
the metabolism of terbutaline and its excretion in the urine. The 
establishment of a correction equation which could standardise for body 
weight and volume distribution of the dose administered would also have 
been an advantage to allow for direct comparisons. Thirdly, when all 
subjects were performing time-trials every effort was made to highlight the 
importance of following the same dietary intake during the 24 hours prior to 
performance, however, it was not possible or feasible to fully track dietary 
intake, and therefore variations in time-trial performance could have been 
attributed to slight variations in nutritional intake.  
 
With regard to chapter 7 the findings suggest that high-intensity exercise 
does not significantly affect FEV1 in the absence of salbutamol in mild 
EVH+ve individuals. This finding may have been associated with: 1) The 
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EVH challenge may be too sensitive and could have highlighted mild positive 
results in individuals who do not exhibit EIB (Rundell et al., 2004; Price et al., 
2014a); 2) The timing of spirometry 5-minutes post-exercise may have been 
too soon to detect changes as individuals may have still been experiencing 
the broncho-protective effects of exercise; 3) The low humidity of the 
exercise environment may have been offset by the use of the mouthpiece 
during online gas analysis as the humidification of the dry air may have 
occurred higher up the respiratory tract due to the micro-climate of the 
mouth-piece, thus not sufficiently provoking the lower airways; 4) The 5 
minute standardised warm-up could have induced a refractory period which 
may have protected against the effects of intense exercise on lung function 
(Anderson et al., 2012).  
 
Chapter 7 would have benefitted from more clinically well-defined asthmatic 
individuals who were positive to the EVH challenge and also showed EVH 
challenge reproducibility in line with the findings of Price et al., (2014a) who 
highlight that with regard to a mild positive EVH challenge test result, more 
than one EVH test is recommended to fully confirm or exclude diagnosis. It is 
possible, therefore, that during exercise in moderate to severe asthmatics 
there will be a reduction in lung function leading to a performance decrement 
during exercise in a low humidity environment that would be offset via 
salbutamol use. 
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8.4  Practical Applications 
 
The findings of this thesis can be applied to current practice with a more 
informed approach to the WADA List of Prohibited Substances and Methods, 
the use of salbutamol at the WADA permitted daily limit does not appear to 
enhance performance following prolonged use, therefore the current 
guidelines appear to be sufficient. The inclusion of a TUE for the use of 
terbutaline would appear to be correct given the inability to distinguish 
between legitimate therapeutic inhaled use and prohibited supra-therapeutic 
or prohibited oral use. Data from this thesis supports the lack of ergogenic 
potential of high therapeutic dosages of terbutaline on 3 km running time-trial 
performance, however investigations into strength and power performance 
are warranted. The use of the EVH challenge to diagnose EIB in individuals 
who exhibit with falls lower than 20% should only be considered an accurate 
diagnosis alongside a comparable alternative test result in association with 
the findings of Price et al. (2014a).   
 
8.5  Suggestions for future studies  
 
Following on from the findings of chapter 4 a suggestion for future research 
would be to establish the variability surrounding urinary salbutamol levels 
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amongst individuals dosing up to and including 1600 µg in either a 24 hour 
accumulated dose or a single acute dose. 
 
With regard to the findings of chapter 5 it would be useful that future 
research should also examine urine concentrations following a minimum 
therapeutic dose of inhaled terbutaline (0.5 mg) versus oral Terbutaline and 
also establish differences in enantiomers in the urine associated with mode 
of administration, the establishment of the urinary concentrations following a 
directly comparable dose would also be extremely useful alongside both 
urinary and plasma measurement of terbutaline. Further research 
incorporating both female Asians and female Afro-Caribbean’s is required to 
fully elucidate any ethnic differences. 
 
Following on from the findings of chapter 6 future research is warranted to 
investigate the effects of therapeutic inhaled terbutaline on strength and 
power performance which has recently been highlighted to be ergogenic 
following a supratherapeutic inhaled dose of terbutaline in studies by both 
Kalsen et al. (2014) and Hostrup et al. (2014). This investigation will also 
benefit from urinary measurements of terbutaline in support of the 
establishment of upper urinary cut-off limits for anti-doping purposes. 
 
Finally with the findings highlighted in chapter 7 future research should 
examine exercise performance in individuals who are mild-moderate 
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EVH+ve and also have a previous diagnosis of physician diagnosed asthma, 
who regularly exercise without the protective effects of inhaled salbutamol. 
Furthermore, symptoms experienced during exercise must also be 
considered when assessing for possible EIB. Spirometry should also be 
performed at more intervals post-exercise (up 15 minutes post-exercise) to 
determine if a drop in FEV1 may occur at a later stage in these individuals. 
 
8.6  Conclusions 
 
The present thesis investigated the legitimacy of the current WADA daily 
limits for salbutamol inhalation finding no improvement in endurance, 
strength and power performance following the inhalation of 1600 µg of 
salbutamol per day for six weeks in non-asthmatic males. This would 
suggest that the current WADA list of banned substances (WADA Prohibited 
List 2014), which allows athletes to inhale up to 1600 µg  over a 24 hour 
period, is sufficient given the findings from this and previous studies (Pluim 
et al., 2011; Dickinson et al., 2014a; Dickinson et al., 2014b; Decorte et al., 
2008, Sporer et al., 2008).  
 
Following on from these findings this thesis investigated the possibility of 
distinguishing between routes of administration of terbutaline identifying 
significant differences in urine concentration following inhaled and oral 
administration with high inter- and intra-individual variability between 
samples such that a clear cut-off value could not be identified. However, the 
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study was able to identify upper thresholds following oral use and inhaled 
use which could possibly be used to identify supra-therapeutic oral use of 
terbutaline in anti-doping tests. Gender differences were identified and 
occurred between male and female Caucasians during the multiple oral 
administration trial, and ethnic differences were identified between male 
Caucasians and male Asians during the single inhaled administration trial.  
 
In addition the present thesis investigated the ergogenic impact of inhaled 
terbutaline. The findings highlight that terbutaline, when taken in therapeutic 
doses (up to 4 mg), does not improve 3 km running time-trial performance in 
males or females. Furthermore, urinary concentrations that were measured 
following 4 mg inhaled terbutaline peaked at 1244.4 ng.mL-1 in both males 
and females, these levels are lower than the upper threshold established in 
chapter 5.  
 
Finally this thesis investigated the impact of salbutamol on lung function 
following 3 km running time-trials in a low humidity (RH: 20-25%) 
environment. The findings highlight that there is a significant increase in 
FEV1 with inhaled salbutamol in both healthy and mild EVH+ve individuals 
however; this did not translate to improved performance during 3km running 
time-trials in either group. Care is warranted in the interpretation of this 
finding as the failure to induce a fall in FEV1 in mild EVH+ve individuals may 
be due to the aggressive nature of the EVH challenge identifying positive 
individuals who may not necessarily exhibit with EIB. 
 208 | P a g e  
 
References 
 
Adcock, I.M., Caramori, G. and Chung, K.F. (1998) New targets for drug 
development in asthma. The Lancet. 272(9643): 1073–1087.  
Anderson SD, Argyros G, Magnussen H, et al. (2001) Provocation by 
eucapnic voluntary hyperpnoea to identify exercise induced 
bronchoconstriction. Br J Sports Med. 35:344–347. 
Anderson SD, Fitch K, Perry C, Sue-Chu M, Crapo R, McKenzie, D. et al., 
(2003) Response to bronchial challenge submitted for approval to use 
inhaled beta2 agonists prior to an event at the 2002 Winter Olympics. J 
Allergy Clin Immunol. 111:44-49. 
Anderson SD. (1997) Exercise induced asthma. In. Kay, A, ed. Allergy and 
allergic diseases. Oxford: Blackwell Scientific. 621-711. 
Anderson, SD. (1985) Exercise-induced asthma: The State of the Art. Chest. 
87:191-195. 
Anderson, SD., Kippelen, P. (2012) Assessment and prevention of exercise-
induced bronchoconstriction. Br J Sports Med. 46:391-396. 
Anderson, SD. (2010) Indirect Challenge Tests. Airway hyper-
responsiveness in asthma: its measurement and clinical significance. Chest. 
138(2):25-30.  
Anderson, SD., Caillaud, C., Brannan, JD. (2006a) β2-agonists and exercise-
induced asthma. Clin Rev All Immunol. 31(2):163-180. 
 209 | P a g e  
 
Anderson, SD., Holzer, K. (2000) Exercise-induced asthma: Is it the right 
diagnosis in elite athletes? J Allergy Clin Immunol. 106:419-428. 
Anderson, SD., Kippelen, P. (2005) Exercise-induced bronchoconstriction: 
Pathogenesis. Current Allergy and Asthma Reports. 5:116-122. 
Anderson, SD., Kippelen, P., (2008) Airway injury as a mechanism for 
exercise-induced bronchoconstriction in elite athletes. Clinical reviews in 
allergy and immunology. 122(2):225-235. 
Ansley, L., Kippelen, P., Dickinson, J., Hull, J. (2012) Misdiagnosis of 
exercise-induced bronchoconstriction in professional soccer players. Allergy. 
67:390-395. 
Arch, JRS., Ainsworth, AT., Cawthorne, MA., Piercy, V., Sennitt, MV., Thody, 
VE. et al. (1984) Atypical B-adrenoceptor on brown adipocytes as target for 
anti-obesity drugs. Nature. 309:163-165. 
Backer, V., Lund, T., Pedersen, L. (2007) Pharmaceutical treatment of 
asthma symptoms in elite athletes – doping or therapy? Scand J Med Sci 
Sports. 17:615-622. 
Barnes PJ. (2008) Immunology of asthma and chronic obstructive pulmonary 
disease. Nat Immunol Rev. 8:183-192. 
Barnes PJ. (2011) Pulmonary pharmacology.  In: Goodman and Gilman’s 
the Pharmacological Basis of Therapeutics 12th Ed. McGraw-Hill 
Publications. 36:1032-1065. 
 210 | P a g e  
 
Barnes, P., Adcock, I. (2009) Glucocorticoid resistance in inflammatory 
diseases. The Lancet. 373(9678);1905–1917 
Barnes, PJ. (2011) Biochemical basis of asthma therapy. The journal of 
biological chemistry. 286(38):32899-32905. 
Beachle T, Earle R, Wathen D. (2008) Resistance Training. In: Beachle, T. 
and Earle, R. Essentials of Strength Training and Conditioning. 3rd ed. 
Champaign, IL: Human Kinetics; p. 377-412 
Benson, DW., Foley-Nelson, T., Chance, WT., Zhang, F., James, JH. & 
Fischer, JE. (1991) Decreased myofibrillar protein breakdown following 
treatment with clenbuterol. Journal of surgical research. 50:1-5. 
Berges, R., Segura, J., Ventura, R. et al. (2000) Discrimination of prohibited 
oral use of salbutamol from authorized inhaled asthma treatment. Clin Chem 
46:1365–1375. 
Borg, G. (1982) Psychophysical bases of perceived exertion. Med Sci Sports 
Exerc. 14:377-81. 
Borges, M., Ferraz, E., Vianna, E. (2011) Bronchial provocation tests in 
clinical practice. Sao Paulo Med J. 129(4):243-249. 
Bos, J. (2006) Epac proteins: multi-purpose cAMP targets. Trends in 
Biochemical Sciences. 31(12):680-686. 
Bougalt, V., Boulet, L. (2011) Airway dysfunction in swimmers. Br J Sports 
Med. 46:402-406. 
 211 | P a g e  
 
Boulet, L-P., Fitzgerald, MJ., Reddel, HK. (2014) The revised 2014 GINA 
strategy report: opportunities for change. Curr Opin Pulm Med. Nov 2014. 
Published Online: (DOI:  10.1097/MCP.0000000000000125) 
Bousquet, J., Jeffery, P., Busse, W., Johnson, M., Vignola, A. (2000) 
Asthma: From bronchoconstriction to airways inflammation and remodelling. 
Am J Respir Crit Care Med. 161:1720-1745. 
Bowman, WC. & Nott, MW. (1969) Actions of sympathomimetic amines and 
their antagonists on skeletal muscle. Pharmacological Reviews. 21(1):27-61. 
British Thoracic Society and the Scottish Intercollegiate Guidelines Network. 
(2009) British guideline on the management of asthma: A national clinical 
guideline. British Thoracic Society. 1-10. 
Brodde, O. and Michel, M. (1999) Adrenergic and muscarinic receptors in 
the human heart. Pharmacological Reviews. 51(4):651-681. 
Calebiro, D., Maiellaro, I. (2014) cAMP signalling microdomains and their 
observation by optical methods. Frontiers in cellular neuroscience. 8(350):1-
9. 
Carraro, S., Corradi, M., Zanconato, S., Alinovi, R., Pasquale, M., Zachello 
F. et al., (2005) Exhaled breath condensate cysteinyl leukotrienes are 
increased in children with exercise induced bronchoconstriction. J Allergy 
Clin Immunol. 115:764-770. 
Caruso J, Signorile J, Perry A, Leblanc B, Williams R, Clark M, et al., (1995) 
The effects of albuterol and isokinetic exercise on the quadriceps muscle 
group. Med Sci Sports Exerc. 27:1471-6. 
 212 | P a g e  
 
Caruso, JF., Hamill, J., De Garmo, N. (2005) Oral albuterol dosing during the 
latter stages of a resistance exercise programme. J Strength Cond Res. 
19(1):102-107. 
Cepero, M., Perez-Portego, Y., Cubria, JC., Reguera, R., Balana-Fouce, R., 
Ordonez, C. et al. (2000) Muscle and serum changes with salbutamol 
administration in aerobically exercised rats. Comparative Biochemistry and 
Physiology Part C. 126:45-51. 
Chester, N., Mottram, D.  (2015) Beta-2 Agonists. Drugs in Sport, Sixth 
Edition, Chapter 7. Routledge Publications, Taylor & Francis Group.   
Choo, JJ., Horan, MA., Little, RA. & Rothwell, NJ. (1992) Anabolic effects of 
clenbuterol on skeletal muscle are mediated by B2 adrenoceptor activation. 
Am J Physiol Endocrinol Metab. 263(26):50-56. 
Collomp, K., Le Panse, B., Candau, R., Lecoq, A., Ceaurriz. (2010) Beta-2 
agonists and exercise performance in humans. Science and Sports. 25:281-
290. 
Cooper, D., Tabbasum, V. (2014) Adenylate cyclase centred microdomains. 
Biochem, J. 462:199-213. 
Decorte N, Verges S, Flore P, Guinot M, Wuyam B. (2008) Effects of Acute 
Salbutamol Inhalation on Quadriceps Force and Fatigability. Med. Sci. 
Sports Exerc. 40:1220–1227. 
Decorte, N., Bachasson, D., Guinot, M., Flore, P., Levy, P., Verges, S., et al. 
(2013) Effect of Salbutamol on neuromuscular function in endurance 
athletes. Med Sci Sports Exerc. 45(10):1925-1932. 
 213 | P a g e  
 
Deshmuck, N., Petroczi, A., Barker, J., Szekely, A., Hussain, I., Naughton, 
D. (2010) Potentially harmful advantage to athletes: a putative connection 
between UGT2B17 gene deletion polymorphism and renal disorders with 
prolonged use of anabolic androgenic steroids.  Substance Abuse 
Treatment, Prevention and Policy. 5: 7-12. 
Dickinson J, Hu J, Chester N, Loosemore M, Whyte G. (2014a) Play On: The 
impact of inhaled Salbutamol on soccer performance In Males And Females. 
Med Sci Sports Ex. 45:5 Supplement 
Dickinson J, Hu J, Chester N, Loosemore M, Whyte G. (2014b) The 
ergogenic and pharmacokinetic impact of short acting β2-agonist an 5 km 
time trial performance. Med Sci Sports Ex. 45:5 Supplement 
Dickinson J, McConnell A, Whyte G. (2011) Diagnosis of exercise-induced 
bronchoconstriction: eucapnic voluntary hyperpnoea challenges identify 
previously undiagnosed elite athletes with exercise-induced 
bronchoconstriction. Br J Sports Med. 45:1126-1131. 
Dickinson J, Whyte G, McConnell A, Harries, M. (2005) Impact of change in 
the IOC-MC asthma criteria: a British perspective.  Thorax. 60:629-632. 
Dickinson J, Whyte G, McConnell A, Harries, M. (2006b) Screening Elite 
Winter Athletes for Exercise Induced Asthma: A Comparison of Three 
Challenge Methods. Br J Sports Med. 40:179-183. 
Dickinson J, Whyte G, McConnell A, Nevill A, Harries, M. (2006a) Mid-
Expiratory Flow Vs. FEV1 measurements in the diagnosis of exercise 
induced asthma in elite athletes. Thorax. 61:111-114. 
 214 | P a g e  
 
Dickinson, J., Hu, J., Chester, N. Loosemore M., Whyte, G. et al. (2014c) 
Impact of ethnicity, gender, and dehydration on the urinary excretion of 
inhaled salbutamol with respect to doping control. Clin J Sport Med. 0:1-8. 
Dickinson, J., Molphy, J., Chester, N. Loosemore, M., Whyte, G. (2014d) 
The ergogenic effect of long-term use of high-dose Salbutamol. Clin J Sports 
Med 0:1-8. 
Donohue, J.F. (2004) Therapeutic Responses in Asthma and COPD* 
Bronchodilators. Chest. 126:125-137. 
Driessen, J., Gerritsma, M., Westbroek, J. et al. (2013) The effect of 
nebulized Salbutamol or isotonic saline on exercise-induced 
bronchoconstriction in elite skaters following a 1500m race: study protocol 
for a randomized controlled trial. Trials. 14:204. doi:10.1186/1745-6215-14-
204. 
Duncan, ND., Williams, DA., and Lynch, GS. (2000) Deleterious effects of 
chronic clenbuterol treatment on endurance and sprint exercise performance 
in rats. Clinical Science. 98:339-347. 
Dwyer, T. (2012) Spirometry: How should we order this bedrock of diagnosis 
and management of asthma and COPD? Respiratory Care. 57(10):1692-
1695. 
Elers J, Mørkeberg J, Jansen T, Belhage B, Backer V. (2012a) High-dose 
inhaled salbutamol has no acute effects on aerobic capacity or oxygen 
uptake kinetics in healthy trained men. Scand J Med Sci Sports. 22:232-239. 
 215 | P a g e  
 
Elers, J., Hostrup, M., Pedersen, L. et al. (2012b) Urine and Serum 
Concentrations of Inhaled and Oral Terbutaline. Int J Sports Med. 
33(12):1026-1033. 
Elers, J., Pedersen, L., Henninge, J. et al. (2010) Blood and urinary 
concentrations of salbutamol in asthmatic subjects. Med Sci Sports Exerc 
42:244–249 
Elers, J., Pedersen, L., Henninge, J., Hemmersbach, P., Dalhoff, K., Backer, 
V. (2011) Urine concentrations of repetitive doses of inhaled salbutamol. Int 
J Sports Med. 32(8):574-579. 
Emery, PW., Rothwell, NJ., Stock, MJ. & Winter, PD. (1984) Chronic effects 
of beta2-adrenergic agonists on body composition and protein synthesis in 
the rat. Bioscience Reports. 4:83-91. 
Fan, L., Chen, Q., Zhang, W., Cao, C. (2013) Sensitive determination of 
illegal drugs of clenbuterol and salbutamol in swine urine by capillary 
electrophoresis with on-line stacking based upon the moving reaction 
boundary. Anal. Methods. 5:2848-2853. 
Fitch K, Sue-Chu M, Anderson S, Boulet L, Hancox R, McKenzie D, et al., 
(2008) Asthma and the elite athlete: Summary of the International Olympic 
Committee’s Consensus Conference, Lausanne, Switzerland, January 22-
24, 2008 J Allergy Clin Immunol. 122:254-260. 
Fitch, K. (2006) Beta-2 agonists at the Olympic games. Clin Rev Allergy 
Immunol 31:259-268. 
 216 | P a g e  
 
Guo, T., Sun, W., Xia, D., et al. (2010) The pharmacokinetics of Fluconazole 
in healthy Chinese adult volunteers: influence of ethnicity and gender. 
Journal of Clinical Pharmacy and Therapeutics. 35:231-237. 
Ha, TNV., Posterino, GS. & Fryer, MW. (1999) Effects of terbutaline on force 
and intracellular calcium in slow-twitch skeletal muscle fibres of the rat. Brit J 
Pharmacol. 126:1717-1724. 
Hakkinen, K., Alen, M., Kraemer, W., Gorostiaga, E., Izquierdo, M., Rusko, 
H. et al. (2003) Neuromuscular adaptations during concurrent strength and 
endurance training versus strength training. Eur J Appl Physiol. 89:42-52. 
Hallstrand, T., Curtis, J., Koepsell, T., Martin, D., Schoene, R., Sullivan, S. et 
al. (2002) Effectiveness of screening examinations to detect unrecognised 
exercise-induced bronchoconstriction. J Pediatr. 141:343-349. 
Hallstrand, T., Moody, M., Aitken, M., Henderson, W. (2005) Airway 
immunopathology of asthma with exercise-induced bronchoconstriction. J 
Allergy Clin Immunol. 116:586-593. 
Hallstrand, T., Wurfel, M., Lai, Y., Ni, Z., Gelb, M., Altemeier, W. et al. (2010) 
Transglutaminase 2, a novel regulator of eicosanoid production in asthma 
revealed by genome-wide expression profiling of distinct asthma 
phenotypes. PLoS One. 5:e8583. 
Hancox, R., Subarrao, P., Kamada, D., Watson, R., Hargreave, F. et al. 
(2002) Beta-2 agonist tolerance and exercise-induced bronchospasm. Am J 
Respir Crit Care Med. 165:1068-1070. 
 217 | P a g e  
 
Hatze, H. (1998) Validity and reliability of methods for testing vertical 
jumping performance. J Applied Biomech. 14:127-149. 
Haverkamp H, Dempsey J, Pegelow D, Miller J, Romer L, Santana M, et al., 
(2007) Treatment of airway inflammation improves exercise pulmonary gas 
exchange and performance in asthmatic subjects. J Allergy Clin Immunol. 
120:39-47. 
Hoffman BB. (2001) Catecholamines, Sympathomimetic Drugs, and 
Adrenergic Receptor Antagonists. In: Goodman and Gilman’s the 
Pharmacological Basis of Therapeutics. McGraw-Hill Publications. 215-269. 
Holgate, ST. (2008) The airway epithelium is central to the pathogenesis of 
asthma. Allergology International. 57:1-10. 
Holley, A., Cohee, B., Walter, R., Shah, A., King, C., Roop, S. (2012) 
Eucapnic voluntary hyperpnoea is superior to methacholine challenge testing 
for detecting airway hyper-reactivity in non-athletes. Journal of asthma. 
49(6):614-619. 
Holzer, K., Anderson, SD., Douglass, J. (2002) Exercise in elite summer 
athletes; Challenges for diagnosis. J Allergy Clin Immunol. 110:374-380. 
Horwitz, R.I., McGill, K.A. and Russe, W.W. (1998) The Role of Lukotriene 
Modifiers in The Treatment of Asthma. American Journal of Respiratory and 
Critical Care Medicine. 157:1363-1371. 
Hostrup, M., Kalsen, A., Bangsbo, J. et al. (2014) High-dose inhaled 
terbutaline increases muscle strength and enhances maximal sprint 
 218 | P a g e  
 
performance in trained men. Eur J Appl Physiol. (DOI 10.1007/s00421-014-
2970-2). 
Ingalls, CP., Barnes, WS. & Smith, SB. (1996) Interaction between 
clenbuterol and run training: effects on exercise performance and MLC 
isoform content. J Appl Physiol. 80(3):795-801. 
Kalsen, A., Hostrup, M., Bangsbo, J. (2013) Combined inhalation of beta2-
agonists improves swim ergometer performance but not high intensity swim 
performance. Scand J Med Sci Sports. 24:814-822. 
Kalsen, A., Hostrup, M., Karlsson, S. et al. (2014) Effect of inhaled 
Terbutaline on substrate utilization and 300-kcal time trial performance. J 
Appl Physiol. (In Press doi:10.1152/japplphysiol.00635.2014) 
Kierzkowska, B., Stanckzyk, J., Kasprzak, JD. (2005) Myocardial infarction in 
a 17-year-old bodybuilder using clenbuterol. Circ J. 69:1144-1146. 
Kim, K., Johnson, J. and Derendorf, H. (2004) Differences in drug 
pharmacokinetics between East Asians and Caucasians and the role of 
genetic polymorphisms. Journal of Clinical Pharmacology. 44:1083-1105. 
Kindermann, W. (2007) Do inhaled beta-2 agonists have an ergogenic 
potential in non-asthmatic competitive athletes? Sports Med. 37(2):95-102. 
Koch, S., Ahn, J., Koehle, M. (2015) High-dose inhaled salbutamol does not 
improve 10-km cycling time-trial performance. Med Sci Sports Exerc. 
[Published ahead of print. April 2015 DOI: 
10.1249/MSS.0000000000000679] 
 219 | P a g e  
 
Koch, S. Karacabeyli, D. Galts, C. et al. (2014) Effects of inhaled 
bronchodilators on lung function and cycling performance in female athletes 
with and without exercise-induced bronchoconstriction. J Sci Med Sport.  
DOI: http://dx.doi.org/10.1016/j.jsams.2014.07.021.  
Koch, S., MacInnis, M., Sporer, B. et al. (2013) Inhaled Salbutamol does not 
affect performance in asthmatic and non-asthmatic cyclists. Br J Sports Med 
0;1-5. 
Larsson, K., Ghaved, D., Larsson, L., Holmer, I., Jorfelt, l., Ohlsen, P. (1997) 
Influence of a beta2-agonist on physical performance at low temperature in 
elite athletes. Med Sci Sports Med. 29(12):1631-1636. 
Le Panse, B., Arlettaz, A., Portier, H., Lecoq, A., Ceaurriz, J., Collomp, K. 
(2006) Short term salbutamol ingestion and supramaximal exercise in 
healthy women. Br J Sports Med. 40:627-631. 
Lynch, G., & Ryall, J. (2008) Role of β-adrenoceptor signalling in skeletal 
muscle: Implications for muscle wasting and disease. Physiol Rev. 88: 729-
767. 
Martineau L, Horan M, Rothwell N, Little R. (1992) Salbutamol, a beta 2-
adrenoceptor agonist, increases skeletal muscle strength in young men.  
Clin Sci. 83:615-21. 
Masoli, M., Fabian, D., Holt, S., Beasley, R. (2004) The global burden of 
asthma: executive summary of the GINA Dissemination Committee Report. 
Allergy. 59:469-478. 
 220 | P a g e  
 
McFadden E, Gilbert I. (1994) Exercise-induced asthma. N Eng J Med 
330:1362-1367. 
McKenzie, D. (2004) Salbutamol and the competitive athlete. Clin J Sports 
Med. 14(5):316. 
McKenzie, D., Rhodes, E., Stirling, D., Wiley, J., Dunwoody, D., Filsinger, I., 
et al. (1983) Salbutamol and treadmill performance in non-atopic athletes. 
Med Sci Sports Exerc. 15(6):520-522. 
Meeuwisse, W., McKenzie, D., Hopkins, S Road, J. (1992) The effect of 
salbutamol on performance in elite nonasthmatic athletes. Med Sci Sports 
Exerc. 24(10):1161-1166. 
Mickleborough, T. (2008) A nutritional approach to managing exercise-
induced asthma. Exerc. Sport Sci. Rev. 36(3):135-144. 
Miller, M., Hankinson, J., Brusasco, V. et al. (2005) Standardisation of 
spirometry. Eur Resp J. 26:319-338. 
Mills, S., Spurlock, ME., and Smith, DJ. (2003) B-adrenergic receptor 
subtypes that mediate ractopamine stimulation of lipolysis. J Anim Sci. 
81(3):662-668. 
Molphy, J., Dickinson, J., Chester, N., Hu, J., Whyte, G. (2014) Prevalence 
of bronchoconstriction induced by eucapnic voluntary hyperpnoea in 
recreationally active individuals. J Asthma. 51(1):44-50. 
Norton K, Marfell-Jone M, Whittingham N, Kerr D, Carter L, Saddington K, et 
al., (2000) Anthropometric Assessment Protocols. In: Gore C, editor. 
 221 | P a g e  
 
Physiological Test for Elite Athletes. Champaign, IL: Human Kinetics; p. 66-
85 
O’Byrne, P.M. (2004) Pharmacologic Interventions to Reduce the Risk of 
Asthma Exacerbations. The American Thoracic Society. 1:105-108. 
Olin, A., Aldenbratt, A., Ekman, A., Ljungkvist, G., Jungerstein, L., Alving, K 
et al. (2001) Increased nitric oxide in exhaled air after intake of a nitrate-rich 
meal. Respiratory Medicine. 95, 153-158. 
Parsons, J., Keading, C., Phillips, G., Jarjoura, D., Wadley, G., Mastronarde, 
J. (2007) Prevalence of exercise-induced bronchospasm in a cohort of 
varsity college athletes. Med Sci Sports Exerc. 39:1487-1492. 
Parsons, JP., Hallstrand, T., Mastronarde, J., Kaminsky, D., Rundell, K., 
Hull, J. et al. (2013) An official American Thoracic Society clinical practice 
guideline: Exercise-Induced Bronchoconstriction. Am J Respir Crit Care 
Med. 187(9):1016-1027. 
Pedersen, L., Winther, S., Backer, V., Anderson, S., Larsen, K. (2008) 
Airway responses to eucapnic hypernea, exercise, and methacholine in elite 
swimmers. Med Sci Sports Exerc. 40(9):1567-1572. 
Pichon, A., Venisse, N., Krupka, E. et al. (2006) Urinary and blood 
concentrations of beta-2-agonists in trained subject: comparison between 
routes of use. Int J Sports Med. 27:187–192. 
Pierce, KL., Premont, RT., Lefkowitz, RJ. (2002) Seven-transmembrane 
receptors. Mol. Cell Biol. 3:639-650. 
 222 | P a g e  
 
Pluim, B., De Hon, O., Staal, B., Limpens, J., Kuipers, H., Overbeek, S., et 
al. (2011) β2-agonists and physical performance: A systematic review and 
meta-analysis of randomized controlled trials. Sports Med. 41(1):1-19. 
Pohjantahti, H., Laitinen, J., Parkkari, J. (2005) Exercise-induced 
bronchospasm among healthy elite cross country skiers and non-athletic 
students. Scand J Med Sci Sports. 15:324-328. 
Prather, ID., Brown, D., North, P., Wilson, JR. (1995) Clenbuterol: a 
substitute for anabolic steroids? Med Sci Sports Exer. 27(8):1118-1121. 
Price, O., Ansley, L., Hull, J. (2014a) Diagnosing exercise-induced 
bronchoconstriction with eucapnic voluntary hyperpnea: is one test enough? 
J Allergy Clin Immunol Pract. 3(2): 243-249.  
Price, O., Hull, J., Backer, V., Hostrup, M., Ansley, L. (2014b) The Impact of 
exercise-induced bronchoconstriction on athletic performance: a systematic 
review. Sports Med. 44:1749-1761. 
Price O., Hull, J., Ansley, L. (2014c) Advances in the diagnosis of exercise-
induced bronchoconstriction. Expert Rev. Respir. Med. 8(2):209-220. 
Prior, J., Nowell, R., Cochrane, G. (1982) High-dose inhaled terbutaline in 
the management of chronic severe asthma: comparison of wet nebulisation 
and tube-spacer delivery. Thorax. 37:300-303. 
Quanjer, PH., Tammeling, GJ., Cotes, JE., (1993) Pedersen, OF., Yernault, 
J-C. Lung volumes and forced ventilatory flows: Report working party. 
Standardisation of lung function tests. European community for coal and 
steel. Eur Respir J. 6(16):5-40. 
 223 | P a g e  
 
Roig, M., Berges, R., Ventura, R. et al. (2002) Quantification of terbutaline in 
urine by enzyme-linked immunosorbent assay and capillary electrophoresis 
after oral and inhaled administrations. Journal of Chromotography. 768:315-
324. 
Rundell, K., Anderson, S., Spiering, B., Judelson, D. (2004) Field exercise 
vs. Laboratory eucapnic voluntary hyperventilation to identify airway 
hyperresponsiveness in elite cold weather athletes. Chest. 125:909-915. 
Rundell, K., Anderson, S., Sue-Chu, M., Bougalt, V., Boulet, L. (2015) Air 
quality and temperature effects on exercise-induced bronchoconstriction. 
Compr Physiol. 5:579-610. 
Rundell, K., Im, J., Mayers, L., Wilber, R., Szmedra, L., Schmitz, H. (2001) 
Self-reported symptoms and exercise-induced asthma in the elite athlete. 
Med Sci Sports Exerc. 33:208-213. 
Rundell, K., Spiering, B., Evans, T., Baumann, J. (2004) Baseline lung 
function, exercise-induced bronchoconstriction and asthma like symptoms in 
elite women ice-hockey players. Med. Sci. Sports Exerc. 36(3):405-410.  
Salpeter, S., Ormiston, T., Salpeter, E. (2004) Meta-analysis: Respiratory 
tolerance to regular β2-agonist use in patients with asthma. Ann Intern Med. 
140:802-813. 
Sanchez A, Collomp K, Carra J, et al. (2012) Effect of acute and short-term 
oral salbutamol treatments on maximal power output in non-asthmatic 
athletes. Eur J Appl Physiol. 112:3251-8. 
 224 | P a g e  
 
Sanchez, A., Borrani, F., Amelie Le Fur, M. et al. (2013) Acute Supra-
therapeutic oral terbutaline administration has no ergogenic effect in non-
asthmatic athletes. Eur J Appl Physiol. 113:411-418. 
Schweizer, C., Saugy, M., Kamber, M. (2004) Doping test reveals high 
concentrations of salbutamol in a Swiss track and field athlete. Clin J Sports 
Med. 14(5):312-315. 
Scollo, M., Zanconato, S., Ongaro, R., Zaramella C., Zachello, F., Baraldi, E. 
(2000) Exhaled nitric oxide and exercise-induced bronchoconstriction in 
asthmatic children. Am J Respir Crit Care Med. 161:1047-1050. 
Sillence, MN. (2004) Technologies for the control of fat and lean deposition 
in livestock. The Veterinary Journal. 167:242-257. 
Simpson, A., Tufvesson, E., Anderson, SD., et al. (2013) Effect of terbutaline 
on hyperpnoea-induced bronchoconstriction and urinary club cell protein 16 
in athletes. J Appl Physiol. 115:1450-1456. 
Skidgel, Ra., Kaplan, AP. And Erdoes, EG. (2011) Histamine, Bradykinin 
and their antagonists. In: Goodman and Gilman’s the Pharmacological Basis 
of Therapeutics 12th Ed. McGraw-Hill Publications. 32:911-935. 
Spiteri, D., Dickinson, J., Greenwell, J., Ingle, L. (2014) Impact of exercise-
induced bronchoconstriction on athletic performance and airway health in 
rugby union players. International SportMed Journal. 15(4): 333-342. 
Sporer, B., Sheel, W., Mckenzie, D. (2008) Dose response of inhaled 
salbutamol on exercise performance and urine concentrations. Med Sci 
Sports Exerc. 40(1): 149-157. 
 225 | P a g e  
 
Sue-Chu, M. (2012) Winter sports athletes: long-term effects of cold air 
exposure. Br J Sports Med 46;397-401. 
The World Anti-Doping Agency (2013). The 2013 Prohibited List 
International Standard. 2013; http://www.wada-
ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-
list/2013/WADA-Prohibited-List-2013-EN.pdf (accessed March 2015) 
UEFA  (2015). UEFA Guide to the WADA Prohibited List and Therapeutic 
Use Exemptions. January 2015. 
(http://www.uefa.org/MultimediaFiles/Download/TUE/uefaorg/Anti-
doping/02/04/27/85/2042785_DOWNLOAD.pdf) 
Unbekandt, M., Olson, MF. (2014) The actin-myosin regulatory MRCK 
kinases: regulation, biological functions and associations with human cancer. 
J Mol Med. 92:217-225. 
Unnithan, V., Thomson, K., Aitcheson, T., Paton, J. (1994) Beta-2 Agonists 
and running economy in prepubertal boys. Pediatr. Pulmonol. 17(6):378-382. 
Van Baak, M., Mayer, L., Kempinski, R., Hartgens, F. (2000) Effect of 
salbutamol on muscle strength and endurance performance in nonasthmatic 
men. Med Sci Sports Exerc. 32(7):1300-1306. 
Ventura, R., Segura, J., Berges, R., Fitch, K., Morton, A., Berruezo, S., et al., 
(2000) Distinction of Inhaled and Oral Salbutamol by Urine Analysis Using 
Conventional Screening Procedures for Doping Control. Ther Drug Monit. 
22(3):277-282. 
 226 | P a g e  
 
WADA (2009) Prohibited List of Substances and Methods. The 2009 
Prohibited List. World Anti-Doping Agency. https://wada-main-
prod.s3.amazonaws.com/resources/files/wada_anti-
doping_code_2009_en_0.pdf (accessed August 2014). 
WADA (2010) Prohibited List of Substances and Methods. The 2010 
Prohibited List. World Anti-Doping Agency.  
http://www.olympic.org/Documents/Fight_against_doping/Rules_and_regulat
ions/WADA_Prohibited_List_2010.pdf (accessed August 2014). 
WADA (2012) Prohibited List of Substances and Methods. The 2012 
Prohibited List. World Anti-Doping Agency. 
http://www.olympic.org/Documents/Fight_against_doping/Rules_and_regulat
ions/06_WADA-2012_ProhibitedList-eng.pdf (accessed August 2014). 
WADA (2014) Prohibited List of Substances and Methods. The 2014 
Prohibited List. World Anti-Doping Agency. http://list.wada-ama.org/wp-
content/uploads/2013/11/2014-Prohibited-List-ENGLISH-FINAL.pdf 
(accessed August 2014). 
WADA (2015) Prohibited List of Substances and Methods. The 2015 
Prohibited List. World Anti-Doping Agency. http://list.wada-ama.org/wp-
content/uploads/2013/11/2014-Prohibited-List-ENGLISH-FINAL.pdf 
(accessed March 2015). 
WADA. (2012) Medical Information to support the decisions of TUECs. 
Asthma. World Anti-Doping Agency, wada-ama.org [online]. Available from 
URL:http://www.wadaama.org/Documents/Science_Medicine/Medical_info_t
 227 | P a g e  
 
o_support_TUECs/WADA_Medical_info_Asthma_v2.3_EN.pdf (Accessed 
Nov 2014) 
Waldeck, B. (1996) Some pharmacodynamics aspects on long-acting B-
adrenoceptor agonists. Gen Pharmac. 27(4):575-580. 
Wenzel, S. (2012) Asthma phenotypes: the evolution from clinical to 
molecular approaches. Nature Medicine. 18(5):716-725. 
Westfall TC. & Westfall DP. (2011a) Adrenergic agonists and antagonists.  
In: Goodman and Gilman’s the Pharmacological Basis of Therapeutics 12th 
Ed. McGraw-Hill Publications. 12:277-333. 
Westfall TC. & Westfall DP. (2011b) Neurotransmission: The autonomic and 
somatic motor nervous system.  In: Goodman and Gilman’s the 
Pharmacological Basis of Therapeutics 12th Ed. McGraw-Hill Publications. 
8:171-218. 
Withers R, Gore C, Gass G, Hahn A. (2000) Determination of Maximal 
Oxygen Consumption ( V O2max) or Maximal Aerobic Power. In: Gore C, 
editor. Physiological Test for Elite Athletes. Champaign, IL: Human Kinetics; 
p. 114-127 
Wrigley T, Strauss G. (2000) Strength Assessment by Isokinetic 
Dynamometry. In: Gore C, editor. Physiological Test for Elite Athletes. 
Champaign, IL: Human Kinetics; p. 155-199. 
 
 
 228 | P a g e  
 
Appendices 
Appendix A 
 
 
 
 
 229 | P a g e  
 
Appendix B 
 
 
 
 
 230 | P a g e  
 
Appendix C 
 
 
 
 
 
 231 | P a g e  
 
Appendix D 
PHYSIOLOGICAL SOCIETY BIOMEDICAL BASIS OF ELITE PERFORMANCE 
The ergogenic impact of sustained high-dose short acting β2-agonist use during a six week 
training programme in healthy individuals 
 
J. Molphy1, J. Dickinson1, N. Chester1, M. Loosemore2 and G. Whyte1 
1Sport and Exercise Science, Liverpool John Moores University, Liverpool, Merseyside, UK 
and 2English Institute of Sport, London, UK 
 
There is little evidence available to demonstrate that inhaled short acting β2-agonists 
provide an ergogenic effect. However, the majority of research in this area has focused on 
acute doses of inhaled β2-agonists. At present there are no investigations examining the 
chronic use of short acting β2-agonist use during training. Ten healthy well-trained males 
(mean ± SD; age 20.4 ±2.1 years; height 178.1 ±8.8 cm; weight 71.2 ±11.3 kg) who had no 
history of asthma and presented with a negative indirect airway challenge, volunteered to 
participate in the study. Athletes were randomly assigned to one of two groups in a 
randomised double blind design; either placebo or 1600μg salbutamol (400μg (4x100μg 
inhalations) at 08:00h, 12:00h, 16:00h and 20:00h every day for 6 weeks). Baseline tests 
consisted of a VO2 peak assessment and a 3km time-trial. Strength assessments consisted 
of isokinetic dynamometry assessment for peak torque during maximal knee extension and 
flexion at slow (60°s-1) and fast (240°s-1) contracting speeds, alongside one repetition 
maximum (1RM) lifts for bench press and leg press, power was assessed via a vertical jump 
test. Subjects then underwent a 6 week training programme, which consisted of two 
resistance sessions and two endurance sessions per week, whilst inhaling either 1600μg 
salbutamol per day or placebo. 
Follow-up assessments for 3 km time-trial, 1RM bench and leg press, vertical jump heights, 
VO2 peak and isokinetic dynamometry were undertaken following 6 weeks of training. 
Mixed-model repeated measures ANOVA were used to compare baseline and 6 week 
assessments of endurance, strength and power between the salbutamol and placebo 
groups. There was a significant decrease in 3km completion time post training programme 
(983.5±183.8 vs. 945.6±186 s, p=0.05) with no difference between groups (salbutamol 
mean change 23.4±16.5 vs. placebo 52.5±37.1 s, p>0.05). There was no significant effect of 
the training programme on maximal isokinetic strength or jump height (p>0.05), nor was 
there a difference between groups (p>0.05). There was a significant increase in VO2 peak 
post-training (52.5±5.4 vs. 57.7±6.6 ml.kg.min-1, p=0.01) with no difference between 
groups (p>0.05). There was a significant increase in 1RM leg strength post-training 
(218.3±45.5 vs. 272.8±48.9 kg, p<0.01) with a significant difference between groups 
(salbutamol mean change 35±24.7 vs. placebo 78.3±55.3 kg, p=0.04). In conclusion there 
were significant improvements in performance variables post-training, however these 
improvements were equal in both groups with no additive effect of inhaled salbutamol on 
any of the performance or physiological variables. The WADA guidelines that permit up to 
1600 μg inhaled salbutamol are appropriate as there appears to be no significant 
performance enhancing effect of taking this dose on a daily basis. 
 
Where applicable, the authors confirm that the experiments described here conform with 
The Physiological Society ethical requirements. 
 
 
 
 232 | P a g e  
 
Appendix E 
Abstract for ACSM 2013 
The Ergogenic Effect of Chronic High Dose Salbutamol 
Molphy, J., Dickinson, J., Chester, N., Loosemoore, M., and Whyte, G., FACSM. 
Liverpool John Moores University, Liverpool, UK, English Institute of Sport, Sheffield, UK, 
University of Kent, Chatham Maritime, UK 
There is limited evidence to suggest the acute inhalation of short acting β2-agonist have an 
ergogenic effect. To date, no study has examined the ergogenic impact following the 
chronic use of inhaled Salbutamol at the WADA upper daily limit (1600 µg). PURPOSE: To 
determine the effect of the WADA upper limit of 1600 μg per day Salbutamol every day for 
six weeks, on endurance, strength, power and body composition. METHODS: Sixteen 
trained male athletes provided written consent and agreed to take part in the study (mean 
+ SD: age 20.1 ± 1.6 years; height 179.9 ± 8.2 cm; weight 74.6 ± 9.1 kg). Participants 
entered into a 6-week, 4 times per week training study having been assigned to one of two 
groups in a double blind design. Group 1 (n=8) inhaled 4 x100 μg of placebo, via pocket 
chamber, 4 times per day for 6 weeks (PLA). Group 2 (n=8) inhaled 4 x100 μg of 
Salbutamol, via pocket chamber, 4 times per day for 6 weeks (SAL). Pre- and post-training 
endurance, body composition, power and strength was assessed. RESULTS: In both groups 
there was an overall improvement in (Pre- Post-) V O2peak (51.7 ± 4.7 –56.8 ± 7.1 ml.min.kg
-
1; 53.1 ± 6.1 –55.0 ± 6.7 ml.min.kg-1); 3 km running time-trial performance (988.6 ± 194.6 – 
947.5 ± 155.5 s; 1040.4 ± 187.4 –1004.2 ± 199.4 s); 1RM bench press (65.7 ± 15.4 – 70.3 ± 
13.8 kg;  64.3 ± 14.0 – 72.5 ± 15.3 kg) and leg press (250.0 ± 76.4 – 282.5 ± 63.6 kg; 217.9 ± 
54.0 – 282.8 ± 51.9 kg) between SAL and PLA, respectively. Peak extension and flexion 
torque, and body composition remained unchanged across the study period. Of note, no 
difference in any endurance; strength and power; or body composition measures were 
noted between SAL and PLA groups pre-, during, or post-intervention. CONCLUSION: There 
was no significant improvement in endurance, or strength and power performance 
following the inhalation of 1600 µg Salbutamol per day for six weeks in non-asthmatic 
males, compared to placebo. The current WADA recommendations, of up to 1600 µg 
inhaled Salbutamol per day, appear sufficient to avoid an ergogenic impact on endurance, 
strength and power performance. Data from this study will assist WADA in the 
implementation of regulations on the use of inhaled short acting β2-agonist and in the 
resolution of contested doping violations. 
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Appendix F 
BASES ORAL PRESENTATION ABSTRACT 2013 
The Ergogenic Effect of Chronic High Dose Salbutamol 
Molphy, J.,1 Dickinson, J.,2 Chester, N.,1 Loosemoore, M.,3 and Whyte, G., 
FBASES1 
1) Liverpool John Moores University, Liverpool, UK,  
2) University of Kent, Chatham Maritime, UK  
3) English Institute of Sport, London, UK,  
 
1) Heart rate monitor Polar Manias heart rate monitor, Polar Electro Oy, Kempele, Finland; 2) Face mask Hans Rudolf, 
Kansas City, MO, USA; 3) Online gas analysis system  Oxycon Pro portable gas analysis system, Jaeger, Carefusion, Kent, 
UK; 4) Pre-injection swab Medlock medical, Oldham, UK; 5) Safety lancet Sarstedt DS1588, Numbrecht, Germany; 6) 
Lactate pro Randox RX Daytona; 7) 
Hawksley micro haematocrit centrifuge Haemospin 1300, Lansing, Sussex; 8) 
Hemocue device Hb201+, Angleholm, Sweden; 9) Motorised treadmill Pulsar, H/P Cosmos, Germany; 10) Non-
motorised treadmill Woodway Curve, Woodway, Wisconsin, USA; 11) Biodex System 3 Pro Isokinetic Dynamometer
 Biodex Medical Inc., Shirley, NY, USA; 12) CETL Gymnasium Centre for Excellence in Teaching and Learning 
(CETL) Building; 13) Skinfold Calipers Harpenden Skinfold Caliper, Baty International, Burgess Hill, West Sussex, UK; 14) 
Microlab ML3500 Spirometer Micromedical, Cardinal Health Ltd, UK. 
 
BACKGROUND: There is limited evidence to suggest the acute inhalation of short 
acting β2-agonist have an ergogenic effect. To date, no study has examined the 
ergogenic impact following the chronic use of inhaled Salbutamol at the WADA 
upper daily limit (1600 µg).  
PURPOSE: To determine the effect of the WADA upper limit of 1600 μg per day 
Salbutamol every day for six weeks, on endurance, strength, power and body 
composition.  
METHODS: Sixteen trained male athletes provided written consent and agreed to 
take part in the study (mean + SD: age 20.1 ± 1.6 years; height 179.9 ± 8.2 cm; 
weight 74.6 ± 9.1 kg). Participants entered into a 6-week, 4 times per week training 
study having been assigned to one of two groups in a double blind design. Group 1 
(n=8) inhaled 4 x100 μg of placebo, via pocket chamber, 4 times per day for 6 
weeks (PLA). Group 2 (n=8) inhaled 4 x100 μg of Salbutamol, via pocket chamber, 
4 times per day for 6 weeks (SAL). Pre- and post-training endurance, body 
composition, power and strength was assessed.  
RESULTS: In both groups there was an overall improvement in (Pre- Post-) O2peak 
(51.7 ± 4.7 –56.8 ± 7.1 ml.min.kg-1; 53.1 ± 6.1 –55.0 ± 6.7 ml.min.kg-1); 3 km 
running time-trial performance (988.6 ± 194.6 – 947.5 ± 155.5 s; 1040.4 ± 187.4 –
1004.2 ± 199.4 s); 1RM bench press (65.7 ± 15.4 – 70.3 ± 13.8 kg;  64.3 ± 14.0 – 
72.5 ± 15.3 kg) and leg press (250.0 ± 76.4 – 282.5 ± 63.6 kg; 217.9 ± 54.0 – 282.8 
± 51.9 kg) between SAL and PLA, respectively. Peak extension and flexion torque, 
and body composition remained unchanged across the study period. Of note, no 
difference in any endurance; strength and power; or body composition measures 
were noted between SAL and PLA groups pre-, during, or post-intervention.  
DISCUSSION: There was no significant improvement in endurance, or strength and 
power performance following the inhalation of 1600 µg Salbutamol per day for six 
weeks in non-asthmatic males, compared to placebo.  
CONCLUSION: The current WADA recommendations, of up to 1600 µg inhaled 
Salbutamol per day, appear sufficient to avoid an ergogenic impact on endurance, 
strength and power performance. Data from this study will assist WADA in the 
implementation of regulations on the use of inhaled short acting β2-agonist and in 
the resolution of contested doping violations. 
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Appendix G 
ABSTRACT FOR ACSM 2014 
The effect of 2 mg and 4 mg inhaled Terbutaline on 3 km running 
time-trial performance in males and females. 
Molphy, J., Dickinson, J., Chester, N., Loosemoore, M., and Whyte, G., FACSM. 
Liverpool John Moores University, Liverpool, UK, English Institute of Sport, 
Sheffield, UK, University of Kent, Chatham Maritime, UK 
Limited research investigating the effects of inhaled Terbutaline on exercise 
performance has led to uncertainty regarding the inclusion of Terbutaline on the 
WADA List of Prohibited Substances and Methods.  PURPOSE: Investigate the 
effect of therapeutic and supratherapeutic doses of Terbutaline on 3 km running 
time-trial performance in males and females. METHODS: Six males (Mean ±SD 
age 25 ± 1.5 years; height 178.3 ± 1.4cm; weight 79.7 ± 6.3 kg) and six females 
(Mean ±SD age 21.7 ± 3.1 years; height 162.4 ± 10.7cm; weight 57.6 ± 6.6 kg) 
provided written consent and agreed to take part in the study. Participants had no 
history of asthma confirmed by a negative eucapnic voluntary hyperpnoea (EVH) 
challenge. All participants completed 3 km running time-trials under three separate 
conditions in a double blind randomised design; placebo, 2 mg and 4 mg inhaled 
Terbutaline. Measurements of time, heart rate, VCO2, VO2, respiratory exchange 
ratio (RER), ratings of perceived exertion (RPE) and blood lactate were taken 
during all trials, a 3-way mixed model analysis of variance was used to compare 
between groups, between conditions and between time-points, significance was set 
at P<0.05 for all analyses. RESULTS: There were no significant differences in time 
taken to complete the 3 km time trial between conditions in either males (922.8 ± 
104.7s; 928.2 ± 118.7s; 951.7 ± 138.5s) or females (1289.5 ± 156.4s; 1285.4 ± 
97.8s; 1245.3 ± 88.2s) for placebo, 2mg inhaled and 4mg inhaled Terbutaline, 
respectively. Both males and females demonstrated significant increases in heart 
rate, VCO2, VO2 and RPE during each time trial (p<0.001).  Mean ± SD increases in 
FEV1 were 11 ± 117 ml; 200 ± 107 ml and 233 ± 81 ml following administration of 
Placebo, 2mg and 4mg inhaled Terbutaline respectively. Heart rate values were 
significantly higher in females than in males (P=0.49) and completion times were 
also higher in females compared to males (P<0.001).  CONCLUSION: There was 
no significant improvement in 3km Time-Trial performance following the inhalation 
of either 2 mg or 4 mg inhaled Terbutaline. The current findings suggest that the 
use of inhaled Terbutaline during exercise provides no performance enhancement, 
however its position on the WADA list still remains unclear due to the difficulties in 
distinguishing between oral and inhaled use.   
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Appendix H 
YIA ABSTRACT FOR ECSS 2015 
URINARY CONCENTRATIONS OF SINGLE AND MULTIPLE 
ADMINSTRATION OF INHALED AND ORAL TERBUTALINE: 
INFLUENCE OF GENDER AND ETHNICITY 
Molphy, J., Dickinson, J. W.,
 
Chester, N. J., Loosemore, M., Whyte, G.
 
Introduction 
 
Elite athletes have a higher prevalence of Exercise-induced bronchoconstriction (EIB) than 
the general population. Treatment for asthma and EIB includes inhalation of short-acting β2-
agonists (SABA). The World Anti-Doping Agency (WADA) has permitted the use of the 
SABA salbutamol for inhalation in therapeutic doses since 2010. In contrast, therapeutic 
doses of the inhaled SABA terbutaline still require a therapeutic use exemption. The purpose 
of the present study was to measure the urine concentrations of terbutaline following single 
and repeated doses of oral and inhaled terbutaline in Caucasian males, Caucasian females, 
Afro-Caribbean males and Asian males to distinguish between routes of administration and 
to allow for comparisons between gender and ethnicity. 
 
Methods 
 
Twenty-two male and eight female subjects (8 male & 8 female Caucasian, 6 male afro-
Caribbean, 6 male Asian) were recruited for the study. All participants were free from 
asthma, EIB and AHR confirmed by no history of disease and a negative eucapnic voluntary 
hyperpnoea (EVH) challenge. Participants were assigned to one of four groups in a cross-
over design: 
1. Single dose of 5 mg oral terbutaline. 
2. Single dose of 4 inhalations of 0.5 mg terbutaline totalling 2mg inhaled. 
3. Repeated doses of 1 mg (2 x 0.5 mg inhalations) of terbutaline at 08:00h, 12:00h, 
16:00h and 20:00h for 2 days. 
4. Repeated doses of 5 mg oral terbutaline at 10:00h and 18:00h for 2 days. 
Participants were required to provide urine samples at 1h, 3h, 6h and 12h time-points post-
final dose. 
 
Results 
 
The study identified upper thresholds following inhaled (1,500 ng.ml
-1
) and oral (2,000 
ng.ml
-1
) administration which could be used to identify the use of supra-therapeutic doses of 
terbutaline. Gender differences existed (406.9±45.4 vs. 678.8±94.8 ng·ml
-1
; P=0.018) for 
male vs. female Caucasians, respectively following multiple oral administration. Ethnic 
differences (372.14 ± 69.7 vs. 131.8 ± 19.7 ng·ml
-1
; P=0.005) were identified following 
single inhaled administration for male Caucasians and male Asians, respectively. 
Discussion 
All trials resulted in the presence of terbutaline in urine. Upper thresholds for urinary 
terbutaline following inhaled and oral administration were observed along with gender 
differences between male and female Caucasians, and ethnic differences between male 
Asians and Caucasians. These upper thresholds could be useful in establishing anti-doping 
limits that can distinguish between routes of administration. Further investigation is 
warranted in order to fully elucidate these findings. Future research should examine urine 
concentrations following a minimum therapeutic dose of inhaled terbutaline versus oral 
terbutaline to provide further distinction between routes of administration. 
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Appendix I 
Statement of Contribution for Chapter 4 
With regard to the ownership of the published work for chapter 4 of this thesis, I 
would like to state the following order of contributions: 
1. John Molphy – Responsible for study design, data collection, participant 
recruitment, statistical analysis, interpretation of results, writing of the 
methods and results sections, jointly responsible for writing of the 
introduction and discussion sections. 
2. John Dickinson – Responsible for securing grant funding, ethical approval, 
study design, participant recruitment, interpretation of results, reviewing 
the writing up of the methods and results sections, responsible for writing 
the introduction and discussion sections. 
3. Neil Chester – Responsible for securing grant funding, ethical approval, 
study design, participant recruitment, proof-reading the writing up of the 
published paper. 
4. Mike Loosemore – Responsible for securing grant funding, ethical approval, 
providing of all medications used in study, proof-reading the writing up of 
the published paper. 
5. Greg Whyte – Responsible for securing grant funding, ethical approval, 
study design, participant recruitment, interpretation of results, proof-
reading the writing up of the published paper. 
I agree that the above statement with regard to the contributions of the 
aforementioned published authors, are correct: 
Signed – John Molphy     ……… …………………      Date …………25/08/15….. 
Signed – Dr John Dickinson  ……… …………………   Date …………03/09/15….. 
Signed – Dr Neil Chester  ……… …………………  Date …………27/08/15….. 
Signed – Dr Mike Loosemore  ……… ………………..   Date …………03/09/15….. 
Signed – Prof Greg Whyte   ……… ………………..   Date …………05/09/15…… 
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Appendix J 
 
 
Published Material: 
 
Dickinson, J., Molphy, J., Chester, N., Loosemore, M., Whyte, G. (2014) The 
ergogenic effects of long-term use of high dose salbutamol. 24(6):474-481. 
 
http://journals.lww.com/cjsportsmed/Abstract/2014/11000/The_Ergogenic_Ef
fect_of_Long_term_Use_of_High_Dose.7.aspx  
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Appendix K 
 
Ventolin (Salbutamol) Manufacturer Guidelines 
 
DATA SHEET  
Ventolin® Inhaler (CFC-Free)  
Salbutamol (as sulphate) Inhaler (CFC-free) 100mcg per actuation.  
Qualitative and quantitative composition Ventolin Inhaler (CFC-Free) comprises a suspension of 
salbutamol sulphate in the non-CFC propellant HFA 134a. The suspension is contained in an 
aluminium alloy can, internally coated with fluoropolymer and sealed with a metering valve. 
Each canister is fitted with a plastic actuator incorporating an atomising nozzle and fitted with a 
dustcap.  
Ventolin Inhaler (CFC-Free) is a pressurised metered-dose inhaler which delivers 100g 
salbutamol (as sulphate) per actuation, into the mouthpiece of a specially designed actuator. 
The inhaler also contains the CFC-free propellant HFA134a. Each canister contains at least 200 
actuations. Pharmaceutical form Pressurised metered-dose aerosol.  
Clinical particulars  
Therapeutic Indications Salbutamol is a selective 2 adrenoceptor agonist indicated for the 
treatment or prevention of bronchospasm. It provides short acting (four hours) bronchodilation 
in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. For 
patients with asthma salbutamol may be used to relieve symptoms when they occur and to 
prevent them prior to a known trigger. Bronchodilators should not be the only or main 
treatment in patients with persistent asthma. In patients with persistent asthma unresponsive 
to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain 
control. Failure to respond promptly or fully to such rescue medication signals a need for 
urgent medical advice and treatment.  
2 Posology and Method of Administration  
Ventolin Inhaler (CFC-Free) is administered by the oral inhaled route only, to be breathed in 
through the mouth. Salbutamol has a duration of action of 4 to 6 hours in most patients. 
Increasing use of 2 agonists may be a sign of worsening asthma. Under these conditions a 
reassessment of the patient's therapy plan may be required and concomitant 
glucocorticosteroid therapy should be considered. In patients who find co-ordination of a 
pressurised metered-dose inhaler difficult a spacer device may be used with the Ventolin 
Inhaler (CFC-Free). Babies and young children may benefit from use of a spacer device with the 
Ventolin Inhaler (CFC-Free). As there may be adverse effects associated with excessive dosing, 
the dosage or frequency of administration should only be increased on medical advice.  
Relief of acute bronchospasm:- Adults: 100 or 200g. Children: 100g, the dose may be 
increased to 200g if required. Prevention of allergen or exercise-induced bronchospasm:- 
Adults: 200g before challenge Children: 100g before challenge, the dose may be increased to 
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200g if required. Chronic therapy:- Adults: Up to 200g four times daily Children: Up to 200g 
four times daily  
On demand use of Ventolin should not exceed four times daily. Reliance on such 
supplementary use or a sudden increase in dose indicates deteriorating asthma (see Special 
Warnings and Special Precautions for Use). Contra-indications Ventolin Inhaler (CFC-Free) is 
contra-indicated in patients with a history of hypersensitivity to any of its components (see List 
of excipients). Non-i.v. formulations of salbutamol must not be used to arrest uncomplicated 
premature labour or threatened abortion. Special Warnings and Special Precautions for Use 3 
The management of asthma should normally follow a stepwise programme, and patient 
response should be monitored clinically and by lung function tests. Increasing use of short-
acting inhaled 2 agonists to control symptoms indicates deterioration of asthma control.  
Under these conditions, the patient's therapy plan should be reassessed. Sudden and 
progressive deterioration in asthma control is potentially life-threatening and consideration 
should be given to starting or increasing corticosteroid therapy. In patients considered at risk, 
daily peak flow monitoring may be instituted. In the event of a previously effective dose of 
inhaled salbutamol failing to give relief for at least three hours, the patient should be advised 
to seek medical advice in order that any necessary additional steps may be taken. Patients' 
inhaler technique should be checked to make sure that aerosol actuation is synchronised with 
inspiration of breath for optimum delivery of the drug to the lungs. Salbutamol should be 
administered cautiously to patients with thyrotoxicosis. Potentially serious hypokalaemia may 
result from 2 agonist therapy mainly from parenteral and nebulised administration. Particular 
caution is advised in acute severe asthma as this effect may be potentiated by concomitant 
treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that 
serum potassium levels are monitored in such situations.  
As with other inhalation therapy, paradoxical bronchospasm may occur, resulting in an 
immediate increase in wheezing after dosing. This should be treated immediately with an 
alternative presentation or a different fast-acting inhaled bronchodilator, if immediately 
available. The specific salbutamol presentation should be discontinued, and if necessary a 
different fast-acting bronchodilator instituted for ongoing use.  
Interaction with Other Medicaments and Other Forms of Interaction Salbutamol and non-
selective -blocking agents, such as propranolol, should not usually be prescribed together. 
Salbutamol is not contra-indicated in patients under treatment with monoamine oxidase 
inhibitors (MAOIs).  
Pregnancy and Lactation There is no information on the effects of salbutamol on human 
fertility. There were no adverse effects on fertility in animals (see Preclinical safety data). 
Administration of medicines during pregnancy should only be considered if the expected 
benefit to the mother is greater than any possible risk to the foetus. 4  
During worldwide marketing experience, rare cases of various congenital anomalies, including 
cleft palate and limb defects have been reported in the offspring of patients being treated with 
salbutamol. Some of the mothers were taking multiple medications during their pregnancies. 
Because no consistent pattern of defects can be discerned, and baseline rate for congenital 
anomalies is 2-3%, a relationship with salbutamol use cannot be established.  
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As salbutamol is probably secreted in breast milk its use in nursing mothers is not 
recommended unless the expected benefits outweigh any potential risk. It is not known 
whether salbutamol in breast milk has a harmful effect on the neonate.  
Effects on ability to drive and use machines None reported.  
Undesirable Effects Adverse events are listed below by system organ class and frequency. 
Frequencies are defined as: very common (1/10), common (1/100 and 1/10), uncommon 
(1/1000 and 1/100), rare (1/10,000 and 1/1000) and very rare (1/10,000) including 
isolated reports.  
Very common and common events were generally determined from clinical trial data. Rare and 
very rare events were generally determined from spontaneous data.  
Immune system disorders Very rare: Hypersensitivity reactions including angioedema, urticaria, 
bronchospasm, hypotension and collapse.  
Metabolism and nutrition disorders Rare: Hypokalaemia. Potentially serious hypokalaemia may 
result from beta2 agonist therapy.  
Nervous system disorders Common: Tremor, headache. Very rare: Hyperactivity. Cardiac 
disorders Common: Tachycardia. Uncommon: Palpitations. Very rare: Cardiac arrhythmias 
including atrial fibrillation, supraventricular tachycardia and extrasystoles. 5  
Vascular disorders Rare: Peripheral vasodilatation.  
Respiratory, thoracic and mediastinal disorders Very rare: Paradoxical bronchospasm.  
Gastrointestinal disorders Uncommon: Mouth and throat irritation.  
Musculoskeletal and connective tissue disorders Uncommon: Muscle cramps. *Tachycardia 
may occur in some patients.  
Overdose The most common signs and symptoms of overdose with salbutamol are transient 
beta agonist pharmacologically mediated events (see Special Warnings and Special Precautions 
for Use and Undesirable Effects). Hypokalaemia may occur following overdose with salbutamol. 
Serum potassium levels should be monitored. Lactic acidosis has been reported in association 
with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, 
therefore monitoring for elevated serum lactate and consequent metabolic acidosis 
(particularly if there is persistence or worsening of tachypnea despite resolution of other signs 
of bronchospasm such as wheezing) may be indicated in the setting of overdose.  
Pharmacological properties  
Pharmacodynamic properties Salbutamol is a selective 2 adrenoceptor agonist. At therapeutic 
doses it acts on the 2 adrenoceptors of bronchial muscle providing short acting (4 to 6 hour) 
bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction..  
Pharmacokinetic properties Salbutamol administered intravenously has a half-life of 4 to 6 
hours and is cleared partly renally and partly by metabolism to the inactive 4'-O- sulphate 
(phenolic sulphate) which is also excreted primarily in the urine. The faeces are a minor route 
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of excretion. The majority of a dose of salbutamol given 6 intravenously, orally or by inhalation 
is excreted within 72 hours. Salbutamol is bound to plasma proteins to the extent of 10%.  
After administration by the inhaled route between 10 and 20% of the dose reaches the lower 
airways. The remainder is retained in the delivery system or is deposited in the oropharynx 
from where it is swallowed. The fraction deposited in the airways is absorbed into the 
pulmonary tissues and circulation but is not metabolised by the lung. On reaching the systemic 
circulation it becomes accessible to hepatic metabolism and is excreted, primarily in the urine, 
as unchanged salbutamol and as the phenolic sulphate. The swallowed portion of an inhaled 
dose is absorbed from the gastrointestinal tract and undergoes considerable first-pass 
metabolism to the phenolic sulphate. Both unchanged salbutamol and conjugate are excreted 
primarily in the urine.  
Preclinical safety data  
In common with other potent selective 2 receptor agonists, salbutamol has been shown to be 
teratogenic in mice when given subcutaneously. In a reproductive study, 9.3% of foetuses were 
found to have cleft palate, at 2.5 mg/kg, 4 times the maximum human oral dose. In rats, 
treatment at the levels of 0.5, 2.32, 10.75 and 50mg/kg/day orally throughout pregnancy 
resulted in no significant foetal abnormalities. The only toxic effect was an increase in neonatal 
mortality at the highest dose level as the result of lack of maternal care. A reproductive study in 
rabbits revealed cranial malformations in 37% of foetuses at 50mg/kg/day, 78 times the 
maximum human oral dose.  
In an oral fertility and general reproductive performance study in rats at doses of 2 and 50 
mg/kg/day, with the exception of a reduction in number of weanlings surviving to day 21 post 
partum at 50 mg/kg/day, there were no adverse effects on fertility, embryofetal development, 
litter size, birth weight or growth rate.  
HFA 134a has been shown to be non-toxic at very high vapour concentrations, far in excess of 
those likely to be experienced by patients, in a wide range of animal species exposed daily for 
periods of two years. Pharmaceutical particulars List of excipients 1,1,1,2-tetrafluoroethane 
(also known as HFA 134a or norflurane).  
Incompatibilities  
None reported. 7  
Shelf Life 24 months Special precautions for storage Replace the mouthpiece cover firmly and 
snap it into position. Ventolin Inhaler (CFC-Free) should be stored below 30C. Protect from 
frost and direct sunlight. As with most inhaled medications in aerosol canisters, the therapeutic 
effect of this medication may decrease when the canister is cold. The canister should not be 
broken, punctured or burnt, even when apparently empty. Nature and contents of container 
Ventolin Inhaler (CFC-Free) comprises a suspension of salbutamol sulphate in the non-CFC 
propellant HFA 134a. The suspension is contained in an aluminium alloy can, sealed with a 
metering valve. Each canister is fitted with a plastic actuator incorporating an atomising nozzle 
and fitted with a dustcap. Ventolin Inhaler (CFC-Free) delivers 100g of salbutamol (as 
sulphate) per actuation. Each canister contains at least 200 actuations. Instructions for 
Use/Handling Testing your inhaler:- Before using for the first time remove the mouthpiece 
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cover by gently squeezing the sides of the cover, shake the inhaler well, and release two puffs 
into the air to make sure that it works. If it has not been used for 5 days or more, shake it well 
and release two puffs into the air to make sure that it works.  
Using your inhaler:- 1. Remove the mouthpiece cover by gently squeezing the sides of the 
cover. 2. Check inside and outside of the inhaler including the mouthpiece for the presence of 
loose objects. 3. Shake the inhaler well to ensure that any loose objects are removed and that 
the contents of the inhaler are evenly mixed. 4. Hold the inhaler upright between fingers and 
thumb with your thumb on the base, below the mouthpiece. 8 5. Breathe out as far as is 
comfortable and then place the mouthpiece in your mouth between your teeth and close your 
lips around it but do not bite it. 6. Just after starting to breathe in through your mouth press 
down on the top of the inhaler to release salbutamol while still breathing in steadily and 
deeply. 7. While holding your breath, take the inhaler from your mouth and take your finger 
from the top of the inhaler. Continue holding your breath for as long as is comfortable. 8. If you 
are to take further puffs keep the inhaler upright and wait about half a minute before repeating 
steps 2 to 6. 9. Replace the mouthpiece cover by firmly pushing and snapping the cap into 
position.  
IMPORTANT:- Do not rush Stages 5, 6 and 7. It is important that you start to breathe in as 
slowly as possible just before operating your Inhaler. Practise in front of a mirror for the first 
few times. If you see 'mist' coming from the top of the inhaler or the sides of your mouth you 
should start again from stage 2. If your doctor has been given you different instructions for 
using your inhaler, please follow them carefully. Tell your doctor if you have any difficulties. 
Cleaning your inhaler:- Your inhaler should be cleaned at least once a week. 1. Remove the 
metal canister from the plastic casing of the inhaler and remove the mouthpiece cover. 2. Rinse 
the actuator thoroughly under warm running water. 3. Dry the actuator THOROUGHLY inside 
and out. 4. Replace the metal canister and mouthpiece cover.  
DO NOT PUT THE METAL CANISTER INTO WATER.  
Medicines classification Prescription Only Medicine 9 Name and address GlaxoSmithKline NZ 
Limited Private Bag 106600 Downtown Auckland NEW ZEALAND Phone: (09) 367 2900 
Facsimile: (09) 367 2506 Date of preparation Issue date: 18 June 2014 Version: 4.0 VENTOLIN® 
is a registered trade mark of the GlaxoSmithKline group of companies 
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Appendix L 
 
Bricanyl (Terbutaline) Manufacturer Guidelines 
 
 
Bricanyl Product Information RITA.000-292-506.7.0 1(8)  
BRICANYL® terbutaline sulfate  
PRODUCT INFORMATION  
NAME OF THE MEDICINE  
BRICANYL is terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a 
sympathomimetic bronchodilator with a degree of selective β2- stimulant activity on the 
respiratory system.  
The chemical structure of terbutaline sulfate is: Molecular formula: (C12H19NO3)2.H2SO4 CAS 
number: 23031-32-5  
DESCRIPTION  
BRICANYL TURBUHALER® is a breath activated multiple dose powder inhaler free from 
propellant, lubricant, preservative, carrier substances or other additives. BRICANYL Elixir is a 0.3 
mg/mL oral solution with sorbitol, glycerol, citric acid - monohydrate, sodium hydroxide, 
sodium benzoate, disodium edetate, ethanol, purified water and raspberry flavour as inactive 
ingredients. BRICANYL Injection solution for injection contains 0.5 mg/mL of terbutaline sulfate 
with sodium chloride, hydrochloric acid (for pH adjustment) and water for injections as the 
inactive ingredients.  
PHARMACOLOGY  
The tertiary butyl group attached to the terminal nitrogen of the terbutaline molecule is 
thought to confer selective stimulation of the pulmonary β2-receptors and only relatively minor 
stimulation of cardiac β1 receptors. The presence of the two phenolic hydroxyl groups in the 
meta positions confers resistance to metabolism by the enzyme catechol-o-methyl transferase. 
The potent bronchospasmolytic effect is rapid in onset and reaches a maximum about 30 
minutes after subcutaneous injection, 1 hour after aerosol and 2 - 3 hours after oral 
administration. The duration of action is between 4 and 5 hours. In addition to its 
bronchospasmolytic effect, terbutaline has also been shown to improve Bricanyl Product 
Information RITA.000-292-506.7.0 2(8) mucociliary clearance. Metabolism of terbutaline sulfate 
which is ingested orally or swallowed following inhalation is principally by conjugation in the 
gastrointestinal mucosa. The drug is absorbed unchanged from the respiratory tract and is 
excreted mainly as such in the urine. Practically all of an administered dose of terbutaline is 
eliminated after 72 hours.  
INDICATIONS  
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For relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, 
and for acute prophylaxis against exercise-induced asthma or in other situations known to 
induce bronchospasm.  
BRICANYL TURBUHALER BRICANYL TURBUHALER is intended for short-term management of 
bronchospasm as well as maintenance therapy. 
BRICANYL Injection BRICANYL injection solution is recommended for acute use only.  
CONTRAINDICATIONS Hypersensitivity to sympathomimetic amines or any other ingredient.  
PRECAUTIONS Cardiovascular diseases and hyperthyroidism Caution is advised when 
terbutaline is administered to patients with thyrotoxicosis and to patients with hypertension, 
coronary artery disease, arrhythmias and tachyarrhythmia. Cardiovascular effects may be seen 
with sympathomimetic drugs, including BRICANYL. There is some evidence from post-marketing 
data and published literature of rare occurrences of myocardial ischaemia associated with beta 
agonists. Patients with underlying severe heart disease (eg ischaemic heart disease, arrhythmia 
or severe heart failure) who are receiving BRICANYL, should be warned to seek medical advice 
if they experience chest pain or other symptoms of worsening heart disease. Attention should 
be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either 
respiratory or cardiac origin. Arrhythmogenic potential β2-stimulants have an arrhythmogenic 
potential which must be considered for each patient when receiving treatment for 
bronchospasm.  
Bricanyl Product Information RITA.000-292-506.7.0 3(8) Diabetes Due to the blood-glucose 
increasing effects of β2-stimulants, extra blood glucose controls are initially recommended 
when diabetic patients are commenced on terbutaline. Sensitivity to sympathomimetic amines 
Some patients may be unusually sensitive to β-adrenergic stimulants. Terbutaline should be 
used with caution when an increased susceptibility to sympathomimetic amines can be 
expected for instance in other patients with hyperthyroidism not yet adequately controlled. 
Lack of response If the usual dose does not provide the usual relief, a non-responsive state may 
be developing. If a previously effective dose lasts less than usual, patients should be instructed 
to consult a doctor.  
Hypokalaemia Potentially serious hypokalaemia may result from β2-agonist therapy. Particular 
caution is recommended in acute severe asthma as the associated risk may be augmented by 
hypoxia. The hypokalaemic effect may be potentiated by concomitant treatments (see 
Interactions with other medicines). It is recommended that serum potassium levels are 
monitored in such situations. Lactic acidosis Lactic acidosis has been reported in association 
with high therapeutic doses of parenteral and nebulised short-acting β-agonist therapy, mainly 
in patients being treated for an acute asthma exacerbation (see Adverse effects and 
Overdosage sections).  
In patients not adequately responding to acute therapy with BRICANYL Injection, consideration 
should be given to the presence of lactic acidosis as a possible contributing factor to ongoing 
respiratory symptoms. Acute asthma If patients with an acute attack of asthma fail to respond 
to a dry powder inhaler of β2-agonist they should be advised to follow their personal asthma 
action plan. Failure to respond to β2-agonists in general can be due to various reasons related 
to drug administration or the disease itself. Particularly in children 5 years or younger, and 
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exceptionally in other cases, inspiratory flow through a dry powder inhaler may not be 
sufficient for optimal drug delivery. If a non-response occurs, medical help should be sought 
while a β2-agonist treatment is continued. In such a situation, and if available, a nebuliser or 
pressurised metered dose inhaler with spacer should be used. (see also Precautions - Lack of 
response).  
Cardionecrosis Animal studies suggest that cardionecrotic lesions may occur with high doses of 
some sympathomimetic amines. On this evidence, it is not possible to exclude myocardial 
lesions as a possible hazard resulting from long-term treatment. Bricanyl Product Information 
RITA.000-292-506.7.0 4(8) Use in pregnancy - Category A Although no adverse effects in 
pregnant women or their foetuses have been reported, care with BRICANYL, as with all other 
drugs, is recommended during the first 3 months of pregnancy. Use in lactation Although 
terbutaline is secreted into breast milk, and milk concentrations are approximately those in 
maternal plasma, two individual case studies indicate that the infant is likely to receive 0.2-
0.7% of the maternal dose (0.4 and 0.7 µg /kg /day respectively), depending (for example) on 
the time of feeding in relation to administration of the drug. In the 4 infants studied this did not 
result in any signs of β-adrenoceptor stimulation. Transient hypoglycaemia has been reported 
in newborn preterm infants after maternal β2-agonist treatment.  
INTERACTIONS WITH OTHER MEDICINES  
Care is recommended if it is proposed to administer terbutaline in concomitant therapy with 
other sympathomimetic amines as excess sympathetic stimulation may occur. β-adrenergic 
blocking drugs, including eye drops, may inhibit the bronchodilating effect of sympathomimetic 
bronchodilators and may increase airways resistance in asthmatic patients. Hypokalaemia may 
result from β2-agonist therapy and may be potentiated by concomitant treatment with 
xanthine derivatives, steroids and diuretics (see Precautions - Hypokalaemia).  
ADVERSE EFFECTS  
Most of the side effects are characteristic of sympathomimetic amines. The incidence and 
severity of particular side effects depends on the dose and rate of administration. An initial 
dose-titration will often reduce side effects. At recommended therapeutic doses, the frequency 
of side-effects is minimal. More common reactions More commonly observed side effects 
include tremor and headache. Commonly observed side effects include nervousness, 
tachycardia, palpitations, tonic muscle cramps and hypokalaemia.  
Bricanyl Product Information RITA.000-292-506.7.0 5(8)  
Less common reactions Cardiovascular Ectopic beats Gastrointestinal Nausea, vomiting, bad 
taste, diarrhoea General Sweating Musculoskeletal Muscle twitching, cramps Nervous system 
Drowsiness, dizziness, sleep disturbance, behavioural disturbances (such as agitation, 
hyperactivity, restlessness) Dermatological Rash, urticaria, exanthema Rare cases of lactic 
acidosis have been reported with high therapeutic doses of Bricanyl injection. Serious or life 
threatening reactions Cardiac arrhythmias (eg atrial fibrillation, supraventricular tachycardia 
and extrasystoles) and myocardial ischaemia have been rarely reported. Overdose of 
terbutaline preparations may produce significant tachycardia, arrhythmia and hypotension (see 
Overdosage).  
In rare cases, through unknown mechanisms, drugs for inhalation may cause bronchospasm.  
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DOSAGE AND ADMINISTRATION  
Inhaled bronchodilators should be used as required rather than regularly. Dosage should be 
individualised. If long-term use of terbutaline is proposed, particularly if the patient is asked to 
take terbutaline in conjunction with other medications, objective pulmonary function testing 
(for example, by peak flow meter or spirometer) may be useful as part of assessment of the 
efficacy or treatment.  
Adults and children over 12 years  
Oral - BRICANYL Elixir (0.3 mg/mL terbutaline) 10 to 15 mL up to 3 times daily.  
Inhalational - BRICANYL TURBUHALER (1 inhalation = 500 μg terbutaline) 1 inhalation as 
required up to every 4 to 6 hours. In severe cases the single dose may be increased to 3 
inhalations. The total daily dose should not exceed 12 inhalations per 24 hours.  
Parenteral - BRICANYL Injection (0.5 mg/mL terbutaline) subcutaneous 0.5 mL. Repeat as 
required up to every 6 hours. Bricanyl Product Information RITA.000-292-506.7.0 6(8)  
Paediatric  
Oral - BRICANYL Elixir (0.3 mg/mL terbutaline) 0.075 mg (0.25 mL)/kg/dose. Repeat as required 
up to every 6 hours.  
Inhalational - BRICANYL TURBUHALER (1 inhalation = 500 μg terbutaline) 1 inhalation as 
required up to every 4 to 6 hours. In severe cases the single dose may be increased to 2 
inhalations. The total daily dose should not exceed 8 inhalations per 24 hours. Use in children 
Dosage schedules for children for oral formulations of terbutaline should be prescribed on a 
mg/kg basis. The larger safety margins with the dry powder formulation permit a less specific 
dosage schedule. Oral administration is indicated in children who are unable to inhale 
satisfactorily via a metered dose inhaler and who do not have access to a compressor/nebuliser 
unit. BRICANYL TURBUHALER is suitable for use by children since it is breath activated and does 
not require co ordination of dose release and inhalation as with use of aerosol inhalers. 
Impaired hepatic function Hepatic failure has not been shown to influence the metabolism of 
terbutaline. However, caution should be exercised in patients with impaired liver function. 
Impaired renal function As terbutaline sulfate is largely excreted in urine, caution should be 
exercised in patients with renal impairment.  
OVERDOSAGE For information on the management of overdose, contact the Poison 
Information Centre on 131126 (Australia). There is a potential for progressive accumulation of 
dry powder in the mouthpiece of the BRICANYL TURBUHALER that could be released if dropped 
(for example, from a table) towards the end of inhaler life. To minimize unnecessary systemic 
exposure to terbutaline, the patients should be advised to, when possible, rinse their mouth 
after each use. Possible symptoms and signs Too frequent administration, as with other 
sympathomimetic agents, may cause nausea, headaches, changes in blood pressure, anxiety, 
tension, restlessness, insomnia, tremor, excitement, tonic muscle cramps, palpitations, 
tachycardia and cardiac arrhythmias. The symptoms and signs are those characteristic of 
excessive sympathetic stimulation. Bricanyl Product Information RITA.000-292-506.7.0 7(8)  
Laboratory findings  
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Hyperglycaemia and lactacidosis (see Precautions section) sometimes occur. β2- agonists may 
cause hypokalemia as a result of redistribution of potassium. Treatment The specific antidote 
for accidental overdosage with terbutaline sulfate is a cardioselective β-adrenergic blocking 
drug such as metoprolol (5-10 mg by slow intravenous injection, repeated if necessary after 5 
minutes). β-blockers should be used with care because of the possibility of inducing 
bronchospasm in sensitive individuals.  
PRESENTATION AND STORAGE CONDITIONS BRICANYL TURBUHALER: 500 μg per inhalation, 
breath activated; propellant and additive free. 100 and 200 doses.  
BRICANYL Elixir: 0.3 mg/mL in bottles of 300 mL BRICANYL Injection: 0.5 mg/mL of 5 x 1 mL 
ampoules.  
Storage conditions BRICANYL TURBUHALER: Store below 30°C. Replace cap firmly after use. 
BRICANYL Elixir: Store below 30°C. BRICANYL Injection: Store below 25°C. Protect from light. 
Solutions containing terbutaline are sensitive to excessive heat and light. Solutions should not 
be used if discoloured.  
NAME AND ADDRESS OF THE SPONSOR AstraZeneca Pty Ltd ABN 54 009 682 311 Alma Road 
NORTH RYDE NSW 2113 POISON SCHEDULE OF THE MEDICINE S3 - Pharmacist Only Medicine 
BRICANYL TURBUHALER S4 - Prescription Medicine BRICANYL elixir and injection Bricanyl 
Product Information RITA.000-292-506.7.0 8(8) DATE OF FIRST INCLUSION IN THE AUSTRALIAN 
REGISTER OF THERAPEUTIC GOODS (THE ARTG) 11th July 1991 DATE OF MOST RECENT 
AMENDMENT 11th November 2013 Bricanyl and Turbuhaler are registered trade marks of the 
AstraZeneca group of companies. © AstraZeneca Pty Ltd 2013 
